Idiopathic epilepsy in the dog: Reasons for referral and assessment from the owner's perspective by Chang, Ya-Pei
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
Idiopathic Epilepsy in the Dog: 
Reasons for Referral and 
Assessment from the Owners’ Perspective
Ya-Pei Chang BVM
A thesis submitted to the Faculty of Veterinary Medicine, 
University of Glasgow
for the degree of 
Master of Veterinary Medicine
Division of Small Animal Clinical Studies 
University of Glasgow Veterinary School
November 2001
©Ya-Pei Chang
ProQuest Number: 10647575
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uesL
ProQuest 10647575
Published by ProQuest LLO (2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
GLASGOW
u n iv e r s it y
LIBRARY:
U 5 G 0  
C o f l  X
11
ABSTRACT
Seizures are the most common neurological disorder in small animal medicine, of which 
40 to 50% of affected dogs are diagnosed as having idiopathic epilepsy. Dogs with 
epilepsy represent a large proportion of the caseload for the neurology service of the Small 
Animal Hospital of University of the Glasgow Veterinary School (SAH-UGVS). The aims 
of this study were to clarify the reasons for owners requesting a second opinion for dogs 
with idiopathic epilepsy. This was undertaken by reviewing seizure management regimens 
instigated at primary veterinary clinics and examining the owners’ perspective of the 
reasons for referral and the seizure management regimen used in SAH-UGVS. 
Information from the owners’ perspective was also thought of value to clinicians in 
assessing seizure management regimens and could potentially raise issues of relevance to 
dogs with epilepsy and their owners, which may be the basis for developing an alternative 
assessment of long-term seizure treatment in veterinary medicine.
A total of 48 dogs referred to SAH-UGVS between March 1999 and April 2001 for 
evaluation of seizures and diagnosed or tentatively diagnosed with idiopathic epilepsy were 
included in this study. Breed, gender, age at the onset of seizure activity, seizure type, 
reasons for referral and previous antiepileptic drug (AED) therapy were reviewed for these 
cases. For 32 cases, the owners’ perspective on reasons for referral to and the seizure 
management regimen used in SAH-UGVS, as well as the exploration of other issues 
relevant to dogs and their owners, were sought by mailed questionnaires. Behavioural 
changes were reported by 11 respondents to the first questionnaire, and the second mailed 
survey was undertaken to clarify the nature and potential causes of behavioural changes in 
these patients.
The study demonstrated that “dogs’ quality of life”, “adequate seizure frequency” and 
“acceptable AED side effects” were the three main concepts considered important by 
owners in assessing the outcomes of seizure management. Furthermore, owning an 
epileptic dog did not have a major impact on owners’ woiiUday-to-day activities and free 
time. The majority of owners did not consider the administration of the medication a 
nuisance and coped well with administering medication more than once daily. For more 
than half of owners, regular veterinary examination and blood sampling for serum AED 
concentrations monitoring did not cause a significant problem. Further diagnostic 
procedures did help most owners understand their dogs’ condition and provided owners 
with more confidence in AED therapy adjustment and accepting the balance between AED 
efficacy and side effects. The majority of owners agreed the cost of further diagnostie 
procedures was worthwhile.
The study suggests that in both undergraduate and post-graduate education, the value of 
measuring AED serum concentrations, as well as the use o f bromide in eanine epilepsy, 
should be emphasised. The study also demonstrated that dogs on potassium bromide alone 
exhibited fewer side effects than dogs on phenobarbitone.
A relatively large proportion of cases studied exhibited behavioural changes, which mainly 
appeared to be AED-related. Clinicians should be aware of the potential for behavioural 
change in idiopathic epileptic patients on AED therapy. Once patients exhibit AED-related 
behavioural changes, a dose reduction or discontinuation of the particular AED may be 
necessary.
Ill
TABLE OF CONTENTS
ABSTRACT..................................................................................................................................... ii
TABLE OF CONTENTS............................................................................................................. iii
LIST OF TA BLES......................................................................................................................viii
LIST OF FIG U R ES......................................................................................................................xi
ACICNOWLEDGEMENTS........................................................................................................xii
DECLARATION......................................................................................................................... xiii
CHAPTER ONE: INTRODUCTION AND THE REVIEW OF LITERATURE 1
1.1 Seizures and E pilepsy............................................................................................................. 2
L L l  Seizures ..............................................................................................................................2
1.1.1.1 Definition.............................................................................................................. 2
1.1.1.2 Phases of Seizure Activity..................................................................................2
1.1.1.3 Seizure Intensity.................................................................................................. 4
1.1.1.4 Type of Seizure.....................................................................................................4
1.1.2 Epilepsy: Definition, Classification and Causes..........................................................6
1.1.3 Functional Aspects o f the CNS Related to Seizure A ctiv ity ....................................... 8
1.1.3.1 General Principles and Basic Mechanisms of Neuronal Excitability.......... 8
1.1.3.2 Basic Mechanisms of Epileptogenesis.............................................................11
1.2 Epidemiology of Idiopathic Epilepsy.................................................................................20
1.2.1 Age and Gender.............................................................................................................. 20
1.2.2 Genetic Aspect o f  Idiopathic Epilepsy ........................................................................ 20
1.3 Diagnostic Evaluation........................................................................................................... 22
1.3.1 Signalment....................................................................................................................... 22
1.3.2 Clinical History .............................................................................................................. 22
1.3.3 Physical Examination.....................................................................................................24
Table of Contents iv
1.3.4 Neurological Examination ............................................................................................24
1.3.5 Laboratory Investigation............................................................................................... 24
1.3.6 Intra-cranial Imaging.....................................................................................................24
1.3.6.1 Structural Im aging............................................................................................. 25
1.3.6.2 Functional Imaging............................................................................................26
1.3.7 Cerebrospinal Fluid A nalysis ...................................................................................... 27
1.3.8 Electroencephalography............................................................................................... 28
1.3.8.1 Electroencephalography and Epilepsy............................................................ 28
1.3.8.2 Electroencephalography in Veterinary M edicine......................................... 28
1.3.8.3 Interictal Paroxysmal Discharges.................................................................... 30
1.4 Antiepileptic Drug Therapy................................................................................................ 31
1.4.1 General Principles o f  Antiepileptic Drug Therapy................................................... 31
1.4.1.1 When to Initiate Treatment...............................................................................31
1.4.1.2 Owner Education............................................................................................... 32
1.4.1.3 Mechanisms of Action of the A ED s................................................................32
1.4.1.4 Choice of Treatm ent..........................................................................................33
1.4.1.5 Clinical Pharmacokinetics................................................................................ 35
1.4.1.6 Therapeutic Drug Monitoring and AED Therapy......................................... 36
1.4.2 Antiepileptic D rugs ........................................................................................................ 40
1.4.2.1 Phenobarbitone...................................................................................................40
1.4.2.2 B rom ide...............................................................................................................45
1.4.2.3 Primidone............................................................................................................ 48
1.4.2.4 Phenytoin............................................................................................................ 49
1.4.2.5 Benzodiazepines................................................................................................ 50
1.4.2.6 Other AEDs......................................................................................................... 51
1.4.3 AED Therapy Withdrawal............................................................................................. 54
1.5 Assessment of Seizure Management.................................................................................. 54
1.5.1 Seizure Frequency.......................................................................................................... 54
1.5.2 Quantitative Assessment o f  Seizure Severity.............................................................. 55
1.5.3 Quality o f  Life Measures in Epilepsy...........................................................................56
1.5.4 Related Information in Veterinary M edicine ............................................................. 57
1.6 Aims of the Study................................................................................................................... 57
Table of Contents v
CHAPTER TWO: MATERIALS AND METHODS........................................................... 59
2.1 Criteria for Entry of Dogs in the Study ........................................................................... 60
2.2 Investigation Protocol for Patient with Epilepsy............................................................ 60
2.3 Seizure Disorder Evaluation and M anagement............................................................. 67
23.1 Categories o f  Seizure Cases Included in This Study .................................................67
2.3.2 Group One....................................................................................................................... 68
2.3.3 Group Two....................................................................................................................... 70
2.4 Questionnaire Study.............................................................................................................. 71
2.4.1 Questionnaire One: An Assessment o f the Seizure Management in Companion 
Animals from  the Owners ’ Perspective......................................................................71
2.4.1.1 Form at..................................................................................................................71
2.4.1.2 Questionnaire Design.........................................................................................71
2.4.1.3 Pretesting............................................................................................................ 74
2.4.1.4 Inelusion Criteria and Implementing Mail Surveys......................................74
2.4.2 Questionnaire Two: Behavioural Changes in Epileptic D ogs ................................ 75
2.4.2.1 Form at..................................................................................................................75
2.4.2.2 Questionnaire Design.........................................................................................75
2.4.2.3 Inclusion Criteria and Implementing Mail Surveys......................................76
2.4.3 Analysis o f  D a ta ............................................................................................................. 76
CHAPTER THREE: RESULTS............................................................................................... 77
3.1 Cases Review............................................................................................................................78
3.1.1 Breed and Sex Distribution ...........................................................................................78
3.1.2 Age at Onset o f  Seizure Activity ................................................................................... 78
3.1.3 Duration o f Seizure History When Presented ............................................................ 79
3.1.4 Seizure Type .................................................................................................................... 80
3.1.5 Reasons fo r  Referral......................................................................................................80
3.1.6 AED Therapy at the Time o f  Referral......................................................................... 81
3.1.7 Behavioural Changes at the Time o f  Referral............................................................ 82
3.2 Questionnaire One: An Assessment of Seizure Management in Companion 
Animals from the Owners’ Perspective.......................................................................... 86
3.2.1 The Response................................................................................................................. 86
1 able of Contents vi
3.2.2 Detailed R esults ........................................................................................................... 86
3.2.2.1 Section A: Establishing the Ideals for Assessing the Outeome of Seizure 
M anagement......................................................................................................86
3.2.2.2 Section B: An Assessment of Seizure Management in their Own Dogs ...89
3.2.2.3 Section C; An Assessment of Quality of Life in Epileptic Dogs................90
3.2.2.4 Section D: An Assessment of Work Associated with Caring for Epileptic 
Dogs....................................................................................................................92
3.2.2.5 Section E: An Assessment of AED Side Effects.......................................... 93
3.2.2.6 Section F: The Impact of Owning an Epileptic Dog on Owners’ Day-to- 
day A etivity.......................................................................................................97
3.2.2.7 Section G: The Impact of Owning an Epileptic Dog on Owners’ 
Ability/decision to Stay Away O vernight.................................................... 98
3.2.2.8 Section H: Owners’ Opinions on Further Investigation of Seizures in their 
Dogs.................................................................................................................. 100
3.3 Questionnaire Two: Behavioural Changes in Epileptic D ogs................................. 105
3.3.1 The Response................................................................................................................. 105
3.3.2 Detailed R esults ............................................................................................................105
3.3.2.1 The Behavioural Change and the Frequency (Q-1, Q-15 and Q-16)....... 105
3.3.2.2 The Onset of the Behavioural Changes (Q-2 and Q -3 )............................. 106
3.3.2.3 Trigger Factors or the Reason of the Certain Behaviour (Q-4 to Q-6).... 107
3.3.2.4 History of Behavioural Problems (Q-7 to Q -9 )...........................................108
3.3.2.5 Behavioural Changes and AED Therapy (Q-10).........................................108
3.3.2.6 Behavioural Changes and Seizure Activity (Q-11 to Q-14 ) ......................109
3.3.2.7 The Response of the Reported Behaviour (Q-17 and Q-18 ) .....................110
3.3.3 Summary o f  Questionnaire Two ................................................................................. 111
CHAPTER FOUR: DISCUSSION.........................................................................................113
4.1 General Aspect of the Study.............................................................................................. 114
The Significance o f the Population Surveyed..................................................................... 114
Reflections on the Response Rate to the Questionnaires..................................................114
The Source o f  B iases ..............................................................................................................115
4.2 Cases Review..........................................................................................................................118
The predisposition to idiopathic epilepsy in certain breeds ............................................118
Comparing clinician’s perception o f reasons fo r  referral with that o f  owners............119
Table ol Contents vii
Factors underlying apparent treatment failure .................................................................. 119
4.3 Assessing Seizure Management from Owners’ Perspective...................................... 121
4.4 Behavioural Changes in Epileptic D ogs..........................................................................123
CHAPTER FIVE: CONCLUSIONS......................................................................................127
APPENDIX ONE
Questionnaire: An Assessment of Seizure Management in Companion Animals from 
the Owners’ Perspective............................................................................................................130
APPENDIX TWO
Questionnaire: Behavioural Changes in Epileptic Dogs....................................................139
REFERENCES............................................................................................................................ 144
V lll
LIST OF TABLES
Table 1.1 Summary of the International Classification of Epileptic Seizures.........................4
Table 1.2 Causes of symptomatic epilepsy................................................................................... 7
Table 1.3 Causes of reactive seizures............................................................................................. 8
Table 1.4 Differential diagnosis of nonepileptic paroxysmal disorder and wealaiess......... 23
Table 1.5 Mechanisms of action of AEDs (Pemcca 1996; Deckers et a l 2000).................. 34
Table 1.6 Pharmacokinetic variables for AEDs in the dog.......................................................44
Table 1.7 Recommended doses for AED in the dog..................................................................44
Table 1.8 Related information of alternative drugs in dogs......................................................52
Table 1.9 Mechanisms leading to deterioration of a patient’s condition............................... 54
Table 2.1 Questions checklist o f clinical history....................................................................... 64
Table 2.2 Checklist of physical examination..............................................................................66
Table 2.3 Routine haematology and biochemistry..................................................................... 66
Table 3. 1 The association between reasons for referral and the duration of seizure history 
when presented..............................................................................................................80
Table 3.2 Current phenobarbitone dose, duration of seizure history and AED history....... 81
Table 3.3 Database of cases in the study; signalment, seizure history, and previous AED 
therapy............................................................................................................................83
Table 3.4 The response rate at different stages...........................................................................86
Table 3.5 Evaluation of the importance of factors in the assessment o f seizure management 
in group with AED therapy.........................................................................................87
Table 3.6 Responses distribution of minimal seizure interval in group with A E D ..............87
Table 3.7 Owners’ perspective of the importance of issues in assessing seizure 
management for respondents with pets not on AED therapy.............................. 88
Table 3.8 Results of minimal seizure interval (Q-A2) in group without AED therapy....... 88
List of Tables ix
Table 3.9 An assessment of seizure management in individual dog of group with AED.... 89
Table 3.10 An assessment of seizure management in individual dog of group without AED 
therapy..........................................................................................................................90
Table 3.11 Results of assessment of epileptic dogs’ quality of life in group with A E D .....91
Table 3.12 Results of question C4 - reasons for the dog’s quality of life deteriorating......91
Table 3.13 An assessment of quality of life in dogs of group without AED therapy.......... 91
Table 3.14 An assessment of work associated with caring for epileptic dogs...................... 92
Table 3.15 Reasons of administration of medication is a nuisance........................................ 92
Table 3.16 AED side effects in all dogs of the study.................................................................93
Table 3.17 The occurrence of side effects in patients with AED therapy.............................. 94
Table 3.18 The degree of owners’ concern in AED subgroups...............................................95
Table 3.19 The occurrence of side effects in dogs with different phenobarbitone dosages 95
Table 3.20 Reasons for dogs currently with no AED therapy................................................. 96
Table 3.21 The impact of owning an epileptic dog on owners’ day-to-day activity in group 
with AED therapy......................................................................................................97
Table 3.22 The impact of owning an epileptic dog on owners’ day-to-day activity in group 
without AED therapy................................................................................................ 98
Table 3.23 How owners organised the care of dogs when they stayed away overnight, in 
the group with AED therapy.................................................................................... 98
Table 3.24 Reasons why seizures in dogs affected their owners’ ability/decision to stay 
away overnight........................................................................................................... 99
Table 3.25 How owners organised the care of dogs when they stayed away overnight, in 
the group without AED therapy.............................................................................100
Table 3.26 Reasons why the previous seizure management considered unsatisfactory .... 101
Table 3.27 Owners’ opinions on further investigation of seizure disorder in group with 
A E D ...........................................................................................................................101
Table 3.28 Owners’ opinions on further investigation of seizure disorder in group without 
AED therapy............................................................................................................102
List oi Tables x
Table 3.29 Owners’ opinions on further investigation of seizure disorder from all responses
of the study................................................................................................................103
Table 3.30 Responses from cases, on which the full investigation protocol performed.... 103
Table 3. 31 The association between the duration of seizure history and reasons for referral 
from owner’s perception......................................................................................... 104
Table 3. 32 The association between the duration of seizure history and reasons for referral 
from clinician’s perception.....................................................................................104
Table 3.33 General comments.....................................................................................................104
Table 3.34 The response rate of the study................................................................................. 105
Table 3.35 Behavioural changes in epileptic dogs................................................................... 105
Table 3.36 The frequency of the behaviour in each dog (Q-1, Q-15 to 16)......................... 106
Table 3.37 The onset of behavioural changes from Q-2 and Q -3 ..........................................107
Table 3.38 Behavioural changes and AED therapy.................................................................108
Table 3.39 The onset and progress of the behavioural changes............................................. 109
Table 3.40 Behaviour and seizure activity................................................................................ 109
Table 3.41 Comparison of certain occumng time of seizure and the behaviour................ 110
Table 3.42 Responses of the behaviour......................................................................................110
Table 3.43 Summary of the responses of individual patient...................................................111
XI
LIST OF FIGURES
Figure 2.1 Investigation protocol for dogs with seizures..........................................................63
Figure 2.2 The Neurological Examination Sheet of SAH-UGVS.......................................... 65
Figure 2.3 Seizure diary .................................................................................................................69
Figure 3.1 Breed distribution........................................................................................................78
Figure 3.2 Distribution of age at onset of seizure activity........................................................79
Figure 3.3 Duration of seizure history when referred................................................................79
Figure 3.4 Seizure type and number of dogs...............................................................................80
Figure 3.5 Distribution of serum phenobarbitone concentrations............................................82
Figure 3.6 Distribution of values for “adequate seizure frequency” ....................................... 89
Figure 3.7 Distribution of side effects in AED subgroups........................................................94
Figure 3.8 Distribution of occurrence of phenobarbitone side effects in dogs with different 
range of dosages.......................................................................................................... 96
Figure 3.9 Distribution of answers of question F2 and F4........................................................97
Figure 3.10 The impact of owning an epileptic dog on owners’ free tim e............................ 99
Figure 3.11 The influence of pet insurance to owners in considering the cost of further 
investigation is worthwhile in group with AED therapy.................................. 101
Figure 3.12 The influence of pet insurance to owners in considering the cost of further 
investigation is worthwhile in group without AED therapy............................ 102
Figure 4.1 The positions of the cut-off points on the VAS in the bias-eliminated calibration 
versus the discrete seven-point scale (labelled A to G )....................................... 116
X ll
ACKNOWLEDGEMENTS
I would like to thank Dr. James Anderson who, as my supervisor, provided constant 
support, guidance, and patience throughout the undertaking of this study. Many thanks to 
Dr. Dominic Mellor, Dr. C.E. Thomson, Dr. Ian Ramsey, Ms Clare Knottenbelt, Dr. Paul 
Wotton for their advice in questionnaire design. I thank the owners for their help with this 
project. Many thanlcs to Sam Long for his contribution to the management of most cases, 
as well as providing his encouragement and patience through my study in Glasgow.
I would like to thank my parents, sisters, and Ted for great support. Special thanks to 
Mariana Perez Fontan, as my best friend in Glasgow, has contributed so much to my 
enjoyment of my time in Glasgow.
X lll
DECLARATION
I, Ya-Pei Chang, do hereby declare that the work carried out in the thesis is original, was 
carried out by myself or with due acknowledgement, and has not been presented for the 
award of a degree at any other university.
CHAPTER ONE
INTRODUCTION AND THE REVIEW OF LITERATURE
Introduction 2
1.1 SEIZURES AND EPILEPSY
1.1.1 Seizures
1.1.1.1 Definition
Seizures are transient and involuntary changes in behaviour or neurological status due to 
paroxysmal, functional disturbances of the forebrain caused by excessive and 
hypersynchronous electrical activity (March 1998; Thomas 2000). Depending on the 
localisation and extent of these discharges, impairment of consciousness, motor function, 
sensory perception, autonomic nervous system function, or behaviour may be observed in 
different types of seizures, as well as at different times in the course of a single seizure 
(Aird et al. 1984; Braund 1994; Oliver et al. 1997).
1.1.1.2 Phases of Seizure Activity
Seizure activity may be divided into components on the basis of elinical findings.
1.1.1.2.1 Prodrome
The prodrome is a long-term indication of a forthcoming seizure. Many human patients 
with generalised seizures experience headache, insomnia, irritability, mood changes, 
lethargy, unusual appetite and a variety of other symptoms for hours to days before a 
seizure. The longer the patient has had seizures the more likely he or she is to be able to 
recognize such prodromal signs (Laidlaw & Richens 1976; Thomas 2000). In a study of 
epilepsy and seizure classification in 63 dogs, 11% of dogs were described as exhibiting 
changes consistent with prodromal behaviour prior to the onset of seizures. In this study, 
signs lasted for between one and twenty-four hours, during whieh the dogs would try to be 
with owners, appeared anxious, were generally restless and expressed atypical behaviour 
e.g. chewing the carpet (Berendt & Gram 1999). The pathophysiology of prodromes is not 
well understood, but prodromes are not associated with abnormal electroencephalographic 
activity and are not part of the ictus (Thomas 2000).
1.1.1.2.2 Aura
The aura is that portion of the seizure which occurs before consciousness is impaired and 
thus is synonymous with a simple partial seizure, which may or may not develop to 
secondary generalisation. It may be that, as in mild partial seizures, the aura is the whole 
seizure (Commission on Classification and Terminology of the International League
introauction j
Against Epilepsy-ILAE 1981). The aura represents the initial abnormal discharge of a 
single group of neurons and usually lasts seconds to minutes (Laidlaw & Richens 1976). 
In human patients with epilepsy, the aura is often reflected clinically by a stereotyped 
sensation, e.g., sensory, visual, auditoiy, or vertiginous (Berendt & Gram 1999). Animals 
may appear restless, hyperexeitable, anxious, pace, liek unpurposefully, salivate 
inappropriately, hide without reason, or express attention-seeking behaviour (Podell 1996; 
March 1998).
1.1.1.2.3 Ictus
The ictus is the main part of the seizure event. The ictus is characterised by involuntaiy 
muscle tone or movement and/or abnormal sensations or behaviour and usually lasts from 
seconds to minutes (Podell 1996). Classifications of seizure type are based on presenting 
symptoms and electroencephalographic changes during ictus and aura.
1.1.1.2.4 Postictal period
The postictal period is the period immediately following the ietus and represents transient 
clinical abnomialities in brain function that are caused by the seizure activity (March 1998; 
Thomas 2000). The length of the postictal phase varies from minutes to days. There is no 
correlation between the severity of the seizure and the duration, nature, or severity of the 
postictal phase (DeLahunta 1983). Animals may exhibit unusual behaviour, disorientation, 
inappropriate urination/defaecation, excessive or depressed thirst and appetite and specific 
neurological deficits of wealcness, blindness, or sensory and motor disturbances (Podell 
1996). Postictal paralysis or Todd’s paralysis refers to the transient paralysis that may 
occur following some partial seizures with focal motor components or with somatosensory 
symptoms (Commission on Classification and Terminology of ILAE 1981). There is 
presently no reliable way to determine clinically whether focal wealaiess after a seizure is 
because of postictal paralysis or because the patient developed secondary cortical 
ischaemia (Fiser & Schachter 2000).
1.1.1.2.5 Interictal period
The interictal period is the time between resolution of any postictal signs and the beginning 
of the next ictus (Thomas 2000).
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1.1.1.3 Seizure Intensity
There are several terms used to describe the intensity of seizure activity. Isolated seizures 
are seizures with an interictal period over 24 hours (Podell 1996). Cluster seizures (serial 
seizures, acute repetitive seizures) are two or more seizures occurring over a brief period 
(minutes to 24 hours) but with the patient regaining consciousness between the seizures. 
Status epilepticus has been defined as a seizure that persists for a 20 to 30 minutes, based 
on the duration thought necessary to induce irreversible brain damage. However, as 
isolated seizures rarely last longer than a few minutes, a more clinically applicable 
definition of status epilepticus is a continuous seizure lasting at least 5 minutes, or two or 
more discrete seizures without full recovery of consciousness between seizures (Thomas 
2000). Status epilepticus is a medical emergency and requires urgent intensive treatment 
to reduce neurological injury (Laidlaw & Richens 1976; Platt & McDonnell 2000).
1.1.1.4 Type of Seizure
According to the International Classification of Epileptic seizures (ICES) (Commission on 
Classification and Terminology of ILAE 1981) seizures can be classified into three broad 
categories: partial seizures, generalised seizures and unclassified seizures (Table 1.1).
Table 1.1 Summary of the International Classification of Epileptic Seizures
I. Partial seizures
A. Simple partial seizures (consciousness not impaired)
1. With motor symptoms
2. With somatosensory or special sensory symptoms
3. With autonomie symptoms
4. With psyehie symptoms
B. Complex partial seizures (eonsciousness impaired)
B.l. Simple partial onset followed by impairment o f consciousness 
With features as in A 1-4 
With automatisms t  
B.2. With impairment of consciousness at onset 
With features as in A 1-4 
With automatisms
C. Partial seizures seeondarily generalised
II. Generalised seizures
A, Convulsive seizures
Tonic-elonie seizures 
Tonic seizures 
Clonic seizures 
Myoclonic seizures 
Atonie seizures
B. Nonconvulsive seizures
Absenee seizures
III. Unelassified seizures
t  Automatisms are deseribed as “eoordinated adapted involuntary motor aetivity occurring during 
the state o f clouding of eonsciousness either in the course of, or after a seizure”.
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1.1.1.4.1 Partial seizures
Partial seizures originate in a small group of neurons that constitute a seizure focus 
(Westbrook 2000). Partial seizures are classified as simple partial seizures (without 
alteration of consciousness) or complex partial seizures (with impaired consciousness). 
Impaired consciousness is defined as the inability to respond nomially to externally applied 
stimuli by virtue of altered awareness and/or responsiveness. There is considerable 
evidence that simple partial seizures usually have unilateral hemispheric involvement and 
only rarely have bilateral hemispheric involvement; complex partial seizures, however, 
frequently have bilateral hemispheric involvement (Commission on Classification and 
Terminology of ILAE 1981).
The symptomatology of partial seizure depends on the location of the focus within the 
brain (Westbrook 2000), In patients with complex partial seizures, aberrations of 
behaviour (automatisms) may occur (Commission on Classification and Terminology of 
ILAE 1981); jaw snapping, fly-biting, chewing or swallowing movements, gastrointestinal 
signs, vocalisation, running, hiding, tail chasing, aggressive behaviour have been described 
(Crowell-Davis et al. 1989; Dodman et al. 1992; Dodman et al. 1996). Impaired 
consciousness may be the first clinical sign of a partial seizure, or the neuronal discharges 
in a simple partial seizure may spread to those area involved in maintaining consciousness, 
resulting in a complex partial seizure (Commission on Classification and Terminology of 
ILAE 1981; Thomas 2000). Both simple and complex partial seizures may generalise. 
This spread may occur so rapidly that the initial focal component is not observed. 
However, with close observation, including videotaped review of the seizures, it has 
become apparent that many dogs with idiopathic epilepsy suffer partial seizures with 
secondary generalisation (Thomas 2000).
1.1.1.4.2 Generalised seizures
Generalised seizures are those in which the first clinical changes indicate initial 
involvement of both hemispheres (Commission on Classification and Terminology of 
ILAE 1981). Generalised seizures are subdivided into convulsive and nonconvulsive 
events. Generalised convulsive seizures are the most common seizure type seen in 
veterinary medicine and are characterised by impaired consciousness coupled with bilateral 
motor signs of either a tonic-clonic, tonic, clonic, myoclonic, or even atonic nature (Podell 
1996).
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In a generalised tonic-clonic seizure, the first part of the ictus is the tonic phase, during 
which there is sustained contraction of voluntary muscles. The animal typically loses 
consciousness and falls to its side in opisthotonus, with the limbs extended. Muscles 
associated with respiration are also affected and irregular respiration usually occurs, which 
may lead to secondary cyanosis. The tonic phase lasts for a minute or so and progresses to 
the clonic phase, during which there is rhythmic contraction of muscles, which is 
manifested as paddling or jerking of the limbs and chewing movements. The clonic phase 
lasts a variable period of time but usually no more than several minutes (Thomas 2000). 
During the ictus, the autonomic nervous system may be disturbed, which leads to the signs 
of salivation, urination and defecation. In a tonic seizure, motor activity consists only of 
generalised muscle rigidity, without a clonic phase. Clonic seizures are less common, in 
which there is no tonic component. Atonic seizures consist of a sudden and often brief loss 
of muscle tone, and myoclonic seizures are characterised by brief shock-like contractions 
that may be generalised or confined to individual muscle groups (Commission on 
Classification and Terminology of ILAE 1981; Thomas 2000).
The major form of nonconvulsive seizure activity is the absence seizure manifested as 
impaired consciousness only (Podell 1996). In man, these are charaeterised by a sudden 
onset interruption of ongoing activities, a blank stare and possibly a brief upward rotation 
of the eyes (Commission on Classification and Terminology of ILAE 1981). Absence 
seizures are poorly documented in animals (Podell 1996).
1.1.1.4.3 Unclassified seizures
The category o f unclassified seizures should be used only when it is impossible to classify 
seizure because of a lack of adequate information (Commission on Classification and 
Terminology of ILAE 1981).
1.1.2 Epilepsy: Definition, Classification and Causes
Epilepsy refers to a chronic brain disorder characterised by recurrent seizures (Knowles 
1998; Thomas 2000). Epilepsy can be classified into three categories: idiopathic, 
symptomatic and cryptogenic. Idiopathic epilepsies are those in which there is no 
identifiable brain abnomiality other than seizures; in human medicine, they are defined by 
age-related onset, clinical and electroencephalographic characteristics, and a presumed 
genetic aetiology. Symptomatic epilepsies are considered the consequence of an 
identifiable cerebral lesion or other specific disease o f the central nervous system.
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Potential causes of symptomatic epilepsy are listed in Table 1.2 (page 7) (Oliver et a l  
1997; Thomas 1998; Thomas 2000). Cryptogenic epilepsy refers to recurrent seizures that 
are presumably symptomatic, but for which the aetiology is not Imown (Hopkins et a l  
1995; Berendt & Gram 1999; Thomas 2000). In veterinary epilepsy nomenclature, 
cryptogenic epilepsy has been rarely mentioned. Most authors define idiopathic epilepsy 
as seizures with no identifiable brain abnormality and the diagnosis is made by ruling out 
extracranial and intracranial causes (DeLahunta 1983; March 1998). In this review the 
common definition in veterinary medicine is used.
Table 1.2 Causes of symptomatic epilepsy
Anomalous Hydrocephalus
Lissencephaly
Degenerative Storage diseases
Neoplastic Primary brain tumor 
Metastatic brain tumor
Inflammation Viral: canine distemper, rabies 
Bacterial: any type
Fungal: cryptococcosis, coccidioidomycosis
Protozoal: toxoplasmosis, neosporosis
Rickettsial: ehrlichiosis. Rocky Moutain spotted fever
Granulomatous meningoencephalitis
Necrotising encephalitis
Steroid responsive meningitis-arteritis
Traumatic (head injury)
Vascular Intracranial haemorrhage 
Brain infarction
A reactive seizure is defined as a reaction of the normal brain to transient systemic insult or 
physiological stress (Podell et a l 1995; Berendt & Gram 1999; Thomas 2000). A patient 
with recun'ing reactive seizures is not defined as having epilepsy because no primary 
chronic brain disorder underlies the seizure activity (Podell 1996). Potential causes of 
reactive seizures are listed in Table 1.3 (page 8) (Collins 1994; O'Brien 1998).
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Table 1.3 Causes of reactive seizures
Metabolic
Immune
Toxic
Alkalosis
Hypoglycaemia
Hypoxaemia
Hyperosmolality: hypernatraemia, nonketonic hyperosmolar diabetes mellitus
Hyponatraemia
Hypocalcaemia
Hypercalcaemia
Hepatic encephalopathy
Renal encephalopathy
Hyperlipidaemia
Polycythaemia
Hypothyroidism
Allergy
Toxins
Drug toxicoses
Animal toxins
Caffeine and other methylxanthines
Hydrocarbons and petroleum distillates
Lead and other heavy metals
Mycotoxins
Pesticides
Plant toxins
Antibiotics: metronidazole, penicillins, cephalosporins 
Anticholinergics
Antihistamine and phenothiazines
5-Fluorouracil
lodinated contrast agents
Ketamine, phencyclidine and other dissociated anesthetics
Lidocaine
Methylxanthines
Nonsteroid anti-inflammatory drugs: ibuprofen, salicylates
Piperazine
Sympathomimetics
Tricyclic antidepressants
Withdrawal of sedatives, hypnotics or anticonvulsants
1.1.3 Functional Aspects of the CNS Related to Seizure Activity
1.1.3.1 General Principles and Basic Mechanisms of Neuronal Excitability
1.1.3.1.1 The action potential
Neuronal excitability is a function of active and selective distribution of ions across cell 
membranes. In the resting state, the neuron is polarised with the inside of the cell being 
more negative than the outside of the cell. Intracellular fluid contains a high concentration 
o f potassium and low concentration of sodium, calcium and chloride and the reverse is true 
for the extracellular fluid. The resting membrane potential (RMP) of approximately 
-70mV is maintained by selective permeability o f the plasma membrane to certain ions, the
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retention of more anions intracellularly than extracellularly and by an energy-dependent 
sodium-potassium pump (Aird et ah 1984).
A change in the permeability of the cell to sodium and/or calcium results in an influx of 
positive charge and a state of depolarisation and generates an excitatory postsynaptic 
potential (EPSP). If the plasma membrane becomes selectively permeable to the chloride 
anion, it results in an influx of negative charge and a state o f hyperpolarisation and 
generates an inhibitory postsynaptic potential (IPSP). The same hyperpolarisation is 
achieved if outward potassium channels are activated (Fiser & Coyle 1991; March 1998). 
The neuron integrates the EPSPs and IPSPs in a manner determined by neurotransmitters 
and neuromodulatory substances acting on the dendritic zone and reaches a state of net 
depolarisation or hyperpolarisation. Neuronal membrane potential is dependent on a 
balance of excitatory and inhibitory forces determined by glutamate, gamma-aminobutyric 
acid (GABA) and a multitude of other neuromudulatory substances acting on neurons (see
1.1.3.1.2 Neuro transmitters, page 9). If the net depolarisation is greater than the threshold, 
an action potential is generated at the axon initial segment region and propagates down the 
axon to the axon terminal or presynaptic site. Activation of voltage-sensitive calcium 
channels here leads to neurotransmitter release. If the neuron is glutamatergic, glutamate is 
released. The released neurotransmitter traverses the synaptic cleft and activates 
postsynaptic receptor(s) on the dendrite of another neuron (March 1998). Both released 
glutamate and GABA are inactivated by uptake into neurons and glia through a sodium- 
dependent, high affinity transport process (Fiser & Coyle 1991; Westbrook 2000).
1.1.3.1.2 Neurotransmitters
There are over 100 neurotransmitters or neuromodulators which are Imown to play roles in 
the system of neuronal excitation. Amongst these, glutamate is the most important 
excitatory neurotransmitter and GABA is the most important inhibitory neurotransmitter 
(Hopkins et al. 1995).
Glutamate and its receptors
Glutamate mediates most excitatory postsynaptic potentials in the CNS; consequently, 
excitatory amino acid receptors have become Imown as “glutamate receptors”. There are 
three major subtypes o f glutamate receptors: kainate (KA), a-amino-3-hydroxy-5- 
methylisoxazole-4-propionic acid (AMPA) and N-methyl-D-aspartate (NMDA), named 
according to the types of synthetic agonists that activate them (Westbrook 2000). The KA
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and AMP A receptors primarily open sodium channels in the membrane (non-NMDA 
channels) (March 1998).
The NMDA receptor subtype has a different role. Under normal physiological conditions, 
magnesium ions produce a block of the NMDA channel. This block is voltage-sensitive so 
that if the neuron depolarises to 10-30mV, magnesium ions are extruded and the channel 
becomes open to the influx of calcium and sodium ions, which results in further 
depolarisation. Calcium influx into neurons also initiates a multiplicity of neuronal 
changes. Amongst these events are changes in second messenger processes critical to 
long-term potentiation and physiological processes related to learning and memory. 
Excessive calcium in the intracellular environment can lead to cell injury and death. The 
voltage-sensitive blockade decreases the response to NMDA at resting membrane 
potentials with sensitivity being restored at depolarised potentials. Thus, an NMDA- 
mediated component of an EPSP is small at resting potentials and maximal during periods 
of sustained neuronal activity and contributes to greater membrane depolarisation (Fiser & 
Coyle 1991; Hopkins et a l  1995).
GABA and its receptors
GABA is the predominant inhibitory neurotransmitter of the cortex and other forebrain 
structures, and its actions at the GABA receptor result in the generation of an IPSP (March 
1998). Recent studies indicate that there are two subtypes o f GABA receptors; denoted 
GABAa and GAB As.
The GAB A A receptor complex is a macromolecular entity with numerous components, 
including a GABA binding site, a chloride channel and several positive and negative 
modulatory sites sensitive to benzodiazepines, barbiturates, beta-carbolines, picrotoxin, 
penicillin and zinc. Binding of GABA to the postsynaptic GABAa receptors changes the 
postsynaptic membrane’s permeability to ions, such as chloride, calcium and potassium; 
however, chloride permeability changes are most significant (Fiser & Coyle 1991). The 
intracellular concentration of chloride is about 15-fold lower than the extracellular 
concentration. Equilibrium potential for chloride ions is usually slightly negative to the 
resting membrane potential (Fiser & Coyle 1991; Hopkins et a l  1995). The opening of 
chloride channels leads to chloride influx, and therefore produces hyperpolarisation and a 
decrease in the state of excitability of the cell (Hopkins et a l  1995; Kandel & Seigelbaum 
2000). Opening of the chloride channel in the GABAa receptor-channel complex can be 
modulated by several factors in addition to binding of GABA to the receptor. For example.
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the GABAa receptor appears to desensitise with continued exposure to G ABA. This 
phenomenon may be important in the origin and spread of neuronal activity associated with 
seizure development (Fiser & Coyle 1991). Numerous substances can influence the 
probability of the channel opening at the GABAa complex, including agonists and 
antagonists. Benzodiazepines and barbiturates are of major clinical importance as 
modulators of the GABAa receptor complex. Representatives o f each of these classes of 
compounds increase the potency of GABA-mediated inhibition (Fiser & Coyle 1991; 
Hopkins et al. 1995) (see 1.4.1.3 Mechanisms of Action of the AEDs, page 32).
The receptors involved in mediating GABA’s presynaptic inhibition are termed GABAb 
receptors. In spinal ganglia cells, GABAb receptor activation reduces calcium influx, 
which in turn reduces (excitatory) neurotransmitter release into the synaptic cleft. 
However, the functions of GABAb receptor in the brain may not be the same as in spinal 
ganglion. The activation of the GABAb receptor opens the potassium channels. Since the 
potassium equilibrium potential of neurons (E’k = -80mV) is always negative to the resting 
potential, the opening of potassium channels leads to an outward (hyperpolarising) 
potassium current (Kandel & Seigelbaum 2000).
1.1.3.2 Basic Mechanisms of Epileptogenesis
The mechanisms of epileptogenesis are not well understood. The pathogenesis of epilepsy 
is multifactorial. Seizures are a symptom of disordered brain function and represent the 
end-point of many different pathological pathways (Avanzini et a l 1992; Podell 1996). 
The pathophysiology of partial seizure and generalised seizure are different (Westbrook 
2000). Most of the current Icnowledge of epilepsy derives from studies of partial seizures 
or partial seizures with secondary generalisation, following structural cerebrocortical 
damage. Minor changes in brain circuits or neuronal properties can give rise to partial 
seizures (March 1998).
1.1.3.2.1 Partial seizure
The defining feature of partial seizures is that the abnormal electrical activity originates 
from a seizure focus. This seizure focus is a small collection of neurons that exhibit 
enhanced excitability. Enhanced excitability may result from many different factors, such 
as altered cellular properties or altered synaptic connections caused by a local scar, blood 
clot, or tumour (Westbrook 2000). It is suggested that the development of focal 
epileptogenic discharges in a population of neurons is due to the interaction of several
Introduction 12
factors: (a) the existence of intrinsic membrane properties which lead to burst-generating 
capacities in specific subsets of neurons, (b) the reduction of inhibitory control 
mechanisms, and (c) excitatory coupling among neurons o f an epileptogenic region 
(Avanzini et a l  1992). The phases in the development o f a partial seizure can be 
arbitrarily divided into the interictal period, followed by neuronal synchronisation, seizure 
spread and finally, secondary generalisation (Westbrook 2000).
Intrinsic burst generation in neurons within a seizure focus
Experimental studies of partial seizures have revealed that individual neurons within an 
epileptic focus have a stereotypic and synchronised electrical response termed the 
paroxysmal depolarisation shift (PDS). Compared with the typical EPSP, the PDS consists 
of a sudden, large (20-40mV), long-lasting (50-200ms) depolarisation, which triggers a 
train of action potentials at the peak of the PDS (Hopkins et a l  1995; Westbrook 2000). 
Both influx of calcium through voltage-gated calcium channels and influx of sodium 
through non-NMDA and NMDA receptor gated channels are believed to give rise to the 
PDS (March 1998). The NMDA receptor gated channel is particularly suited to enhance 
excitability because its contribution is increased by membrane depolarisation and it allows 
Ca^’*’ to enter the neuron (Westbrook 2000). During the interictal period, the PDS is 
followed by an after-depolarisation spike hyperpolarisation (after-hyperpolarisation, AHP). 
Voltage- and calcium-dependent outward potassium currents, as well as feedback 
inhibition of the neuron (both GABAA-receptor mediated IPSPs and GABAg-receptor 
mediated activation o f outward potassium currents), contribute to this hyperpolarising 
event (March 1998; Westbrook 2000).
Most neurons normally do not exhibit PDS behaviour. However, pyramidal neurons in 
lamina V of the cerebral cortex and in the CA3 area of the hippocampus are described as 
exhibiting this bursting characteristic under normal physiological conditions (Avanzini et 
a l  1992; March 1998; Westbrook 2000; Ure & Perassolo 2000). Nonnally, intact 
inhibitory systems prevent excessive excitation o f the adjacent zones (March 1998).
Many factors can influence the excitability of neurons within the seizure focus. Injuries to 
the brain appear to change the intrinsic membrane properties, which alter the input-output 
relationships of single cells, making them intrinsically more excitable and capable of firing 
at higher frequencies during depolarisation (Avanzini et a l  1992). Changes in glutamate 
receptor type, number, spatial distribution and/or sensitivity are found after an injury. 
Following neuronal damage, voltage-gated calcium channels may become abnoiTnally
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sensitive and the sodium-potassium pump may become dysfunctional. Pump failure results 
in partial membrane depolarisation, activation of both voltage-gated calcium channels and 
NMDA receptor-mediated channels and enhanced neuronal excitability (March 1998).
As long as the PDS is restricted to approximately 1000 neurons that constitute the seizure 
focus, there are no clinical manifestations (Westbrook 2000). The synchronised activity of 
multiple neurons produces marked regional extracellular negativity due to an influx of 
positive ions into the depolarising neurons. This can be detected at the surface of the skull 
and underlies the interictal spike or sharp on the electroencephalogram (Hopkins et a l 
1995).
Breakdown o f  surrounding inhibition
During the interictal period, the PDS is confined to the seizure focus by the after­
hyperpolarisation. As mentioned above (see Intrinsic burst generation in neurons within a 
seizure focus, page 12), the after-hyperpolarisation is partly generated by feedback 
inhibition of the neuron (Westbrook 2000). Post-synaptic inhibition, mediated by release 
of G ABA, is powerful and widespread in cortical circuits and serves as a control 
mechanism that prevents development of synchronous epileptiform discharge (Avanzini et 
a l 1992). Inhibition circuits include “feedback inhibition” and “surrounding inhibition” or 
“lateral inhibition”. In feedback inhibition, activated pyramidal neurons excite inhibitory 
interneurons, which then feedback to inhibit the pyramidal neurons that had caused them to 
be activated. In surrounding inhibition, in addition to inhibiting neighbouring neurons, 
many interneurons also send an extensive network of collateral axons to pyramidal neurons 
in adjacent cortical zones, resulting in the formation of an unexcitable area outside the 
primary excited zone and restricting the lateral spread of epileptiform activity across the 
cortex (March 1998).
Computer modelling of neuronal networks suggests that only small decrements of 
inhibition are required to make a system discharge excessively. Inhibition is a dynamic 
process, which is altered with use (Hopkins et a l 1995). Repetitive activation of cortical 
circuits causes a depression of synaptic inhibition in normal brain tissue through decreases 
in the IPSP due to increased intracellular chloride concentration and presynaptic inhibition 
of GAB A release (Avanzini et a l 1992). In addition, the GABAa receptor appears to 
desensitise with continued exposure to G ABA (Fiser & Coyle 1991). In a teleological 
sense, it is an advantage to reduce inhibition in a pathway under heavy use. If the decrease 
o f inhibition is excessive, it may result in seizures (Hopkins et a l 1995). Injuries to the
Introduction 14
brain can lead to both morphological and functional loss of inhibition, which includes loss 
of GABAergic neurons and synapses (the breakdown of feedback and surrounding 
inhibition), reduced cerebrospinal fluid (CSF) and tissue G ABA concentrations, and 
decreased GAB A receptor expression and sensitivity (Avanzini et a l  1992; March 1998). 
All of these factors make inhibition less effective and, in turn, cause increased activity in 
excitatory circuits, activation of latent excitatory connections, and increased triggering of 
burst discharges (Avanzini et a l  1992),
Changes in excitatory neuronal connectivity
The number of recurrent excitatory connections in a population of neurons is a vital 
element in the development of epileptogenesis. For example, cortical injury might lead to 
epileptogenesis through development of new recurrent excitatory circuitry due to axonal 
sprouting (Avanzini et a l 1992). Damaged excitatory axons or excitatory axons that have 
lost their postsyiiaptic neurons may sprout new axon collaterals that form abnormal 
connections with other excitatory neurons or with the dendritic processes of the excitatory 
neuron itself (March 1998).
Factors related to synchronisation
A  dynamic enhancement of synaptic excitability due to recurrent activity in excitatory 
circuits may be a critical factor in epileptogenesis. Augmentation o f glutamate-induced 
postsynaptic effects, especially in NMDA receptors, would increase EPSP amplitudes, 
enhance the PDS and generally increase neuronal excitability (March 1998). Changes in 
the density and distribution of glutamate receptor subtypes on postsynaptic neurons and 
alterations in the NMDA subtype of glutamate receptors are also found following repetitive 
seizures (Avanzini et a l  1992).
Large increases in extracellular potassium commonly occur after excessive neuronal 
activity, mainly due to the outward movement of potassium during repolarisation. 
Defective potassium uptake by astrocytes and dysfunction of the sodium-potassium pump 
may also be involved in increasing extracellular potassium (March 1998). Increased 
extracellular potassium directly depolarises neighbouring axon terminals and reduces 
outward potassium currents during the hyperpolarisation following PDS, leading to longer 
duration PDS. Increases in extracellular potassium also interfere with transport of chloride 
out of neurons and indirectly depresses synaptic inhibition (Avanzini et a l 1992). Poor 
glutamate uptake by dysfunctional or energy-deprived astrocytes causes high
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concentrations of glutamate to accumulate at excitatory synapses, with subsequent 
excessive activation o f postsynaptic glutamate receptors (March 1998). Other
synchronising mechanisms include burst discharges in the axonal terminal arborisations of
neurons, electrical interactions between groups of tightly packed cells (ephaptic
interaction) and direct conduction of currents from cell to cell through non-chemical 
synapses (gap junctions) (Avanzini et a l 1992).
Regional spread and diffuse generalisation o f epileptiform activity
If inhibition is reduced, other neuronal aggregates are excited through different pathways. 
Successful recruitment of a critical number of areas with synchronised depolarisation leads 
to a seizure (Podell 1996). The spread of epileptiform activity from the focus generally 
follows the same pathways as normal cortical activity. Generalisation of a partial seizure 
to ipsilateral and contralateral cortical areas occurs along intra- and interhemispheric 
pathways (Westbrook 2000). An important mechanism of secondary generalisation 
involves thalamocortical circuits. Excitatory events in the cortex result in depolarisation of 
thalamocortical axon terminals. Antidromic activity in these axons causes excitation of 
thalamic nuclei, which subsequently project back to multiple cortical areas. Orthodromic 
activation of corticothalamic fibres also contributes to thalamic recruitment. Activation of 
the midbrain reticular formation may also promote secondary generalisation due to its 
Imown diffuse projection back to the cerebral cortex (March 1998).
Interictal -Ictal Transitions
Six steps lead from focal epileptogenesis to clinical epilepsy: (1) the generation of 
enhanced physiological responses; (2) PDS (observed as interictal spikes on EEG); (3) 
focus spread to perifocal neurons; (4) the utilisation or breakdown of control mechanisms 
within brain circuits that limit the propagation of seizure discharges via preferred routes of 
spread; (5) the appearance of secondary foci in regions synaptically linked to the primary 
focus; (6) the emergence of clinical seizures (Ure & Perassolo 2000).
Reasons for transition from interictal discharges to ictal episodes associated with clinical 
signs of seizures are unlmown (Avanzini et a l 1992). A combination of increased NMDA 
receptor function and depressed GABAergic transmission due to reduced release of G ABA 
and receptor desensitivisation may well be responsible for the onset of a clinical seizure 
(Ure & Perassolo 2000).
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Other factors involved in interictal-ictal transition might be the release of substances that 
cause long-term increase in neuronal excitability through activation of intracellular second 
messenger systems, coupled to changes in the conductance of membrane ion channels 
(Avanzini et ah 1992). The decrease or blockade of potassium currents produced by 
acetylcholine increases neuronal excitability and depresses the after-hyperpolarisation 
(AHP) that normally follow repetitive discharges, and thus it may result in higher firing 
frequencies (Fiser & Coyle 1991; Avanzini et a l 1992). Serotonin, although generally 
viewed as more inhibitory than excitatory, also has the effect o f AHP blockade (Aird et a l 
1984; Fiser & Coyle 1991; Avanzini et a l 1992). Other factors contributing to 
synchronisation, such as non-synaptic mechanisms, may also be important for interictal- 
ictal transitions (Avanzini et a l  1992).
1.1.3.2.2 Generalised seizure
A primary generalised seizure shows simultaneous disruption of normal brain activity in 
both cerebral hemispheres from the onset (Westbrook 2000). The discharge 
synchronisation mechanisms generating this seizure type are poorly understood (Ure & 
Perassolo 2000). A “centrencephalic” concept has been proposed, in which paroxysmal 
discharges arise from brain stem and project to the cerebral cortex (March 1998). 
FurtheiTnore, in generalised tonic-clonic seizures, the discharge synchronisation 
mechanisms of the tonic phase may correlate with epileptogenic circuits in the brain stem 
and the clonic phase may relate to the limbic system (Ure & Perassolo 2000). However, 
cun*ent theories focus on the cerebral cortex as the primary generator of generalised tonic- 
clonic seizures (Niedermeyer 1996).
The generalised nature strongly indicates a diffuse cerebrocortical problem. However, the 
brain can dynamically change over time even if the original epileptogenic area was focal 
(March 1998). EEG recordings in human patients with primary generalised epilepsy have 
revealed that bilateral synchrony is not precise and small time differences exist between 
discharges from each side (Niedermeyer 1996). Studies of idiopathic epilepsy in Labrador 
Retrievers have found an initial asymmetry in epileptifomi activity (Heynold et a l 1997). 
It may be possible that, in patients with primary generalised seizures, an early subclinical 
hyperexcitable focus gradually induces hyperexcitability of neurons in other cortical and 
subcortical areas over time through the process of activity-dependent long-term 
potentiation (see 1.1.3.2.4 Long-term effects of epileptic activity, page 18) (March 1998).
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The pathogenesis of generalised epilepsy may arise from morphological abnormalities or 
functional defects. In morphological abnormalities, multifocal (e.g., cortical dysplasia) or 
diffuse changes in neurons or their connectivity may be present (Hopkins et al. 1995), and 
recuri'ent and anomalous excitatory connections between these groups of neurons have 
been hypothesised to lead to the diffuse paroxysmal epileptiform discharges. Functional 
defects at neurochemical or cellular level can affect the cerebral cortex diffusely. In 
idiopathic epilepsy, a generalised neurotransmitter imbalance due to abnomialities of 
synthesis, release, or re-uptake probably plays an important role (March 1998). Decreased 
G ABA concentrations and increased glutamate concentrations in the CSF were found in 
dogs with idiopathic epilepsy (Podell & Hadjiconstantinou 1997). This suggests that 
altered G ABA and glutamate values might be indicative of a state of chronic over 
excitation in the brain of dogs with idiopathic epilepsy, although whether this finding is a 
cause or consequence of recun'cnt seizures is unknown. Deficits at the synaptic, membrane 
receptor and ion channel level (ion channelopathy) could alter intrinsic neuronal 
excitability. A diffuse dysfunction of ligand or voltage-gated ion channels could also 
predispose to seizures (March 1998).
1.1.3.2.3 Seizure termination
The factors that determine seizure duration and termination are not completely understood. 
Reduction of presynaptic glutamate release, restoration o f sodium-potassium ATPase 
pump and inhibitory system function are necessary for seizure termination (March 1998). 
The release o f transmitters may be depleted with ongoing stimulation. In addition, 
prolonged exposure to glutamate produces a reduction o f the depolarising response of a 
neuron (Fiser & Schachter 2000).
Intracellular acidification may be another factor resulting in termination of epileptiform 
discharges. During seizure activity, neurons accumulate hydrogen ions, resulting in 
acidification of the intracellular environment (Xiong et al. 2000). Hydrogen ions compete 
with other ions at the ion channel associated with NMDA. This competition may partially 
attenuate NMDA receptor and channel-mediated hyperexcitability. The pH shift 
associated with neuronal activity serves as a local feedback signal due to the marked pH 
sensitivity of many ion channels, enzymes and even receptors. Thus, intracellular 
acidification may be an important restraining force preventing neuronal activity from 
reaching concentrations that threaten the integrity of normal brain function (Fiser & 
Schachter 2000).
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Increased extracellular potassium after a seizure also affects brain excitability. In general, 
mild increases in potassium lead to hyperexcitability, but increases to concentrations 
greater than 20-30 mM produce a spreading depression and cessation of neuronal activity 
(Fiser & Schachter 2000; Xiong et al. 2000).
The neuromodulator adenosine is another key compound in inhibiting the initiation and 
continuation of seizure activity, as well as regulating the postietal state (Avanzini et al. 
1992; Fiser & Schachter 2000). Adenosine has prominent inhibitory actions on synaptic 
transmission. During a seizure, adenosine is released in large quantities (Avanzini et al. 
1992). In addition, adenosine A1 receptor density increases after repeated seizures in 
young rats. Both of these represent an attempted control mechanism for the seizures (Fiser 
& Schachter 2000).
Prolonged seizure activity (status epilepticus) can cause deleterious physiological changes, 
including hypertension, tachycardia, hypoglycaemia, acidosis and hyperthermia. The 
initial physiological response is a massive release of adrenaline and noradrenaline into the 
eireulation (Platt & McDonnell 2000). Respiratory compromise due to convulsive activity 
of muscles associated with respiration can cause cyanosis and acidosis (Thomas 2000). 
The release of systemic lactate during generalised convulsive activity also contributes to 
acidosis. However, although hyperthermia, hypoxia, hypertension and acidosis play a role 
in creating neuronal damage, the ongoing seizure activity also contributes substantially to 
neuronal damage (Platt & McDonnell 2000). Excessive stimulation with the release of 
glutamate causes NMDA receptors to open cation channels to calcium, leading to 
excessive increase in intracellular calcium. Increased intracellular calcium can activate a 
self-destructive cellular cascade involving many calcium-dependent enzymes, such as 
phosphatases, proteases and lipases. Lipid peroxidation can also cause production of free 
radicals, which damage vital cellular proteins and lead to cell death (Westbrook 2000).
1.1.3.2.4 Long-term effects of epileptic activity
As mentioned previously (see Breakdown of surrounding inhibition, page 13 and Factors 
related to synchronisation, page 14), recurrent activity will potentiate excitatory synapses 
and depress inhibitory synapses over time. Activity-dependent synaptic plasticity refers to 
the enhancement of synaptic strength (increased EPSP amplitudes) after periods of 
recuri'ent activity. A use-dependent increase or long-term potentiation of NMDA receptor 
efficacy is believed to occur during normal processes, such as learning and memory, but 
this may also occur during epileptogenesis (March 1998). Furthermore, changes in the
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density and distribution of glutamate receptor subtypes on postsynaptic neurons and 
alterations in the NMDA subtype of glutamate receptors are also found following repetitive 
seizures (Avanzini et a l 1992),
Mirror Focus
Interictal cortical spiking may propagate via association tracts to the homologous region of 
the opposite hemisphere and evoke secondary spiking. If this secondary spiking becomes 
independently active, it is called a mirror focus and may persist even after the primary 
focus becomes inactive (March 1998).
Kindling
Kindling refers to a phenomenon related to both development of epilepsy and to the nonnal 
physiological processes concerned with learning and memory, in which the short, 
intermittent and subthreshold electrical stimulation of a brain structure induces a 
progressive inerease in brain exeitability (Aird et a l 1984; Avanzini et a l  1992; Hopkins 
et a l  1995). Kindling is a process in which, following the initial subconvulsive stimuli, a 
nonepileptic region of the brain evokes electrical discharges, which become more 
extensive and prolonged with repeated stimuli and develop seizure activity. Once present, 
the enhanced sensitivity to electrical stimulation is lifelong (Westbrook 2000; Najm et al. 
2001). NMDA receptor activation seems to play a major role in kindling. Also, many 
neurotransmitters or neuromodulators are probably involved, e.g. G ABA, norepinephrine, 
serotonin and aeetyleholine. Sprouting, axonal growth and synaptic reorganisation have 
been described in the kindled structure. Such plasticity would be likely to involve seeond 
messenger system (Avanzini et a l 1992).
A combination of the effects mentioned above in a patient which continues to have 
seizures would increase the number of areas of the brain able to initiate a seizure. 
Consequently, the suceessful medical management of such a patient may be more 
challenging (Podell 1996).
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1.2 EPIDEMIOLOGY OF IDIOPATHIC EPILEPSY
Idiopathic epilepsy is the most common cause of recurrent seizures in dogs (Podell et a i
1995). The reported prevalence in different breeds ranges between 0.5 percent and 4.1 
percent (Kathmann et al. 1999). Most dogs with idiopathie epilepsy (75 to 90 pereent) 
exhibit generalised tonic-clonic seizures with loss of consciousness. Other types of 
seizures, including simple and complex partial seizures and partial seizures with secondary 
generalisation, have been reported; some patients have more than one type of seizures 
(Jaggy & Bernardini 1998; Thomas 2000).
1.2.1 Age and Gender
The first seizure in dogs with idiopathic epilepsy usually oceurs between the age of six 
months and five years of age and most commonly between one and three years of age 
(Heynold et a l 1997). Oeeasionally, dogs outside the expected age range are affected 
(ICnowles 1998). According to other reports, the first seizure occurs between the age of 
two months and ten years, with approximately 50 percent to 60 percent of cases between 
one and three years old (Podell et a l  1995; Heynold et al. 1997; Jaggy & Bernardini 1998; 
Kathmann et al. 1999).
Male dogs have been reported to be slightly more affected than female dogs in most studies 
(Thomas 2000). Recent studies of genetic aspects in single breeds have revealed different 
results. In Labrador retrievers. Golden retrievers and Belgian tervueren, males and females 
were equally affeeted, and in Bernese mountain dogs, males were significantly more 
affected than females (Jaggy et al. 1998; Kathmann et a l 1999; Famula & Oberbauer 
2000).
1.2.2 Genetic Aspect of Idiopathic Epilepsy
In most breeds suspected of having a genetic basis for epilepsy, evidence for heritability is 
based on encountering recurrent generalised seizures in dogs of eertain breeds more 
frequently than those breeds appear in the general population (Knowles 1998). However, 
the exact mode of inheritance has not been defined (Jaggy et a l  1998). Those breeds of 
dogs whieh have been reported to have a genetic factor or high incidence of idiopathic 
epilepsy include the Beagle, Belgian Tervuren, Keeshond, Dachshund, Gemian shepherd 
dog (Alsatian), Labrador retriever. Golden retriever, Bernese mountain dog. Border Collie, 
Scottish shepherd dog, horaks laborhound, toy poodle. Cocker spaniel, Irish setter.
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miniature schnauzer, Siberian husky, St Bernard, wire haired fox terrier and boxer (Falco 
et al. 1974; Cunningham & Fambaeh 1988; Famula et al. 1997; Knowles 1998; Jaggy et 
al. 1998; Kathmann et al. 1999; Famula & Oberbauer 2000; Quesnel 2000).
A pedigree analysis in keeshonds suggests that the predisposition to idiopathic epilepsy in 
this breed appears to be determined by a single autosomal recessive gene (Hall & Wallace 
1996). Results of pedigree analyses in Labrador retrievers and Bernese mountain dogs 
support the hypothesis that idiopathic epilepsy has a polygenic, recessive mode of 
inheritance in these two breeds of dogs (Jaggy et al. 1998; Kathmann et al. 1999). In 
addition, the clinical expression of idiopathic epilepsy is variable in terms of onset, 
frequency and severity of seizures. Therefore, other factors that trigger seizures must play 
a role. Seizures in dogs with idiopathic epilepsy may be triggered concomitantly by 
internal stress including mental tension and physical stress. Studies in retrievers have 
shown that a multifactorial mode of inheritance, ineluding both genetic as well as 
environmental factors, could be responsible for the transmission and expression of 
idiopathic epilepsy (Heynold et al. 1997). Furthermore, some differences were noticed 
between Labrador retrievers and Bernese mountain dogs. It was found that, in Bernese 
mountain dogs, the offspring of epileptic parents had a significantly earlier onset of 
seizures than the offspring of healthy parents. In addition, males were significantly more 
affected than females. It was concluded that idiopathic epilepsy in Bernese mountain dogs 
might have a different mode of inheritance compared to retriever breeds. The variable 
expression of the disease is probably influenced either by modifier genes or an additive 
gene effect (Kathmann et al. 1999).
Studies in the Belgian tervueren suggest that, although in this breed seizures have a 
complex pattern of inheritance, a single major locus model with a general effeet on seizure 
expression is likely. A single putative locus with a large effect appears to increase the risk 
of seizures with homozygous individuals exhibiting seizures and heterozygotes having an 
increased susceptibility to seizure. The data also support the concept that seizure disorders 
are likely to be polygenic (Famula et al. 1997; Famula & Oberbauer 2000). However, 
additional objective test-mating programmes would be neeessary to define the exaet mode 
of inheritanee (Jaggy et al. 1998; Kathmann et al. 1999).
In the case of canine idiopathic epilepsy, genetic factors are largely presumed to influence 
a patient’s basic threshold of seizures (Knowles 1998). In the threshold value model, each 
animal inherits a genetically detemiined predisposition to seizures and, if a certain 
threshold of stimulation is exceeded, seizures may occur (Cunningham & Fambaeh 1988).
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The genetic mechanisms involved in a predisposition to seizures are not clearly
understood. Based on the hypotheses outlined above, it is likely that different modes of
inheritanee and expression may exist between breeds, possibly refleeting different
aetiologies. Such factors may result in differences in the clinical expression of disease in 
terms of onset, frequency and severity of seizures, as well as responses to standard 
treatments between breeds.
1.3 DIAGNOSTIC EVALUATION
The diagnosis of idiopathie epilepsy is based on the ruling out of other extracranial and 
intracranial diseases that may cause seizures. No positive diagnostic finding can 
substantiate the diagnosis (Oliver et al. 1997).
1.3.1 Signalment
As described above (see 1.2.1 Age and Gender, page 20), the first seizure in dogs with 
idiopathic epilepsy usually occurs between the age of six months and five years, but dogs 
outside the expected age range can also be affected. Certain breeds of dogs have been 
described as having a high incidence of idiopathic epilepsy, although idiopathie epilepsy 
can occur in any breed of dogs.
1.3.2 Clinical History
Acquiring a thorough and accurate history is important in approaching a seizure case. The 
first group of questions includes general health details and information related to familial 
history of seizures, vaceination status, travel, trauma and toxin exposure potential, previous 
medical and surgical treatment (including anaesthetics), evidence of allergy (especially 
food allergy) and drug administration (Podell 1996). The next group of questions relates to 
seizure activity and the first issue to be addressed is whether the patient is having seizures. 
The major differential diagnostic consideration is paroxysmal or syncopal disorders listed 
in Table 1.4 (page 23) (Podell 1996; Feldman & Nelson 1996; Knowles 1998; Thomas 
2000). Infonnation related to seizure type, duration, frequency, preictal phase, postictal 
phase and trigger factor should be recorded. The status of the patient’s cerebrocortieal 
function between seizures should be ascertained, looking for evidence of abnormalities 
such as behavioural changes, visual disturbanees and gait abnomialities. The existence of
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interictal signs is strongly indicative of structural cerebral problems (Podell 1996; Thomas
2000).
In a study of seizure classification in 50 dogs from a nonreferral-based population, a 
diagnosis of idiopathic epilepsy was statistically more probable when the dog was between 
1 and 5 years o f age at the first seizure, when the dog was a large breed (> 15 kg), when the 
seizure occurred between 8 AM and midnight, or when the interval between the first and 
second seizure was longer than 4 weeks. A diagnosis o f symptomatic epilepsy was 
statistically more probable when the dog was less than 1 or more than 7 years old at the 
first seizure, when the first seizure was a partial seizure, or when the first seizure occurred 
between midnight and 8 AM. A diagnosis of reactive seizures was statistically more 
probable only when the interval between the first and seeond seizure was shorter than 4 
weeks (Podell et a l 1995).
Table 1.4 Differential diagnosis of nonepileptic paroxysmal disorder and weakness
Neuromuscular disorders
Myasthenia gravis 
Narcolepsy or cataplexy
Normal or abnormal movements during sleep, rapid eye movement sleep disorder
Vestibular dysfunction
Tremor disorders
Canine distemper myoclonus
Behaviour disorders (stereotype)
Tetanus
Discospondylitis
Idiopathie polyradiculoneuritis (Coon Hound paralysis)
Polymyositis
Polyarthritis
Idiopathie polyneuropathy 
Pain (e.g., cervical disc disease)
Cardiovascular disorders
Congenital: anatomical defects
Acquired: tachyarrhythmias or bradyarrhythmias, bacterial endocarditis 
Neoplasm: haemangiosarcoma 
Coagulopathy (warfarin-induced)
Metabolic disorders
Polycythaemia
Hypoadrenocorticism
Hyperviscosity syndrome
Phenochromocytoma
Normal insulin, hypoglycaemia
Anaemia
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1.3.3 Physical Examination
A thorough physical examination is important to detect signs of systemic illness that might 
suggest an underlying cause for seizures (Thomas 2000). The information from physieal 
examinations also helps to differentiate seizures from nonepileptic paroxysmal disorders. 
In addition, funduscopic examination may provide indireet evidence of active or inactive 
systemic infections, optic nerve oedema, retinal haemorrhage, or optic nerve infiltration 
(Knowles 1998).
1.3.4 Neurological Examination
A complete neurological examination should be performed to detect any persistent 
neurological deficits. Cerebral lesions often cause focal and relatively subtle deficits such 
as proprioceptive deficits in one side or blindness in one visual field (Thomas 2000). 
Other cranial nerve function tests are also important as other cranial nerve deficits may 
suggest a multifocal or diffuse problem. When performing a neurologieal examination 
shortly after a seizure, any deficits (usually generalised), such as ataxia, depression, or 
blindness, may be a result of postictal disturbances, such as postictal paralysis or Todd’s 
paralysis(see 1.1.1.2.4 Postictal period, page 3), and may not indicate underlying brain 
disease. If focal or generalised deficits are detected, the examination should be repeated in 
24 to 48 hours to differentiate postictal effects from persistent interictal deficits (Knowles 
1998; Thomas 2000).
1.3.5 Laboratory Investigation
Complete blood counts, platelet count, standard biochemical profile and urinalysis are 
usually perfomied. Results of these investigations help to rule out extracranial causes for 
seizures and also provide baseline values for assessing possible side effects o f antiepileptic 
drug therapy (Knowles 1998). Further metabolic screens, such as serum bile acid 
concentrations, thyroid function tests, lead concentrations and serum antibody tests for 
toxoplasmosis, neosporosis and canine distemper virus, should be performed if the history 
and/or examination are suggestive (Thomas 2000).
1.3.6 Intra-cranlal Imaging
The purpose of intra-cranial imaging in epilepsy is to screen for potential intracranial 
disease as a potential cause of seizure activity. Brain imaging in epilepsy ean be divided
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into structural or functional imaging (Hopkins et al. 1995). Cun'cntly in veterinary 
medieine, the emphasis is on structural brain-imaging modalities, which include computed 
tomography (CT) and magnetic resonance (MR) scanning. In human medicine, besides 
structural imaging, functional imaging plays an important and growing role in the clinical 
assessment and research investigation of patients with epilepsy. Techniques include single 
photon emission eomputed tomography (SPECT), positron emission tomography (PET), 
functional MR imaging (fMRI) and magnetic resonance speetroscopy (MRS). Epilepsy is 
particularly challening from an imaging interpretation perspective as, in addition to fixed 
abnormalities, transient abnomialities related to interictal electroencephalographic spikes 
or seizures may be detected with a variety of functional imaging techniques (Richardson
2001).
1.3.6.1 Structural Imaging
Computed tomography is a specialised radiographic technique that generates transverse 
images (Oliver et al. 1997). It utilises a series of narrow, highly collimated X-ray beams 
that pass through the patient and are collected by an aiTay of sensitive detectors. The X-ray 
souree is rotated around the patient to produce multiple projections of the same anatomical 
region (Braund 1994). CT exeels in the detection of osseous changes within the cranium. 
Modern CT scanners can differentiate the ventricular system, the grey and white matter of 
the cerebral cortex, the thalamus and the basal nuelei.
The principles of interpretation of CT scans and conventional radiography are similar. 
Changes in size, shape, position, density and margins of organs determine the presence of 
abnormalities (Braund 1994). Distortion of the lateral ventricles, midline shift of the falx 
cerebri and displacement of brain parenchyma are typical findings in many brain lesions 
(Tueker & Gavin 1996). Lysis or proliferative lesions in bones of the calvarium also help 
ascertain the presence of a lesion (Braund 1994). Abnormal brain tissue is described as 
hyperdense, isodense, or hypodense relative to normal surrounding brain tissue. 
Pathological conditions that cause hyperdense areas within the brain parenchyma include 
mineralisation, haemoii'hage, increased cellularity and scar tissue formation. Oedema and 
aeute haemorrhage cause hypodense areas within or around the brain (Tucker & Gavin
1996). Further visual enhancement of blood vessels, organ parenchyma and lesions can be 
accomplished with intravenous injection of iodinated contrast agents during imaging. The 
use of contrast media usually enhances the meninges, choroid plexus and the pituitary 
gland beeause their capillaries are fenestrated and permit passive diffusion of contrast 
medium into the suiTounding parenchyma. Contrast medium does not normally enter the
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brain parenchyma because of the blood brain bam er (BBB). After intravenous 
administration, iodine leaks out of damaged capillaries and outlines the vascular portions 
o f the lesion (Braund 1994). Lesions with relatively homogeneous eellularity and 
vascularity show a uniform enhancement pattern. A heterogeneous or ring pattern of 
enhancement is associated with lesions lacking cellular uniformity or undergoing foeal 
necrosis and haemorrhage (Tucker & Gavin 1996).
In human medicine, structural imaging with MR is the dominant technique in the routine 
clinical investigation of patients with epilepsy (Richardson 2001). MR imaging is based 
on detecting the electromagnetic emissions of hydrogen nuclei after a strong magnetic field 
is applied and released (Tucker & Gavin 1996). The number of hydrogen protons and their 
local chemical environment affect the signal received by the MR seanner and ultimately 
determine the appearance of the image (Braund 1994). MR imaging improves 
differentiation within soft tissues with similar density (improved contrast resolution); 
however, dense bone and air laek signals for imaging because of the inability of the 
protons to relax in the dense bone matrix and the relative lack of hydrogen nuclei in air. 
Two principal forms of image, termed T l- and T2-weighted, are produced (Oliver et al.
1997). Air and cortical bone appear dark on both T l- and T2-weighted images. Fluid 
(oedema, CSF) appears dark on Tl-weighted images and bright on T2-weighted images. 
Most lesions result in an increase in fluid within the lesion and/or oedema in suiTOunding 
brain parenchyma and thus appear bright on T2-weighted images (Braund 1994). The 
most commonly used contrast agent is the paramagnetic element gadolinium (Gd) in the 
form of gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA). The contrast agent 
acts in a manner similar to the iodinated contrast agents used in CT. The main differenee 
is that MR does not visualise the gadolinium but produees an image of the protons that 
their relaxation are influenced in the presence of Gd (Tucker & Gavin 1996). After 
contrast medium administration, many brain lesions are enhanced on Tl-weighted images 
and the bright area can be differentiated from the surrounding dark-appearing brain 
oedema (Braund 1994).
1.3.6.2 Functional Imaging
Imaging of cerebral blood flow with SPECT and imaging o f cerebral metabolic rate with 
18-flurodeoxyglucose (*^FDG) PET are widely used in human epilepsy centres. Other 
techniques, such as MRS, fMRI and neuroreceptor imaging studies with both PET and 
SPECT, are in occasional clinical use, are undergoing clinical development, or have been 
used in researeh studies (Richardson 2001).
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SPECT has been the most widely used functional imaging technique in epilepsy. This 
technique uses isotope-labelled tracers to image the distribution of cerebral blood flow. In 
addition, there have been a few studies of specific receptors in the brain (benzodiazepine 
receptors). Cost, availability and ability to image ictal events are the advantages of this 
technique; relatively low resolution, lack of quantification o f measured parameters and 
relatively limited choiee of measurable variables are the disadvantages (Hopkins et a l 
1995; Richardson 2001).
Some principles of PET are similar to those of SPECT, but PET relies on short-lived 
positron-emitting isotopes and on simultaneous deteetion o f pairs of photons. 
Quantification and high resolution have been strengths of PET in comparison with SPECT. 
Blood flow, metabolic rate and a very wide range of receptor, enzyme and transporter 
parameters can be measured accurately and with high spatial resolution (Hopkins et a l 
1995; Richardson 2001).
Functional imaging is said to give better results than structural imaging in patients with 
partial seizures in terms of latéralisation and localisation, and the results of functional 
imaging appear to correlate better with clinical and electrophysiological data. However, 
these teehniques may be demonstrating the effects and not the cause of epilepsy in some 
cases (Hopkins et a l  1995). The presence of a focal abnomiality in the brain of a patient 
with epilepsy may give rise to a reorganisation of the topographical representation of 
cortical functions, which may be of research interest or may be o f clinieal importanee when 
mapping essential functions prior to resective surgery. It is essential that all functional 
imaging studies should be interpreted with reference to high-quality high-resolution MR 
structural imaging (Richardson 2001).
1.3.7 Cerebrospinal Fluid Analysis
If imaging is non-diagnostic, CSF should be collect for analysis. CSF should not be 
collected if increased intracranial pressure is suspected or such anaesthetic techniques that 
may reduce intra-cranial pressure should be used and the owner appraised of the potential 
risk. Removal of CSF from eerebelloniedullai'y or lumbar cistern causes a pressure 
gradient, and herniation of the cerebellum through the foramen magnum and/or herniation 
of the temporal cortex trough the tentorial notch may occur (Oliver et a l  1997). Spaee- 
occupying lesions, including neoplasms and abscesses, haemon'hage, noneommunicating 
hypertensive hydrocephalus, cerebral oedema associated with brain injury and generalised 
brain inflammation, can cause increased intracranial pressure (DeLahunta 1983). Thus,
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perfomiing imaging prior to CSF collection to rule out potential causes of increased 
intracranial pressure is necessary for decreasing the risk of CSF collection.
One ml per 5 kg of body weight of CSF can be safely removed (Chrisman 1992). Basic 
CSF analysis includes cell-counts, cytology and total protein concentration. Analysis 
should be performed within 30 minutes of eollection for aceurate cell counts and cytology 
because CSF cells deteriorate rapidly (Oliver et a l 1997). If CSF analysis reveals 
abnormalities, CSF culture, titres for infectious causes of encephalitis, protein 
electrophoresis and/or Immunoelectrophoresis may be helpful (Chrisman 1992; Thomas 
2000).
1.3.8 Electroencephalography
1.3.8.1 Electroencephalography and Epilepsy
Electroencephalography (EEG) is a record of the spontaneous eleetrical activity of the 
cerebral cortex (Holliday 1999). In human medicine, EEG remains a test of fundamental 
importance in epilepsy as it provides unique funetional information. In patients with an 
established seizure disorder, the EEG findings may help to eonfirm the diagnosis of 
epilepsy, assess the type of epilepsy, identify a lateralised epileptogenic focus, indicate the 
most appropriate medication that should be prescribed, provide a guide to prognosis and 
provide a means to doeument the course of the disorder. In patients with behavioural or 
other disturbances that could be epileptie in nature but over which there is some 
uncertainty, the presence of paroxysmal discharges on EEG increases considerably the 
likelihood that attacks are indeed epileptic (Hopkins et a l  1995). Although EEG generally 
only records electrical potential at the scalp surface, a number of techniques have been 
devised to allow a three-dimensional reconstruction of the origin of EEG electrical activity 
(source loealisation). These teehniques have a number of inherent assumptions and 
disadvantages. Therefore, in the situation of pre-surgieal evaluation, invasive electrode 
studies or functional imaging are often used to add further anatomical information 
(Richardson 2001).
1.3.8.2 Electroencephalography in Veterinary Medicine
In veterinary medicine, a number of articles dealing with the technical aspects of EEG, or 
case reports using EEG as a diagnostic aid in the diagnosis of canine epilepsy, have been 
published (Srenk & Jaggy 1996; Jaggy & Bernardini 1998; Holliday & Williams 1998). In 
addition, the use of EEG to link episodic abnormal behaviour and seizure activity has been
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reported (Breitschwerdt et a i 1979; Crowell-Davis et al. 1989; Dodman et al. 1992; 
Dodman et al. 1996). Veterinary EEG technique has been adapted from the aeeepted 
human “international 10-20 system” of electrode placement on the scalp and subsequently 
modified (Berendt et al. 1999). Certain characteristies in skull anatomy and the nature of 
animals substantially affeet the use of EEG in veterinary medicine.
The frontal sinus, which is located chiefly between the outer and the inner tables of the 
frontal bone, interrupts the EEG reeording from frontal lobe of cerebral cortex. As the size 
and form of the frontal sinus are dependent on skull form and age, the locations of EEG 
electrodes need to be modified in different ages and breeds of dogs. In addition, the facial 
and substantial masticatory muscles have the potential to generate muscle potentials during 
EEG recording, which are the most common and often the most troublesome artefaets 
observed. Muscle activity causes intermittent or continuous relatively high frequency 
activity that can partially or completely obscure background rhythms (BGR) (Holliday
1999).
Unlike EEG recording in humans, animals usually require restraint to perform the 
proeedure. Artefacts caused by movements of the patient and by muscles in the region of 
the recording electrodes are significant problems in non-sedated patients (Holliday 1999). 
Different protocols for sedation or anaesthesia for EEG recording have been deseribed to 
resolve the problem. However, certain anaesthetic agents ean induee spikes and other 
drugs can suppress spikes thus confusing interpretation (Srenk & Jaggy 1996; Holliday & 
Williams 1998; Holliday 1999). Chlorpromazine (2 mg/kg intravenous injection) has been 
reported to increase the incidence of interictal paroxysmal discharges in epileptic dogs 
(Redman et al. 1973). Although it has similar phamiacologieal characteristics, 
acepromazine has not been established as having a similar effect (Holliday & Williams 
1998).
There is a body of veterinary neurologists who prefer to perfonn EEG recording in dogs 
with sedation as they believe that the use of anaesthesia is best avoided as it is likely to 
mask significant abnomialities. Furthermore, sedative drugs in doses sufficient to render 
the animal drowsy when undisturbed minimise or eliminate diffieulties with movement and 
muscle artefacts and permit recording during all stages of sleep, which is an important part 
of the protocol (Holliday 1999). There is another group of neurologists who prefer to 
reeord EEG in dogs under general anaesthesia (medetomidine for premedication and 
propofol for anaesthesia). Based on the observations of a transient pattern of paroxysmal 
discharges (spindles) with asymmetrical distribution, it was concluded those findings
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reflect neuronal discharges caused by epilepsy, rather than aetivity induced by anesthetic 
agents (Srenk & Jaggy 1996).
1.3.8.3 Interictal Paroxysmal Discharges
The reeording of EEG during the patient’s clinical episodes may be particularly helpful in 
determining whether the episodes are indeed seizure disorder in nature and whether they 
have a focal or lateralised origin (Hopkins et al. 1995). As episodes usually occur 
unpredictably, the likelihood of obtaining ictal recordings is not high unless prolonged 
recordings are made or episodes are provoked. However, even if a episode can be 
recorded, as mentioned above, the EEG recording may be so obscured by muscle and 
movement artefacts that little useful information ean be gained from it (Holliday 1999).
The interietal EEG reeording is potentially abnormal in epileptie dogs and may exhibit 
features that help to establish the diagnosis. Possible findings inelude paroxysmal 
discharges and are composed of one or more of the following in epileptic dogs: spikes, 
multiple spike eomplexes, sharp waves, multiple sharp-wave complexes, spike-and-slow- 
wave complexes (Holliday & Williams 1998). Such epileptiform activity may be focal, 
multifocal, or diffuse and may appear unilaterally or bilaterally; if  bilaterally, it may be 
synehronous or asynchronous and symmetrical or asymmetrical (Aminoff 1986).
The routine EEG may be normal in some patients with epilepsy and may, also, 
occasionally show apparent epileptifonn changes in people with no history of epilepsy 
(Hopkins et al. 1995). In human studies, epileptifonn activity has been observed in the 
initial EEG of 2.2-4% of patients without seizures (Aminoff 1986). The probability of 
demonstrating abnormal interictal epileptiform activity in a human patient increases with 
the number of EEG recordings in the individual patient. Approximately 50% of the 
patients demonstrated abnormal epileptifonn activity in the first EEG reeording, increasing 
to 84% by the third and to 92% by the fourth recording (Berendt et al. 1999). In studies of 
EEG in dogs with epilepsy, abnonnal EEG activity was identified in the first EEG in 65- 
86% of the dogs and no paroxysmal discharges were found in healthy dogs (Jaggy & 
Bernardini 1998; Berendt et al. 1999), The proximity of a seizure to the EEG examination 
may influence the amount of epileptiform activity present in the EEG. The closer the 
examination to a seizure and/or the higher the seizure frequeney, the greater the probability 
that EEG findings will be positive (Berendt et al. 1999).
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EEG has been suggested to be a valuable diagnostic aid in confirming a clinical diagnosis 
of canine epilepsy by some veterinary neurologists. In addition, results from some studies 
show that similarities exists between dogs and humans with epilepsy (Berendt et a l 1999). 
However, veterinary EEG teehnique has not been standardised and different veterinary 
neurologists use different modifications of human electrode placements, EEG montages 
and anaesthesia protocols. Due to these factors, comparing the results from different EEG 
laboratories and assessing the value of EEG in canine epilepsy is difficult.
1.4 ANTIEPILEPTIC DRUG THERAPY
1.4.1 General Principles of Antiepileptic Drug Therapy
Once a diagnosis of idiopathic epilepsy has been established, the decision on whether 
antiepileptic drug (AED) therapy should be instigated is based on the frequency and 
severity of the animal’s seizures, as well as the owner’s needs and willingness to comply 
with recommendations for treatment regimens and monitoring (Lane & Bunch 1990). The 
ideal outcome of AED therapy for patients with epilepsy is to be seizure-free without side 
effeets. However, in human medicine, even with the advent o f new AEDs, a significant 
number of people with epilepsy still eannot achieve this goal (Glauser & Pippenger 2000). 
A more realistic goal is perhaps to decrease the number o f seizures, the severity of 
individual seizures and postictal complications to a level that does not substantially 
compromise the quality of life for the dog and family, whilst avoiding serious side effects 
associated with the use of AED therapy (Podell 1996; Thomas 2000). Most authors agree 
that one isolated seizure every 6 to 8 weeks is acceptable and seizure control represents a 
50% deerease in seizure frequency without concomitant AED intoxication (Knowles 
1998).
1.4.1.1 When to Initiate Treatment
In general, it is not suggested to instigate AED therapy after the first isolated seizure in 
dogs, as evaluation of the underlying seizure pattern and any response to AED therapy will 
be compromised (Knowles 1998). In dogs with idiopathie epilepsy, AED therapy is 
usually started when (a) two or more isolated seizures have oceurred within a 6-week 
period, (b) two or more cluster seizure episodes oceur within an 8-week period, or (c) 
status epilepticus has occurred (Podell 1996). It should be remembered that a prolonged
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delay in starting AED therapy might result in progressive seizure activity associated with 
development of mirror foei and kindling, as mentioned above. In a long-term study of 
idiopathic epilepsy in 54 Labrador retrievers, the authours concluded that dogs with a low 
total number of seizures prior to treatment responded significantly better to phenobarbitone 
treatment (Heynold e? n/. 1997).
1.4.1.2 Owner Education
Proper owner education is an important factor in seizure management in companion 
animals. Owners must understand AED therapy is not curative and that seizure control 
does not equal elimination (Lane & Bunch 1990; Podell 1996). They must be informed 
that AED therapy may involve a lifetime, daily treatment regimen and that regular 
administration of medication is important. Potential side effects of AED therapy must be 
explained, including the potential deleterious effeets of long-term use and the mild side 
effects that commonly occur when first starting AED therapy, which may precipitate an 
alaimed owner to cease therapy prematurely (Thomas 2000). Owners should always be 
warned not to stop AED suddenly due to the risk of precipitating seizures. Regular re- 
evaluation and drug serum concentration monitoring are necessary and keeping a seizure 
diary, which includes the time, date and characteristics of each seizure, any side effects and 
other relevant eomments, is helpful in assessing seizure management (Lane & Bunch 1990; 
Knowles 1998). Finally, owners should be informed not to alter treatment without the 
advice of the veterinarian (Thomas 2000).
1.4.1.3 Mechanisms of Action of the AEDs
Antiepileptic drugs block seizure initiation and propagation by blocking abnormal events 
in a single neuron or the synchronisation of related neurons (Boothe 1998). Mechanisms 
of AED action can be classified into three broad categories: (a) enhancement o f inhibitory 
processes via faeilitated action of GAB A, (b) reduction of excitatory transmission and (c) 
modulation of membrane eation conductance. Binding of GABA, benzodiazepines or 
phenobarbitone to the GABAa receptor will result in inereased chloride permeability and 
subsequent membrane hyperpolarisation. Drugs that increase the availability of GABA to 
receptors by inhibition of degradation or re-uptake pathways will also enhance inhibitory 
neurotransmission. Reduction of excitatory neurotransmission can also be accomplished 
by altering glutamate-mediated neurotransmission. Drugs that block sodium channels 
prevent depolarisation of the presynaptic neuronal membrane and thus reduce release of 
the excitatory neurotransmitter glutamate. Some drugs may be able to block the function
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of the NMDA receptor and thus prevent post-synaptic depolarisation (Podell 1998). Drugs 
acting on more than one mechanism tend to be most effective (Boothe 1998). The 
probable main mechanisms of action o f antiepileptic drugs are listed in Table 1.5 (page 34) 
(Perucca 1996).
However, there is no clear correlation between the putative primary mechanism of action 
of different drugs and their effieacy in different seizure types. These inconsistencies may 
be explained by the fact that available information on mechanisms of action is still scarce 
and fragmentary, with many drugs probably having additional actions apart from those 
listed in Table 1.5 (page 34) (Perucca 1996).
1.4.1.4 Choice of Treatment
Criteria for selection of suitable AED for use in dogs includes: a preparation that can be 
administered two to three times per day, has documented efficacy and is well tolerated by 
the canine patient (Podell 1998). Several limitations exist in the selection of AEDs for use 
in veterinary medicine: (a) toxicity, (b) tolerance, (c) inappropriate pharmacokinetics, and 
(d) expense. Many AEDs that work directly at the sodium membrane ionic level to prevent 
neuronal depolarisation cannot be used in veterinary medicine because of either a high risk 
of toxicity or a short elimination half-life. Therefore, most drugs used in veterinary 
medieine are in the same mechanistie category and work by hyperpolarising the resting 
neuronal cell membrane (Podell 1996).
Monotherapy is the goal of treating dogs with idiopathic epilepsy to reduee possible drug- 
drug interactions and adverse effects (Podell 1998). There is little evidence of synergistic 
action amongst the AEDs and polytherapy has several potential disadvantages, including 
increased cost, the need to monitor and interpret serum concentrations of multiple drugs, 
potential drug interactions and more complicated dosing schedules (Thomas 2000). 
Usually, a drug given as monotherapy is titrated to a maximally tolerated dose before the 
decision is made to try another drug. If the dog responds to the seeond drug, the 
veterinarian should attempt to withdraw the first drug gradually and only if this is 
unsuccessful should polytherapy be continued (Thomas 2000; Deckers et a l 2000).
Introduction 34
ooo<N
I
Q
vo
g;
n
i
Q
<
fiI
o(/)s
•3fi
■gO)
g
"g
I
"S
I
I
I
B
a §=s
t g
<
o
o fcûp
1) -g
^ 1 1  o 3
§
I
f
I
II
i l
&
<gii
(4-1O
I
il
Oh X )
+
+
I
g-
Im
t
I
I
1
1
g
■gJII
il
î
•S
g
I
I>
<+H
0
1
PQ
(+H
O
I
6
I
§
1
g
Icd
II
3 ^ .
t
+
+
+
IIX,
g
X
<
i
g
I
X
I
I
o
î
s
+
î
+
g
I
I
g
I
ô
t
■sto
I
■*■(13z
1
I"o
i
+
+
î
■S î .
Il
1
ÜX0
1 
I
î
g
I
L
g
;3O x3
I ic3 <U
li
î
t
t
ât
■g
I I
I
I
I
>(tHO
I
m
Ii
o
g
+
t
t
i
Ii
I
g
i
o
g
I
î
cd}
•c
I
0XO
1
I
I
•st
0
1C3
ilc
I ^cO o
II
CTd
I
introauction 35
However, in one review of AED polytherapy based on mechanisms of action, it was 
concluded that the AED polytherapy with different meehanisms o f antieonvulsant action 
may in fact enhance effectiveness. In particular, combining a sodium channel blocker with 
a dmg enhancing GABAergic inhibition appears to be advantageous. Combining two 
GABA mimetic drugs or combining a kainate antagonist with an NMDA antagonist may 
enhance efficacy, but tolerability is sometimes reduced. Combining two sodium channel 
blockers seems less promising (Deckers et a l 2000). However, this approaeh eannot be 
fully applied with the current inadequate state of understanding of the pathophysiology of 
seizures in the eanine patient and the basic mechanisms of action o f AEDs (Perucca 1996).
1.4.1.5 Clinical Pharmacokinetics
Desirable pharmacokinetic properties for an AED include high oral bioavailability, 
negligible plasma protein binding, efficient penetration across the blood-brain barrier, a 
half-life compatible with once or twice daily dosing and linear kinetics. Lack of extensive 
biotransformation is also advantageous because it is normally associated with predietable 
kinetics and low susceptibility to drug interactions (Perucca 1996).
Most AEDs are well absorbed following oral administration, but food will slow the rate of 
absorption of some drugs (Boothe 1998; French & Gidal 2000).
The extent of protein binding has pharmacokinetie importance since it is the unbound 
fraction of the drug that readily crosses cell membranes during the processes of 
distribution, receptor interaction and renal or hepatic elimination (Perucca 1996). Most 
AEDs are lipid-soluble and are distributed to a volume that exceeds total body water (i.e., 
greater than 0.6 1/kg) (Boothe 1998). Protein binding, lipid solubility and degree of 
ionisation at physiological pH affect penetration of AED into CSF, which would influence 
the speed of onset of therapeutic effect (Perucca 1996). Lipid solubility is the most 
important factor that influences AEDs’ entry into CSF. At equilibrium, however, the CSF 
concentrations of these drugs are directly proportional to the non-protein-bound fraetion in 
the serum (Lane & Bunch 1990).
Because they are lipid-soluble, most AEDs must be eliminated by hepatic metabolism. 
Some reactive Phase I metabolites can interact with and damage sunounding tissues. 
Hepatotoxicity is a common effect of long-term use of AEDs metabolised by the liver 
(Boothe 1998). Any drugs metabolised by the liver can potentially influence drug 
metabolising enzyme systems and interactions are common. Some AEDs are enzyme
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inducers, some are inhibitors, whereas some are both, with the nature of the interaction 
depending on the drug and that with which it interacts (Glauser & Pippenger 2000). 
Hepatic inducers increase the synthesis of enzymes that are associated with a proliferation 
of hepatocyte smooth endoplasmic reticulum. Enzyme induction is a gradual, dose- 
dependent process, and the time to complete manifestation of an induction interaction 
depends on the half-life of the inducing drug and the synthesis rate o f the metabolising 
enzymes (French & Gidal 2000). An increased rate of drug metabolism will increase 
clearance and elimination half-life of many drugs in patients on chronic therapy (Boothe 
1998). Phenobarbitone is an auto-inducer, causing a progressive reduction in its own 
elimination half-life with long-term use (Podell 1996). Drugs that impair or inhibit drug 
metabolising enzymes, such as cinietidine, ketoconazole and chloramphenicol, will 
decrease drug metabolism of AEDs and thus potentially increase serum concentration 
(Boothe 1998).
After initiation of long-term oral therapy, drug accumulates in the body until the rate of 
clearance equals the rate of administration, at which point a steady-state equilibrium is 
achieved. The maintenance dose is the daily dose necessary to maintain steady-state 
equilibrium. Within one half-life, approximately 50% of a steady-state equilibrium is 
achieved and 97% occurs after five half-lives have elapsed (Boothe 1998). Complete 
steady-state equilibrium is achieved at the completion of seven half-lives (Glauser & 
Pippenger 2000). The full clinical effectiveness of an AED is not achieved, nor should it 
be evaluated, until steady state has been achieved after any dosage change (Glauser & 
Pippenger 2000). When therapeutic serum concentrations are required earlier, a loading 
dose can be administered. Simplistically, the loading dose is a sum of all the daily doses 
that would have been administered prior to steady-state concentration minus the amount 
that would be eliminated during this period (Thomas 2000). The major disadvantages of a 
loading dose o f an AED is that there is no time for tolerance to the sedative side effect to 
occur, thus, lethargy and ataxia occur more commonly than with gradual increases in drug 
concentration. Both loading and maintenance dose are based on population deposition 
parameters. Individual differences in drug elimination may result in therapeutic failure 
with either dosing regimen (Boothe 1998).
1.4.1.6 Therapeutic Drug Monitoring and AED Therapy
Variability amongst patients makes the relationship between dose and serum drug 
concentrations unpredictable for the individual patient (Boothe 1998). In addition, the 
correlation between the observed clinical effects of AEDs and their serum concentrations is
Introduction 37
much better than that between the AEDs’ observed clinical effects and total daily dose 
(Glauser & Pippenger 2000). Blood drug concentration monitoring can be selectively and 
appropriately utilised to help optimise drug administration, determine if tolerance is 
present, detect poor compliance and minimise side effects, especially when it may be 
related to patient-specific pharmacokinetic or pharmacodynamic problem (Podell 1998; 
Glauser & Pippenger 2000).
Clinical AED monitoring is useful in the following situations.
Establishing “baseline” effective concentrations
When the patient has achieved the goals of therapy, a trough serum concentration of AED 
should be obtained to document the serum concentration associated with the successful 
outcome (Boothe 1998). If the patient later develops breakthrough seizures or toxicity, 
repeat AED serum concentrations can be compared to an individual’s “baseline” 
previously effective non-toxic concentration to help determine the cause of the new 
problem (Glauser & Pippenger 2000).
Evaluating potential causes for lack of efficacy
In a large population, the distribution of AED serum concentrations after a fixed dose 
should be a bell-shaped curve. The vast majority of patients exhibit concentrations within 
the target range (mean ± 2SDs) expected from a dosage based on body weight. Patients 
with AED concentrations < mean - 2SDs for the fixed dose can be considered genetically 
“fast metabolisers” (Glauser & Pippenger 2000). Persistent, unusually low and variable 
serum concentrations may suggest a “fast metaboliser” or poor owner or patient 
compliance (Podell 1998; Glauser & Pippenger 2000). Detailed history and close 
supervision of AED intake help to distinguish between these two situations. AED serum 
concentrations increase sharply with a monitored AED intake at a constant daily dose in 
patients with noncompliance, whereas fast metabolisers demonstrate no change in serum 
concentrations (Glauser & Pippenger 2000).
Evaluating potential causes for loss of efficacy
The most common situation underlying a loss of AED efficacy is drug tolerance. It can be 
either metabolic or functional in nature and the relationship between drug dose and serum 
concentration helps to distinguish them (Podell 1998). Metabolic tolerance occurs with 
AEDs that are inducers of hepatic metabolising enzymes. The auto-induction allows a 
progressive reduction in elimination half-life with long-term use and higher doses are 
progressively needed to maintain the same therapeutic concentration (Podell 1996). With
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metabolic tolerance, there is no parallel increase in serum concentration as the dose 
increases. In contrast, with functional tolerance, there is a parallel increase in serum 
concentration as the drug dose increases (Podell 1998). The lack of response can develop 
for several reasons: (a) the BBB can develop altered transport mechanisms to limit drug 
entry into the brain, (b) phenobarbitone receptors in the brain can down-regulate with 
chronic exposure and (c) pathophysiological progression of brain pathology resulting in 
multiple seizure foci or changes in neurotransmission may lead to loss of drug efficacy 
(Podell 1996).
Administration of either multiple AEDs or a combination of AED and drugs for other 
conditions can modify any of the processes of absorption, metabolism, distribution and 
elimination, possibly resulting in complex interactions (French & Gidal 2000). Hepatic 
induction may be one of the impacts of drug-drug interaction. As discussed above, the rate 
of drug metabolism will increase clearance and elimination half-lives of many drugs if a 
patient receives continuous therapy with the inducing drug (Podell 1998; Glauser & 
Pippenger 2000).
Noncompliance is also a potential cause of loss of efficacy. A reduction in trough serum 
concentration of 20% or more is suggestive of a compliance problem (Podell 1998). In 
human medicine, breakthrough seizures in neonates, infants, young children and pregnant 
women can be due to altered or changing AED pharmacokinetics resulting from their 
physiological circumstances (Glauser & Pippenger 2000). In dogs, occasionally, unspayed 
bitches experience an increase in seizure frequency during oestrus. The same effect can 
happen in neutered dogs on oestrogen therapy for urinary incontinence (Knowles 1998).
Judging “ room to manoeuvre” or when to change AED therapy
In many cases of refractory epilepsy, inadequate dosages, incorrect dosing intervals or 
insufficiently high serum concentrations are the causes o f unacceptable seizure frequency 
(Knowles 1998). Peak and trough samples can be collected and used to calculate the AED 
half-life so that the dosing interval can be modified if  necessary (Boothe 1998). If a patient 
is titrated to and above a reasonable “target dose” and no response is seen, evaluation of a 
serum concentration may be helpful to determine the next step as whether increasing the 
dose of the AED should be considered or changing AED should be undertaken (Glauser & 
Pippenger 2000).
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Evaluating potential causes for toxicity
Patients with AED levels > mean + 2SDs for a fixed dose can be considered genetically 
“slow” metabolisers. They require lower doses of an AED to achieve the same plasma 
concentration and the desired therapeutic effect. Therapeutic drug monitoring facilitates 
identification o f the slow metabolisers, so their medication regimen can be appropriately 
adjusted to fit their individual metabolic patterns (Glauser & Pippenger 2000).
The normal process of maturation involves a large number of physiological changes that 
can dramatically alter drug utilisation. In human medicine, children utilise drugs at a faster 
rate than adults and therefore require more medication on a body-weight basis than adults 
to achieve the same therapeutic drug concentration. As the maturation process continues, 
the ability to bind drugs to plasma protein decreases. Geriatric patients often exhibit 
reduced rates of drug elimination and therefore require reduced drug dosages. Failure to 
adjust the therapeutic regimen to compensate for the associated physiological changes may 
result in exposure to unnecessary and prolonged drug toxicity (Glauser & Pippenger 2000).
Acute or chronic uraemia can dramatically decrease the elimination of a drug that is 
primarily dependent on urinary excretion, and renal failure can alter the protein-binding to 
albumin characteristics of many drugs (French & Gidal 2000). In both situations, the ratio 
of free drug to total drug concentration is high enough to produce a clinically evident toxic 
effect, even if the total serum drug concentrations are within optimal therapeutic range. 
Hepatic disease can extensively alter a given therapeutic response by impairing a patient’s 
ability to metabolise drugs. In all these situations, therapeutic drug monitoring provides 
means of accurately calculating and correcting dosage regimens to coincide with the 
disease status of the patient (Glauser & Pippenger 2000).
Drug-drug interaction is another potential cause of AED toxicity. In a patient receiving 
AED polytherapy and exhibiting side effects, therapeutic drug monitoring can assess which 
AED is most likely to be causing the problem (Glauser & Pippenger 2000). As mentioned 
above, drugs that impair or inhibit drug metabolising enzymes will decrease the 
metabolism of an AED and thus potentially increase the serum concentration of the drug 
(Boothe 1998). Protein-binding interactions commonly occur when two highly protein- 
bound drugs (>90% bound) are administered and compete for a limited number of binding 
sites. When one drug displaces another highly bound drug from its plasma protein-binding 
site, the free fraction may dramatically increase. The unbound drug is available to interact 
not only with pharmacological receptors but also with hepatic enzymes, thus total systemic
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clearance also increases. The net effect is difficult to predict and free serum drug 
monitoring may be useful (French & Gidal 2000).
Circumstances or intervals for measuring serum concentrations are summarised here: (a) at 
steady state when seizures are controlled, to establish baseline for future comparisons; (b) 
each time AED therapy fails to control seizures; (c) anytime following dose alteration, to 
establish a new steady state; (d) every 6 months, in order to detect changes proactively that 
might indicate potential therapeutic failure; and (e) for drugs that have a long half-life, 
blood concentrations should be monitored at one drug half-life and at steady state.
Sampling at one drug half-life is proactive since drug concentration will be only halfway to 
final steady-state concentration. If a loading dose is used, besides the two blood 
concentrations mentioned above, samples should be taken 1 or 2 days after loading dose. 
By comparing the post-loading dose blood concentration and that after one half life, failure 
to maintain the target concentration with the maintenance dose can be detected earlier 
(Boothe 1998). In general, trough serum concentrations should be measured if there is 
poor seizure control to determine if an inadequate dose is being given, and peak 
concentrations measured when there is a concern of drug toxicity (Podell 1998). Fasting 
samples are preferred as lipidaemia will render the results of many tests invalid (Boothe 
1998).
Special handling precautions are not necessary for samples intended for therapeutic drug 
monitoring. However, serum separator tubes should be avoided as silicon contained in 
these tubes may bind AED. These tubes should either not be used or serum should be 
withdrawn from the tubes immediately after centrifugation (Boothe 1998).
1.4.2 Antiepileptic Drugs
1.4.2.1 Phenobarbitone
Clinical use o f  phenobarbitone
Phenobarbitone is reported to be effective in 60% to 80% of dogs with epilepsy if serum 
concentrations of the drug are maintained within recommended therapeutic ranges (Boothe 
1998). The mechanism, pharmacokinetics and clinical use of phenobarbitone are detailed 
in Table 1.5 (page 34), Table 1.6, and Table 1.7 (page 44). The initial dose is 2-3.5 mg/kg 
every 12 hours with serum concentration measured after 2 weeks (Podell 1996; Podell 
1998; Boothe 1998; Thomas 2000). If seizures are not controlled, doses can be increased 
gradually until the maximum range has been reached or adverse effects become apparent
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(Boothe 1998). Two methods are suggested as to how to adjust the dose in such 
circumstances: (a) increase the dose 25% each time, (b) adjust the dose with the following 
formula in order to increase serum concentration by 5 gg/ml (Podell 1998; Boothe 1998).
Desired concentration
New total # mg daily = Cunont # mg daily x Actual concentration
Due to auto-induction, it is usually necessary to increase the initial dose to maintain a 
stable trough therapeutic serum concentration (Thomas 2000). In some patients, auto­
induction may eventually shorten the half-life to 36 hours or less and an 8-hour dosing 
interval may be necessary to minimise fluctuation of serum concentrations. Measurement 
o f both peak and trough concentrations is required to estimate current half-life (Boothe
1998).
In general, trough serum concentration is useful to determine if an inadequate dose is being 
given. Different serum concentration monitoring programs are suggested. In one program, 
it is suggested that trough serum concentrations are measured at 14, 45, 90, 180, 360 days 
after the initiation of treatment, at 6-month intervals thereafter and if a dog has more than 
two seizure events between these times (Podell 1998). Another program suggests that 
serum concentrations are measured at 2 weeks (peak and trough), at 8 to 12 weeks (trough) 
to detect induction, then 6-month intervals (trough) and when a dog has breakthrough 
seizures (peak and trough) (Boothe 1998). In one study of the effect of timing of blood 
collection on serum phenobarbitone concentrations, it was revealed that there is no 
therapeutically relevant change (defined as 30% change in this study) in serum 
phenobarbitone concentrations using the 12 hourly dosing interval in most epileptic dogs 
(91% of dogs with stable serum concentrations). Nine percent of dogs with therapeutically 
relevant changes in serum concentrations were found to have relatively short elimination 
half-lives (Levitski & Trepanier 2000).
Side effects o f  phenobarbitone
Polyphagia, polydipsia, polyuria, lethargy and sedation are the most commonly 
documented side effects of phenobarbitone (Podell 1996). Polyuria is primarily due to an 
inhibitory action on the release of antidiuretic hormone, however, dogs may develop an 
apparent psychogenic polydipsia with associated polyuria (Podell 1998; Boothe 1998). 
Sedation is the main dose limiting effect o f phenobarbitone, and hindlimb wealcness and 
ataxia may occur in some dogs (Boothe 1998; Thomas 2000). All these effects may be 
long lasting and may persist in some cases for the duration of treatment. However, often 
they resolve after 1 to 2 weeks of therapy (Boothe 1998).
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Hyperactivity and restlessness can occur, especially during the first few weeks of therapy 
(Thomas 2000). It is also described as an infrequent problem that appears not to be dose 
related and which will resolve typically within 1 week of starting the treatment (Podell
1996). In human medicine, it is reported that hyperactivity occurs in 50 to 80% of 
children, even with low serum phenobarbitone concentrations. This paradoxical effect has 
also been described in the elderly (Harden 2000).
As discussed above, in dogs, phenobarbitone is a potent hepatic microsomal enzyme 
inducer by causing proliferation of the hepatocyte endoplasmic reticulum, which in turn 
increases the synthesis of cytochrome P450 enzyme (French & Gidal 2000). The same 
mechanism can cause increased serum liver enzyme activation without causing actual 
hepatocellular damage or biliary stasis, making it difficult to distinguish increases caused 
by enzyme induction from those caused by hepatic disease during phenobarbitone 
treatment (Muller et a l  2000a). The extent of the enzyme-inducing effect on hepatic 
enzymes varies among individuals. A few studies of effects of long-term phenobarbitone 
on the liver in dogs revealed that alkaline phosphatase (ALP) and alanine transaminase 
(ALT) can increase significantly over long time, whilst y-glutamyltransferase (GGT) may 
increase transiently and albumin may decrease transiently. There are no significant 
changes in aspartate transaminase (AST), bilirubin and fasted bile acid (Chauvet et a l 
1995; Foster et a l 2000; Muller et a l 2000a). This suggests that ALP, ALT and GGT are 
of limited diagnostic value because of the effects of enzyme induction (Muller et a l 
2000a). The increased concentrations of ALT caused by enzyme induction are commonly 
smaller than those found after hepatocellular necrosis or bile duct occlusion (Dayrell-Hart 
et a l 1991; Muller et a l 2000a). Abnormal values for AST, serum albumin, total bilirubin 
and fasting bile acids in dogs treated with phenobarbitone cannot be attributed to the 
enzyme-inducing effect of the drug (Muller et a l 2000a).
Phenobarbitone can cause non-pathological changes in hepatic clinical laboratory tests, but 
hepatotoxicity is also a potential side effect (Boothe 1998). It is still unclear whether 
phenobarbitone-induced hepatotoxicity represents an idiosyncratic drug reaction or the 
extreme of a spectrum of toxicosis that develops in all dogs on chronic phenobarbitone 
treatment (Muller et a l 2000a). It is reported that a serum phenobarbitone concentration 
above 35 pg/ml had the highest correlation with the development of hepatotoxicity 
(Dayrell-Hart et a l 1991). Finding greater increases in ALT activity than in ALP activity 
might be useful in recognising hepatic toxicosis, but this only occuned in 50% cases in a 
report of 18 dogs with phenobarbitone toxicosis. In addition to hepatic function tests 
(sulfobromophthalein excretion, pre- and post-parandial bile acid concentrations, resting
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plasma ammonia concentration and ammonia tolerance test), toxicosis also can be 
associated with an increased serum concentration with unchanging dose (Dayrell-Hart et 
al. 1991). Hepatotoxicity may be reversible if detected early and the phenobarbitone is 
withdrawn, however, this adverse effect can be iiTeversible and ultimately fatal (Thomas 
2000). The incidence of serious hepatotoxicity can be reduced by avoiding combination 
therapy (of more than one drug metabolised by the liver), using therapeutic drug 
monitoring to achieve adequate serum concentrations at the lowest possible dose and by 
evaluation of clinical pathology every 4 to 6 months while the patient is on therapy 
(Boothe 1998).
It is also found that phenobarbitone treatment at therapeutic dosages in dogs can 
significantly decrease total thyroxine (TT4) and free thyroxine (FT4) after 5 weeks of 
treatment, and thyroid-stimulating hormone (TSH) may have a delayed compensatory 
increase after 27 weeks of treatment (Gaskill et al. 1999; Muller et al. 2000b). These 
changes are not necessarily associated with clinical signs of hypothyroidism or the degree 
of seizure control (Gaskill et al. 1999). Clinical trials evaluating the effects thyroid 
hormone supplementation in phenobarbitone-treated dogs with low serum T4 
concentrations have not been reported (Gaskill et al. 1999). Changes in markers of thyroid 
function (TT4, FT4 and TSH) can persist for 1 to 4 weeks after discontinuation of 
phenobarbitone. To avoid false positive results, it is recommended that thyroid testing 
should be performed at least 4 weeks after discontinuation of phenobarbitone 
administration (Gieger et al. 2000). In addition, in studies of effects of long-term 
phenobarbitone treatment on the adrenal axis and adrenal function tests in dogs, it revealed 
that phenobarbitone treatment does not affect the adrenal axis or two adrenal function tests, 
the ACTH stimulation test and low-dose dexamethasone suppression test (Chauvet et al. 
1995; Muller et al. 2000b).
Phenobarbitone has been associated with bone marrow dyscrasias causing depression of 
one or all bone marrow cell lines, which are rare side effects and may represent an 
idiosyncratic reaction rather than a dose-related effect (Boothe 1998; Jacobs et al. 1998). 
It has been reported that neutropaenia, thrombocytopaenia and/or anaemia have developed 
after phenobarbitone or primidone treatment for 2 to 5 months (Jacobs et al. 1998). These 
changes resolve with withdrawal of the drug (Boothe 1998; Jacobs et al. 1998; Thomas
2000). The possible underlying mechanisms include drug-induced immune-mediated 
disease or a direct cytotoxic effect on committed stem or circulating cells due to toxic drug 
metabolites (Jacobs et al. 1998).
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1.4.2.2 Bromide
Clinical use o f  bromide
The primary indication for the use of bromide as an AED in veterinary medicine has been 
in combination with phenobarbitone in refractory epilepsy, which has been reported to 
improve seizure control in about 58 to 83% of dogs with idiopathic epilepsy (Schwartz- 
Porsche 1992; Podell & Fenner 1993; Trepanier et al. 1998). Because bromide is not 
subject to hepatic metabolism and is not bound to plasma protein, it is the choice of AED 
in patients that have developed liver disease. Bromide is also effective as monotherapy 
(Thomas 2000).
The mechanism of the antiepileptic action of bromide is not completely understood. Like 
chloride ions, bromide ions are distributed mostly to the extracellular space, however, 
bromide does accumulate intracellularly in neurons and appears to cross neuronal chloride 
channels more readily than chloride. G ABA enhances this influx of bromide, leading to 
neuronal hyperpolarisation, and thereby stabilises neurons against excitatory input from 
epileptic foci (Trepanier 1995). In humans, the antiepileptic effects correlate with plasma 
concentration. The data for the pharmacokinetics and clinical use of bromide in the dog 
are described in Table 1.6 and Table 1.7 (page 44) (Boothe 1998). Bromide is not 
metabolised by the liver, excreted predominantly by glomerular filtration and reabsorbed 
by the renal tubules in competition with chloride (Trepanier 1995). High chloride intake 
increases bromide elimination, which increases the dose requirement (Trepanier & Babish 
1995; Shaw et al. 1996). Renal insufficiency decreases bromide elimination, thus, if 
bromide is administered in dogs with mild renal dysfunction, a reduced dose should be 
used and serum bromide concentration should be monitored closely to avoid toxicity. 
Bromide should be avoided in dogs with more serious renal dysfunction (Trepanier 1995). 
In humans, the variability between therapeutic and toxic serum bromide suggests that 
individuals differ in their tolerance of bromide. As in humans, dogs show individual 
sensitivity differences (Schwartz-Porsche 1992). Overall, factors which may affect 
bromide sensitivity include the physical condition of the dog, food and salt intake, 
dehydration, vomiting, diarrhoea, impaired renal function and individual variability (Yohn 
et al. 1992).
Bromide is available as potassium bromide or sodium bromide (Boothe 1998). There is no 
difference in efficacy for the potassium or sodium salt although sodium bromide is more 
difficult to dissolve in water compared to potassium bromide (Trepanier 1995; Podell 
1998). If sodium bromide is used, the dosage (usually reported in the literature for
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potassium bromide) should be decreased by 15% to account for the higher bromide content 
of the sodium salt (Boothe 1998; Thomas 2000). Potassium bromide is preferred when 
sodium intake must be restricted (e.g. congestive heart failure, hypertension, or hepatic 
disease) and sodium bromide should be used if hypoadrenocorticism or renal disease exists 
that may prevent normal potassium homeostasis (Trepanier 1995; Podell 1998; Thomas 
2000).
The suggested initial dose is 30 to 40 mg/kg daily with the dose subsequently being 
adjusted based on the clinical effects and the results of therapeutic monitoring (Schwartz- 
Porsche 1992). The target range of serum bromide concentration is approximately 1 to 2 
mg/ml when used in combination with phenobarbitone and 2 to 3 mg/ml when used as 
monotherapy (Trepanier 1995; Thomas 2000). In a retrospective study of therapeutic 
serum drug concentrations in 122 epileptic dogs, it was revealed that, in dogs treated with 
bromide and phenobarbitone, the reasonable therapeutic range (the lower 10 '^^  and upper 
90^ percentiles of the dogs in the study) for serum bromide concentrations is 0.81 to 2.40 
mg/ml, and for bromide treatment alone, the range is 0.88 to 3.00 mg/ml (Trepanier et al. 
1998). Some dogs may require or be tolerant of doses of 80 mg/kg/day or serum bromide 
concentrations of 4 mg/ml, however, the maximum dose is always dictated by the patient’s 
clinical response and side effects of the bromide (Knowles 1998; Thomas 2000) .
As the time for steady state equilibrium of bromide is 3 to 4 months, a loading dose is 
recommended to achieve therapeutic concentrations more rapidly. The maintenance dose 
must also be given each day. Based on a volume of distribution of 0.3 L/kg and a target 
concentration of 1.0 to 1.5 mg/ml, the suggested loading dose of bromide is 450 to 600 
mg/kg. In addition, a “mini” loading dose of 225 to 250 mg/kg is suggested to increase the 
serum bromide concentration by about 0.5 mg/ml. The loading dose is split over 5 days to 
reduce the side effects of sedation and gastrointestinal irritation (see Side effects of 
bromide, page 47).
As mentioned above (1.4.1.6 Therapeutic Drug Monitoring and AED Therapy, page 36), if 
a loading dose is used, the first serum bromide concentration should be measured at 1 or 2 
days after the loading dose finished. Whether or not a loading dose is given, serum 
bromide concentrations should be measured at 1 month (one half-life) and 3 to 4 months 
(steady state) after the initiation of treatment (Boothe 1998). If serum bromide 
concentrations are within therapeutic range, and seizures are well controlled, therapeutic 
drug monitoring can be performed every 6 to 12 months unless problems arise. Monitoring 
should be more frequent in dogs with abnormal renal function, a fluctuating diet, or in
introduction 4 /
geriatric dogs (Trepanier 1995). Given the long half-life o f bromide, the timing of the 
blood samples is not critical (Thomas 2000).
Side effects o f  bromide
Bromide toxicosis (bromism) has been well described in humans and is associated with 
neurological (headache, lethargy, partial amnesia, hallucinations, delirium, ataxia, stupor), 
gastrointestinal and dermatological signs (erythematous dermatitis) (Trepanier 1995; 
Podell 1996; Nichols et al. 1996). In one experimental study, dogs given sodium bromide 
at 100 mg/kg for 6 weeks had minimal side effects, whereas those given the drug at 
dosages of 200 to 500 mg/kg for 4 to 26 weeks developed shivering, ataxia, skin lesions, 
stupor, coma and death (Nichols et a l  1996).
Due to the primary indication of bromide in veterinary medicine as adjunctive AED to 
phenobarbitone, most of the documented side effects in dogs are observed in combination 
with phenobarbitone, which include polydipsia, polyuria, polyphagia, transient sedation, 
ataxia and hind limb wealaiess (Schwartz-Porsche 1992; Podell & Fenner 1993). 
Polydipsia, polyuria and polyphagia are well-documented side effects of phenobarbitone 
treatment in dogs, and it is difficult to ascertain whether or not bromide is exacerbating 
these effects (Podell & Fenner 1993). Sedation, ataxia and hind limb weakness are related 
to the anticonvulsant actions of the drug and dogs with higher concentrations are more 
severely affected, suggesting a dose-dependent effect (Podell & Fenner 1993; Boothe 
1998). Vomiting can occur probably because of the direct gastric irritation caused by the 
hypertonic bromide salt (Thomas 2000). Administering the drug with food, dividing the 
daily dosage into multiple doses and the use of sodium bromide instead of potassium 
bromide are helpful in preventing vomiting (Trepanier 1995; Boothe 1998). Skin lesions 
have not been reported in dogs treated with pharmacological doses of bromide (Trepanier 
1995). Abnormal behaviour such as irritability or restlessness has also been reported and 
usually requires a reduction in dose (Thomas 2000).
Most o f the adverse neurological effects of bromide associated with therapeutic doses in 
dogs are mild and appear to resolve with a reduction in the dosage of any concurrent AED 
(Trepanier 1995). Bromide intoxication to the point of stupor is rare, especially with close 
monitoring of serum bromide concentrations (Podell 1996). In cases of bromide 
intoxication, bromide elimination may be increased by administering 0.9% NaCl 
intravenously or feeding a high-chloride diet. Loop diuretics also enhance bromide 
elimination by blocking chloride and bromide reabsorption (Nichols et al. 1996). Dogs
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should be monitored carefully for seizure breakthrough as serum bromide concentrations 
decrease (Trepanier 1995).
1.4.2.3 Primidone
Clinical use o f  primidone
In dogs, primidone is primarily metabolised in the liver to phenobarbitone and 
phenylethylmalondiamide (PEMA), with a small residual serum concentration of 
primidone (Cunningham et al. 1983). All three compounds have some anticonvulsant 
effect. Primidone is rapidly eliminated in the dog and shows considerable fluctuations in 
its plasma concentrations. PEMA is only weakly active and does not play a major role in 
the anticonvulsant effect in the canine patient (Schwartz-Porsche et al. 1985). Compared 
with primidone and PEMA, phenobarbitone has longer a half-life and is much more potent 
in its anticonvulsant effect, and it is thought to be responsible for more than 85% of the 
total anticonvulsant activity of the primidone in dogs (Cunningham et al. 1983; Boothe 
1998). Correlating with this is the observation that serum phenobarbitone concentrations 
in patients on primidone therapy can be correlated with primidone efficacy and should be 
monitored rather than those of primidone (Cunningham et al. 1983). Target therapeutic 
ranges are the same as for phenobarbitone (Boothe 1998).
Some clinical studies suggest there is no advantage to the use o f primidone over the use of 
phenobarbitone as an AED in most dogs (Farnbach 1984a; Schwartz-Porsche et al. 1985). 
If primidone is used, it probably should be given TID for maximal effectiveness, since it 
and PEMA both have shorter half-lives than phenobarbitone and presumably any 
additional benefit from this drug would be due to the presence o f these additional 
anticonvulsants (Farnbach 1984b).
The conversion ratio o f primidone to phenobarbitone is 3.8:1. A patient should receive 
approximately 65 mg of phenobarbitone for each 250 mg primidone (Farnbach 1984a).
Side effects o f  primidone
The side effects of primidone are similar to phenobarbitone (Boothe 1998). In one study 
comparing the therapeutic efficacy of phenobarbitone and primidone in dogs, serum 
measurements of ALP, ALT and glutamate dehydrogenase (GLDH) were increased in 
approximately 70% of dogs treated with primidone, whereas such changes were only 
observed in 6.7% of dogs on phenobarbitone medication (Schwartz-Porsche et al. 1985). 
Histopathological changes after 6 months of primidone treatment include hepatocellular
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hypertrophy and necrosis, lipidosis and extramedullary haematopoiesis (Bunch et a l 
1985).
1.4.2.4 Phenytoin
Clinical use o f  phenytoin
Phenytoin is very effective in controlling seizures in man. However, it has not proven to 
be an effective AED in dogs due to the poor absorption (average bioavailability 36%) and 
too short a half-life to maintain adequate serum concentrations (Farnbach 1984b; Boothe 
1998). In humans, the commonly stated therapeutic range for phenytoin is 10 to 20 pg/ml. 
Laboratory studies indicate that, in dogs, at least 35 mg/kg TID are needed to reach 
therapeutic concentrations (Oliver et a l 1997). In one clinical study of 77 dogs given 
phenytoin with the daily dose ranging from 3 to 129 mg/kg/day, it was observed that even 
high dosages are incapable of sustaining serum concentrations adequate for seizure control 
(Farnbach 1984b). In addition, phenytoin is an inducer o f hepatic microsomal P450 
enzymes. Even if a therapeutic serum concentration was achieved, the likelihood is this 
would only persist only for 2 to 3 days (Boothe 1998).
Due to strong protein-binding at therapeutic concentrations, saturation kinetics for its 
metabolism and hepatic microsomal enzymes induction, phenytoin has narrow therapeutic 
index and high risk for drug-drug interactions in humans (Boothe 1998; Glauser & 
Pippenger 2000). As dose adjustments produce disproportionately large changes in serum 
concentrations and its metabolism varies considerably between individuals, many human 
patients show symptoms and signs of intoxication at some point (Feely 1999). Serum 
phenytoin concentration should be monitored closely (Glauser & Pippenger 2000).
Side effects o f  phenytoin
Polyphagia, polydipsia and polyuria may be seen in animals medicated with phenytoin. 
Phenytoin can cause changes in hepatic clinical laboratory tests, which include increased 
ALP activity and decreased albumin concentration (Bunch et a l  1985). Histopathological 
changes after 6 months of phenytoin treatment include hepatocellular hypertrophy and 
necrosis, lipidosis and extramedullary haematopoiesis. A toxic hepatopathy with 
intrahepatic cholestasis has been reported with phenytoin administration when combined 
with either phenobarbitone or primidone (Bunch et a l 1985; Boothe 1998). Toxicity may 
be related to generation of toxic metabolites, and induction o f enzymes may increase the 
formation of toxic metabolites that may contribute to hepatotoxicity (French & Gidal 
2000).
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1.4.2.5 Benzodiazepines
Clinical use o f  benzodiazepines
Benzodiazepines, such as diazepam, clonazepam and clorazepate, are potent AEDs, but 
several characteristics limit their use for long-term therapy (Podell 1998; Thomas 2000). 
The half-lives are short and frequent administration is required to maintain adequate serum 
drug concentrations (Thomas 2000). Due to hepatic induction, benzodiazepines’ serum 
concentrations tend to decrease with time when in chronic use; thus, subsequent dose 
increases are usually necessary. Tolerance to the anticonvulsant activity of diazepam and 
clonazepam develops rapidly within 1 to 2 weeks in dogs (Boothe 1998). Cross-tolerance 
to benzodiazepines may occur with long-term use, and it prevents effective use of 
diazepam or midazolam to stop status epilepticus in emergency situation (Podell 1998; 
Thomas 2000). Benzodiazepines are also known to develop physical dependence. After 
prolonged treatment, sudden withdrawal of benzodiazepines can precipitate seizures and 
clinical signs including anorexia with weight loss, lethargy, tremor and, in some dogs, 
hyperthermia may occur (Scherld & Frey 1986).
Diazepam and clonazepam are not effective AEDs for long-term therapy due to the 
features listed above. However, as clorazepate has a longer half-life and tolerance to 
anticonvulsant activity does not develop so rapidly as with diazepam and clonazepam, it is 
more suitable for chronic use and can be used as an add-on AED (Boothe 1998). However, 
similar problems may arise as with chronic oral use of short-acting benzodiazepines 
(Podell 1998). In addition, there are other features of clorazepate that may influence its 
clinical value. The half-life of clorazepate is less than 12 hours and doses that are 
accidentally missed can result in seizures (Boothe 1998). As the half-life is short, 
measurement of both peak and trough drug concentrations are recommended to document 
fluctuations in plasma drug concentrations. Clorazepate often increases serum 
phenobarbitone concentrations, which can lead to side effects; thus, serum phenobarbitone 
concentrations should also be monitored closely (Boothe 1998; Thomas 2000). These 
increases are usually evident by the first month of therapy but may take longer. 
Furthermore, clorazepate concentrations tend to decrease with time despite no change in 
dose, and increases o f the dose are usually required to maintain the baseline serum drug 
concentration. In some animals, 8-hourly rather than 12-hourly dosing may be necessary 
to avoid both toxic and subtherapeutic concentrations (Boothe 1998). Serum 
concentrations of phenobarbitone and clorazepate should be monitored at 2 and 4 weeks 
after initiating clorazepate administration (Boothe 1998; Thomas 2000).
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Side effects o f  benzodiazepines
Side effects of benzodiazepines include sedation, ataxia, polyphagia and, in some cases, 
hyperactivity. Multiple oral doses of 2 mg/kg at 12-hour intervals for 3 weeks caused 
significant decreases in serum albumin and increases in serum urea nitrogen, but 
concentrations were within normal reference ranges (Boothe 1998),
1.4.2.6 Other AEDs
In human medicine, up to 1993, five AEDs have predominated in seizure management. 
However, despite their remarkable effectiveness, these drugs fail to produce complete 
seizure control in about 30% of cases. These drugs are also far from ideal in terms of side 
effects and adverse drug interactions, and there is a need for new drugs with improved 
efficacy or tolerability (Perucca 1996). Several new AED have been approved for use in 
man since 1993.
In veterinary medicine, the choices of AED are much more limited. Phenobarbitone and 
bromide are the best AEDs documented for efficacy and tolerance in dogs. In general, 
clinicians should avoid the use of primidone, phenytoin and short-acting benzodiazepines 
for the reasons outlined above. Clorazepate may be a choice o f add-on AED, but the 
potential cross-tolerance and physical dependence limit its use.
Refractory epilepsy is not uncommon in dogs. Approximately 30% of dogs are never well 
controlled with phenobarbitone and/or bromide (Knowles 1998) and alternative AEDs are 
still in demand. Some new AEDs have been applied in veterinary medicine recently but, 
for most o f them, further clinical studies are needed to confirm their efficacy and 
tolerability in dogs (see Table 1.8, page 52).
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1.4.3 AED Therapy Withdrawal
In most dogs, a lifetime AED therapy is usually necessary to control seizures. However, 
attempted withdrawal of AED medication is reasonable in some dogs that have been 
seizure-free for 1 to 2 years. The dose should be gradually tapered over a period of about 6 
months (Thomas 2000). In some situations, the use of AEDs aggravates epilepsy (acute 
idiosyncratic side effects, chronic dose-related side effects and inverse pharmacodynamic 
effects may occur) and withdrawal of AED therapy may be desirable. The mechanisms 
leading to deterioration of a patient’s condition are listed below (in Table 1.9) (Genton 
2000). If AED withdrawal is undertaken, this should be done gradually. It is 
recommended that AED dosage is decreased in 25% decrements with 2- to 4-week 
intervals (Boothe 1998).
Table 1.9 Mechanisms leading to deterioration of a patient’s condition
Consequence Suggested approach
Maladjustment to disease/ limited 
access to AED
Refusal o f diagnosis or AED 
Irregular intake o f AED 
Low compliance 
Repeated withdrawal 
Seizure, serial seizures 
Non-conventional treatments 
Increased side-effects o f AED
Global approach; counselling
Overdose Side-effects
Increased seizure frequency 
New seizure types
Reduce dosage (monitor blood 
concentrations)
Acute idiosyncratic side effects Acute illness Withdraw quickly; use other AED
Chronic dose-related side effects Chronic illness Withdraw slowly; use other AED
Tolerance Secondaiy increase of seizure
frequency
withdrawal seizure
Substitute slowly with other AED
Inverse pharmacodynamic effect Increased seizure frequency 
new seizure types
Withdraw quickly; revise diagnosis; 
use other AED
1.5 ASSESSMENT OF SEIZURE MANAGEMENT
1.5.1 Seizure Frequency
Within the field of epilepsy, seizure frequency is used as a clinical assessment tool and 
reduction in seizure frequency is considered a key outcome measure in clinical practice and
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in trials of antiepileptic therapy. Measures of seizure frequency include seizure frequency 
or transformation of such data into percentage change from a baseline frequency or a rate 
based on frequency per specified time period (e.g., number per month). In clinical trials, 
key measurements have included the number or the proportion of patients whose seizure 
frequency or rate decreased or reached a specified range, as well as the number of months 
patients have been seizure free. The standard end point has been the proportion of patients 
whose seizure frequency decreases by >50% from baseline (Cramer & French 2001). 
From a clinical point of view, a compelling measure of efficacy would be the number of 
patients who are seizure free during the study. However, because many patients enrolled 
in clinical trials have demonstrated refractoriness to medical therapies, 100% seizure 
reduction is rarely achieved and is therefore not a useful end point for comparing 
treatments in a single trial (Lesaffre et a l  2000).
1.5.2 Quantitative Assessment of Seizure Severity
In human medicine, there is increasing recognition that traditional measures such as seizure 
counts do not capture the broad range of outcomes that may be relevant in evaluating the 
clinical impact of the growing number of medical and surgical interventions now available 
(Birbeck et a l  2000). Two aspects are considered to also be important for outcome 
assessment: seizure severity and quality of life measurement (Birbeck et a l 2000; Cramer 
& French 2001). Quality of life measurement is discussed in the next section (1.5.3 
Quality o f Life Measures in Epilepsy, page 56).
Several seizure rating scales are designed for quantitative assessment of seizure severity in 
human medicine, and the core components that most scales focus on include seizure 
frequency, seizure type, seizure duration, postictal events, postictal duration, automatisms, 
seizure clusters, laiown patterns, warnings, tongue biting, incontinence, injuries and 
functional impaimient. Initially, questionnaires were designed from physician-based 
assessment, followed by patient-based assessment, to evaluate both the severity of ictal 
events and the impaet of seizures from the perspective of the patient. However, the 
usefulness of the existing scales is limited by lack of data on responsiveness (Cramer & 
French 2001).
Responsiveness is a measure of the degree to which an instrument is capable of detecting 
change over time with alterations in disease state or in response to treatment and an 
indicator of longitudinal validity (Birbeck et a l 2000). Another limitation is 
appropriateness. All scales suffer from having a limited number of questions that may or
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may not cover seizure severity for an individual. In addition, some items in the scales may 
not relate to treatment effect at all. All the scales also suffer from an arbitrary scoring 
system. For most scales, further work is needed to define how much change in the total 
score would indicate a clinically appropriate requirement to change therapy. The 
application of such scales in clinical trials is also complicated by the questions over their 
appropriateness. Frequency of administration, consistency among interview technique, 
interpretation of marginal situations and other problems complicate the use and scoring of 
scales (Cramer & French 2001).
1.5.3 Quality of Life Measures in Epilepsy
A number of quality of life measures for epilepsy have been developed in human medicine 
over the last several years (Birbeck et al. 2000). Within the health field, quality of life has 
been variously defined as the emotional response to circumstances, the impact of illness on 
social, emotional, occupational and family domains, personal well-being, the match 
between expectations and reality, satisfactory functioning in physical, social and emotional 
terms and the ability of a person to meet his or her needs (Flopkins et al. 1995). Studies of 
patients with epilepsy have provided information pertinent to all the above definitions. 
Measurement of aspects of the experience and activities of epileptic patients is generally 
carried out by means of questionnaires. Questionnaires may be completed by patients, 
clinicians, or relatives of patients (Hopkins et a l 1995; O'Donoghue et al. 1998; Birbeck et 
a l 2000; Sabaz et a l 2000). Generally, a measure of quality of life, based on a clear 
conceptual model and with a eontent derived directly from patients themselves, would be 
of great value in optimising care and treatment (Birbeck et al. 2000).
The assessment of quality of life in epilepsy should take account of issues that have been 
identified as being relevance to people with epilepsy. Ideally, such assessments should be 
based on questionnaires designed for se lf  completion, based on a clear theoretical model of 
quality o f life where the content has been generated directly from interviews with wide 
variety of people with epilepsy (Hopkins et al. 1995). There should be a clear idea of 
precisely what is being measured by the questionnaire and its applicability to the patients 
and their current situations (Sabaz et al. 2000). The measure should be thoroughly tested 
for reliability, validity and its sensitivity to differences in epilepsy severity (Hopkins et a l 
1995; Sabaz et al. 2000). Measurement analyses that do not take into account seizure 
frequency may be overestimating the quality of life impaimient of seizure-free patients and 
underestimating the impairment of those experiencing one or more seizures per month 
(Leidy et al. 1999). There are considerable differences in expectations, values and
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perceptions of health between cultures and misleading results may be obtained by using 
culturally inappropriate measures. Therefore, the questionnaire should be developed, or 
retested in the country in which it is to be used (Hopkins et al. 1995).
Despite the desirability of assessing epilepsy outcomes more broadly, a recent literature 
review revealed only four AED randomised trials for epilepsy that included a 
comprehensive measure of health-related quality of life (Birbeck et al. 2000). Apart from 
the problems related to measurement design (described above), epilepsy has several 
features that make measurement of quality of life particularly difficult. Patients vary 
enormously in the problems they experience and in the way they adapt to their condition. 
In addition, problems may arise less from the condition itself than from the perception of 
epilepsy by others as well as by the patient (Hopkins et al. 1995).
In general, it can be said that attempts to measure quality of life in epilepsy have suffered 
from an overemphasis on measurement and an under emphasis on quality of life. There 
has been a gap between quantitative and qualitative research (Hopkins et al. 1995).
1.5.4 Related Information in Veterinary Medicine
In veterinary medicine, reduction in seizure frequency is the main outcome measure both 
in clinical practice and in trials of antiepileptic therapy. Neither seizure rating scales for 
quantitative assessment of seizure severity nor quality of life measures have been 
developed in veterinary medicine. One study was undertaken, in the Columbus Ohio area, 
to evaluate owners’ perception of the effect that epilepsy and long-term phenobarbitone 
therapy had on the quality of pet and owner lifestyle (Lord & Podell 1999). This study has 
revealed the concerns of owners in canine epilepsy and the information may be useful for 
the design of quality of life measure in dogs.
1.6 AIMS OF THE STUDY
Seizures are the most common neurological disorder in small animal medicine. Many dogs 
are effectively managed in primary veterinary clinics; however, dogs with epilepsy 
represent a large proportion of the caseload for the neurology service of Small Animal 
Hospital of University of Glasgow Veterinary School (SAH-UGVS). It is proposed that 
referral relates to dissatisfaction with the outcome of seizure management or a desire to
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confirm the diagnosis as far as possible. This study was undertaken to clarify the reason 
for requesting further assessment.
Seizure management regimens instigated at primary veterinary clinics and SAH-UGVS 
were reviewed in the study. Owners’ perspective of the reasons for referral and seizure 
management regimen used in SAH-UGVS were also explored, as such information was of 
potential value to clinicians in assessing seizure management regimens. Furthermore, 
information from the owners’ perspective could potentially raise issues of relevance to 
other dogs with epilepsy and their owners, which may be the basis for developing an 
alternative assessment of long-term seizure treatment in veterinary medicine.
CHAPTER TWO
MATERIALS AND METHODS
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2.1 CRITERIA FOR ENTRY OF DOGS IN THE STUDY
Dogs that were referred to Small Animal Hospital of University of Glasgow Veterinary 
School between March 1999 and April 2001 for evaluation of seizures and satisfied one of 
the following criteria are included in this study: (a) dogs diagnosed with idiopathic 
epilepsy by full seizure investigation, (b) dogs with unremarkable physical and 
neurological examination as well as blood clinicopathological analyses, and tentatively 
diagnosed with idiopathic epilepsy without specific investigation of intracranial diseases. 
Patients found to have symptomatic epilepsy or reactive seizures were excluded from the 
study.
2.2 INVESTIGATION PROTOCOL FOR PATIENT WITH EPILEPSY
The diagnosis o f idiopathic epilepsy is one of exclusion of other likely causes of seizures 
(see 1.3 DIAGNOSTIC EVALUATION, page 22). The full diagnostic protocol for canine 
seizure disorders at the SAH-UGVS includes history, physical and neurological 
examinations, haematology and biochemistry, specified serological tests, CT scan, and 
CSF analysis. The processes are detailed in Figure 2.1 (page 63).
History details for dogs included in this study are summarised in Table 2.1 (page 64). A 
full physical examination was performed after history taking to detect clinical signs that 
may relate to nonepileptic paroxysmal disorders or extra-cranial causes of seizures (Table 
2 .2, page 66).
Full neurological examination (detailed in Figure 2.2, page 65) is carried out to detect 
interictal neurologic deficits. When this was performed shortly after a seizure and focal or 
generalised abnormalities were obtained, neurological examination was repeated in 24 
hours in order to differentiate postictal effects from persistent interictal deficits.
Laboratory investigation was performed to rule out extracranial causes of seizures. Tests 
of haematology and biochemistry are listed in Table 2.3 (page 66). Further serological
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tests include fasting and post-prandial bile acids, serum titres o f toxoplasma, neospora, and 
canine distemper virus, and serum lead concentration.
CT and CSF sampling were performed under general anesthesia. Even though most dogs 
in the study (with seizures only and no interictal signs) had normal neurological status 
between seizures, the anaesthetic protocol should still concentrate on not causing 
deterioration of neurological function in these patients. In patients with deteriorated 
neurological status, the ideal anaesthetic agent should provide general anaesthesia while 
reducing cerebral metabolic oxygen requirement (CMO2R), reduce cerebral blood flow 
(CBF), and should not promote seizures (Golder 1999).
Protocol described below, with some variation, was used in dogs in this study, depending 
on individual patient’s requirement. Patients were premedicated with pethidine (2 mg/kg 
IM). Prior to induction, the dog was pre-oxygenated by facemask with 100% oxygen for 5 
minutes and administered 1 mg/kg IV of lignocaine. Diazepam at 0.2-0.5 mg/kg IV and 
thiopentone or propofol (with dose to affect) were used for induction. Maintenance was 
with low concentration of isoflurane in 100% oxygen or propofol infusion with high- 
inspired oxygen concentration supplement. Diazepam was administered prior to 
thiopentone or propofol to reduce the required dose of these two anaesthetic agents, as well 
as for its anti-epileptic properties. Benzodiazepines also decrease the incidence of 
myoclonus induced by propofol. Barbiturates decrease CMO2R and CBF at induction 
doses. In addition, barbiturates maintain the cerebral vascular responsiveness to changes in 
mean arterial blood pressure and Pa CO2. The effect of propofol on CMO2R and CBF is 
similar to barbiturates. Inhalation agents decrease CMO2R but increase CBF by depressing 
vascular autoregulation. This effect is much greater with halothane than isoflurane, and 
isoflurane increases blood flow more evenly throughout the brain compared to halothane 
(Golder 1999).
Intra-cranial imaging was performed by a third generation transverse slice CT unit (Excel 
2400 Elite®, Elscint Ltd, Haifa, Israel). The dog was positioned in sternal recumbency 
with forelimbs pulled alongside the chest, and the head was extended and supported on a 
radiolucent headrest. Scanning was undertaken at 120 KV, 300 mAs, with a 240 mm 
diameter scan field size, 256x256 image matrix, standard resolution and soft tissue 
reconstmction filter. In medium and large size of dogs, a bed increment of 5 mm and 5 
mm slice width were used, and in small size of dogs 2.5 mm bed increment and 2.5 mm
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slice were selected. The scanning area extended from the occipital protuberance to the 
cribriform plate. Images were acquired using a scan angle of 360° and a scan time of 2 
seconds. Post-contrast scans were performed following intravenous administration of 2 
ml/kg of non-diffusible iodinated compound sodium iothalamate (70% weight/volume, 420 
mg iodine/ml, Conray 420, Mallinclcrodt Medical Ltd, Northampton, England, UK). Post­
contrast slices were taken at the same levels as the initial study, starting around 20 seconds 
after injection of contrast media finished.
CSF analysis was performed if the result of intra-cranial imaging was unremarkable. 
Three-inch 20 gauge or 1.5-inch 22 gauge spinal needles were used for CSF sampling and 
fluid was collected in plastic plain tube. CSF examination included physical appearance, 
cellularity (total and differential cell count) and protein content. Manual 
(haemocytometer) and/or machine count were performed for total cell count. The 
differential cell count was determined following cytocentrifugation (cytospin3 R^). If 
results of all tests were unremarkable, the diagnosis of idiopathic epilepsy was made.
Materials and Methods 63
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Figure 2.2 The Neurological Examination Sheet of SAH-UGVS 
1) SUBJECTIVE .................................................................................................
2) OBJECTIVE  
Observation
Mental 
Posture 
Gait
Limbs affected 
Other (e.g. fits)
Alert Depressed Disorientated Stupor Coma
Normal Head Tilt Tremor Falling
Normal Ataxia Stiffness Dysmetria Circling
Pelvic Limbs Tetra Hemi Mono
Key: 4=exaggerated; 3=increased; 2=normal; 1=decreased; O=none; NE=not evaluated
W eakness
Hopping 
Wheelbarrow 
Ext. postural thrust 
Hemistand/walk
Left Fore Right Fore Left Rear Right Rear
Ext. Carpi Rad. 
Patellar 
Pedal
P roprioception Left Fore Right Fore Left Rear Right Rear
Paw Position
Reflex Step
Hip Sway
Placing-tactile
Placing-visual
UMN or LMN Left Fore Right Fore Left Rear Right Rear
Muscle Bulk
Muscle Tone
Panniculus and Sacral Segments
Panniculus 
Anal reflex 
Tail
Bladder
Cut-off If Yes: Level on L Level on R
Left Right
Voluntary movement
Control Bladder size Ease of expression
Pain
Hyperaesthesia Cervical Thoracic Lumbar L-Sacral
Superficial Pain L-Fore R-Fore L-Hind R-Hind
Deep pain L-Fore R-Fore L-Hind R-Hind
Cranial Nerves
Vision 2 
Menace 2,7 
PMR-stim L 2,3 
PMR-stim R 2,3 
Pupil size 2,3 Symp. 
Fundic Exam 
Vest.eye move. 
Strabismus 8,3,4,6 
Nystagmus 8,3,4,6
L R
Facial Sens, max 
mandibular 
Ophthalmic 5 
Mast. Muscle 5 
Facial muscle 7 
Palpable 5,7 
Gag 9,10 
Tongue 12 
Sympathetic
L R Comments CN
Summary o f Neuro log ica l Exam;
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Table 2.2 Checklist of physical examination
General
Mucous membranes
Circulatory
Respiratory
Eyes
Digestive
Abdominal palpation
□ Pyrexia
□ Weight loss
□ Anorexia
□ Lethargy
□ Wealoiess
□ Polydipsia/polyuria
□ Dehydration
□ Oedema
□ Foul-smelling breath
□ Bruising or bleeding tendencies
□ Retarded growth
□ Enlargement of the calvaria
□ Persistent sutures and fontanelles of the skull
□ Pale mucous membrane
□ Oral ulcers
□ Heart murmurs
□ Arrhythmia
□ Dyspnoea
□ Sneezing
□ Nasal discharge
□ Uveitis
□ Chorioretinitis
□ Vomiting or diarrhoea
□ Icterus
□ Mass palpated
□ Ascites
Table 2.3 Routine haematology and biochemistry
Haematology
RBC WBC PET
Hb Band neutrophils MPV
HCT Neutrophils PCT
MCV Lymphocytes PDW
MCH Monocytes
MCHC Eosinophils
RDW Basophils
Biochemistry
Sodium Urea Total bilirubin Total pro
Potassium Creatinine Alkaline phosphatase Albumin
Na: K ratio Glucose Aspartate transaminase Globulin
Chloride Cholesterol Alanine transaminase Albumin:
Calcium Triglyceride y-glutamyltransferase
Phosphate
iviateriais ana ivietnoas o /
2.3 SEIZURE DISORDER EVALUATION AND MANAGEMENT
2.3.1 Categories of Seizure Cases Included in This Study
Cases included in this study are divided into two categories.
Group One
Group One included dogs referred to SAH-UGVS with recent-onset seizure disorder 
(shorter than 6-month history) and diagnosed as idiopathic epilepsy following evaluation as 
described in 2.2 INVESTIGATION PROTOCOL FOR PATIENT WITH EPILEPSY (page 
60). A total of 27 dogs were included in this group. In three cases, the diagnostic 
procedures were only perfomied to achieve the level of tentative diagnosis of idiopathic 
epilepsy due to lack of intra-cranial imaging facility (n=T) or owners’ decision of not 
performing specific intra-cranial investigation (n=2). In these dogs, no history and clinical 
signs suggested extra-cranial or intra-cranial causes of seizures, and no significant 
abnormalities were determined on haematology, biochemistry, and/or specified serological 
tests. All dogs had had greater than 2-year seizure history when data collecting for the 
study finished in April 2001. Given to the chronic seizure history without any interictal 
signs, diagnosis of seizure disorder in these cases were thought likely to be idiopathic 
epilepsy, and it was decided to include these cases in the study.
Group Two
This group included dogs referred to SAH-UGVS with a chronic history o f seizures 
(greater than 6-month history). A total of 21 dogs were included in this group. In 14 
cases, the full investigation was undertaken to make the final diagnosis of idiopathic 
epilepsy. In 7 patients, the diagnostic procedures were only performed to achieve the level 
of tentative diagnosis of idiopathic epilepsy due to owners’ decision of not performing 
intra-cranial investigation. In this subgroup, no history and clinical signs suggested extra- 
cranial or intra-cranial causes of seizure disorder, and no significant abnormalities were 
detemiined on routine haematology, biochemistry, and/or specified serological tests.
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2.3.2 Group One
Seizure frequency and seizure type
After the diagnosis of idiopathic epilepsy was made, if the dog had had only one isolated 
seizure, seizure monitoring was suggested. In cases which had had generalised seizures 
and the frequency of these had been more than two or more isolated seizures occurring 
within a 6- to 8-week period, two or more cluster seizure episodes within an 8-week 
period, or status epilepticus, treatment was indicated. In dogs with partial seizures, due to 
the variety in seizure severity between dogs, the decision of whether to medicate relied on 
individual cases and owners’ attitude after seizure management and AED side effects were 
discussed with owners.
AED regimen
In most cases, phenobarbitone was the first-line AED used in SAH-UGVS, with initial 
starting dose as 3 mg/kg ql2h. Trough serum phenobarbitone concentration was 
monitored in 2 weeks. Phenobarbitone dosage was adjusted depending on individual 
response. When the serum phenobarbitone concentration was within the upper therapeutic 
range but seizure frequency was still unacceptable or severe side effects of phenobarbitone 
had shown, potassium bromide was added as the second AED. Potassium bromide was 
also used as a first-line AED in young and geriatric dogs due to its perceived lower 
toxicity. The initial starting dose of potassium bromide used was 30 mg/kg daily, with a 
loading dose 450 mg/kg divided into 5 days. Semm bromide concentration monitoring 
was suggested at day 6 or 7 and week 4. If the paired serum concentrations were within 
the therapeutic range, or seizure frequency responded to bromide, it was suggested that 
serum bromide concentrations were measured again in month 3 to 4, and then every 6 
months. If serum bromide concentration was lower than the therapeutic range, or seizure 
frequency was not satisfactory, the maintenance dose was increased in a 10 mg/kg 
increment alone or with a minimal loading dose 250 mg/kg divided into 5 days.
If the dog had had cluster seizures or status epilepticus for most seizure activities, the use 
o f diazepam 0.5 to 1 mg/kg per rectum when a seizure occurred was prescribed to the 
owner for the control of cluster seizures or status epilepticus at home.
In order to monitor the clinical response, owners were requested to record seizure episodes 
and severity in a seizure diary (Figure 2.3, page 69).
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2.3.3 Group Two
Investigation of cases with chronic seizure history can be divided into two parts: 
confirming the diagnosis of idiopathic epilepsy and seizure management evaluation.
In addition to the historical questions listed in Table 2.1 (page 64), further information was 
sought relating to potential causes of uncontrolled seizure activity, which included dog / 
owner compliance with medication requirement, history o f sudden withdrawal of AED, 
details of AED therapy and clinical responses on seizure frequency and severity. Full 
seizure investigating procedures were performed, and at the same time, serum drug 
concentrations were measured (trough and/or peak level for phenobarbitone). As 
mentioned previously, in some dogs, diagnostic procedures were only performed to make 
the tentative diagnosis due to owners’ decision not to go further, but based on the age of 
seizure onset, no history and clinical signs that suggested intra-cranial diseases, and 
unremarkable results of routine haematology, biochemistry and/or specified serological 
tests, idiopathic epilepsy was the most likely diagnosis.
In cases treated with phenobarbitone, if phenobarbitone was given with a rough treatment 
time, a strict 12-hour interval medication was requested. If a high serum phenobarbitone 
concentration was not obtained (>30 pg/ml), increased phenobarbitone dosage was 
suggested. If serum phenobarbitone level was within the upper therapeutic range and 
seizure frequency was still unacceptable, or the dog showed undesired side effects, 
potassium bromide was added as the second AED with the regimen described previously 
(2.3.2 Group One, AED regimen, page 68). Potassium bromide was titrated until a high 
serum bromide concentration was achieved (up to 3.5 mg/ml) or unacceptable side effects 
occurred. Owners were informed about the influence of chloride content in the diet to 
serum bromide concentration in order to minimise the fluctuation of serum bromide 
concentration.
Diazepam was prescribed, if  thought necessary, via rectal administration. The use of a 
seizure diary (Figure 2.3, page 69) was recommended to produce an objective record of the 
patent’s progress.
Materials ana Metnoas v i
2.4 QUESTIONNAIRE STUDY
2.4.1 Questionnaire One: An Assessment of the Seizure Management in 
Companion Animals from the Owners’ Perspective
Owners’ perspective on reasons for refeiTal to and the seizure management regimen used in 
SAH-UGVS, as well as the exploration of other issues relevant to dogs and their owners, 
were sought by mailed questionnaires.
2.4.1.1 Format
The questionnaire was designed as an A5-size booklet by using a landscape orientation on 
A4-size paper and folded along the midline. Responses are thought to be higher if 
questionnaires are presented in a booklet format with front and back covers reserved for 
contents, aiming at stimulating interest rather than obtaining infonuation from the 
respondent (Dillman 1978).
On the front cover, a title of ‘Your Pet, Its Seizures, and You’ and a subtitle of ‘An 
Assessment of Seizure Management in Companion Animals from the Owners’ 
Perspective’ were placed. A brief introduction was provided, including aims of the study, 
the topics of the questionnaire, and an invitation for further comment. The University of 
Glasgow logo was placed at the top of the front cover, the name and address of the 
department at the bottom, in order to establish greater trust among subjects. On the back 
cover, a statement of appreciation, an invitation to make additional comments and plenty of 
blank space were provided. At the bottom, a question as to whether the respondent would 
like to receive a copy of questionnaire results was asked. The effect of sending results to 
respondents is thought to increase response (Dillman 1978).
2.4.1.2 Questionnaire Design
Question types used in the questionnaire included open-ended questions, closed-ended 
questions with ordered answer choices, and partially close-ended questions (Dillman 
1978). In addition, the visual analogue scale was used, which is a technique to measure 
subjective phenomena. The visual analogue scale is a self-reporting device, consisting of a 
straight line anchored at either end by the extremes o f the measured phenomenon, which 
provides a continuous range of possible values. Respondents were required to indicate the 
extent of the measured variable on a visual analogue scale by marking a cross somewhere 
on the line corresponding to the amount of the phenomenon (Hopkins et a l  1995;
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Svensson 2000). The visual analogue scale has been established as valid and reliable in a 
range of clinical and research applications, although there is also evidence of increased 
error and decreased sensitivity when used with some subject groups (McConuack et a l  
1988).
The whole questionnaire included a total of ten sections. At the beginning of each section 
an instruction of how to answer questions was described. The topic of each section and 
related questions are listed below.
Section A designed/aimed to evaluate, in the broad term, how owners assess seizure 
management. Several factors were suggested and subjects were asked how important they 
felt each factor was by using a visual analogue scale. Factors provided in the section 
included:
 ^ Seizure frequency.
 ^ AED side effects.
 ^ The animal’s quality of life.
 ^ Influence of caring for an epileptic dog on owners’ lifestyle.
 ^ Cost of seizure management.
In order to understand more about how important subjects feel that seizures are controlled 
to an adequate degree, one question of what seizure frequency subjects consider reasonable 
was asked. Two more questions were designed to explore additional factors, also 
important to subjects, and how important they are.
Section B designed/aimed to evaluate, by visual analogue scales, how subjects perceive 
their own dog’s seizure management with the same factors listed in Section A.
Section C designed/aimed to elicit information on the animal’s quality of life subsequent 
to the onset of seizure by close-ended question and partially close-ended questions. 
Questions were related to:
 ^ General daily activity.
 ^ Interaction between the animal and family members.
 ^ Overall assessment of the animal’s quality of life and, if perceived to have 
deterioration, to explore the reason.
Section D designed/aimed to explore how owners perceive the extra-work associated with 
caring for their epileptic dogs by visual analogue scales. Basic infonuation was obtained at 
first, including numbers of people who are primarily responsible for caring for the epileptic
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dog and relationship of these people. Extra work related to caring for an epileptic dog 
included:
 ^ The administration of the medication.
 ^ Regular veterinary examination and blood sampling to monitor serum drug 
concentration.
 ^ Seeking emergency veterinary treatment due to breakthrough cluster seizures or status 
epilepticus.
If subjects perceived the administration of the medication is a nuisance, one further 
question (partially close-ended question) was asked to explore the reason.
Section E designed/aimed to assess AED side effects and how owners are worried about it. 
Questions included which side effects the dog has shown (close-ended questions) and how 
these specific side effects woriy the owner (visual analogue scales). Listed side effects 
were:
 ^ Increased appetite 
 ^ Drinking more 
 ^ Urinating more 
 ^ Sleeping much more than before 
 ^ Ataxia 
 ^ Restlessness 
 ^ Itchiness
 ^ Vomiting and/or diarrhoea
Section F designed/aimed to evaluate the influence of caring for an epileptic dog on their 
owners’ work. Questions were separated into two groups by whether the owner is in 
employment / education / training.
Section G designed/aimed to evaluate the influence of caring for an epileptic dog on 
owners’ free time, in which questions were focused on if the epileptic dog affects owners’ 
ability or decision to stay away from home overnight.
Section H designed/aimed to explore owners’ concerns about their dogs’ seizures by visual 
analogue scales. Questions were related to three aspects:
 ^ Concerns about the ability to control seizures.
 ^ Concerns about their dogs having further seizures.
 ^ Concerns about seizures leading to injury or death of their dog.
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Section I designed/aimed to elicit information on the reason for referral, owners’ opinions 
on further investigation, and the influence of pet insurance on owners’ decision to pursue 
further investigation.
Section J  designed/aimed to assess how owners perceive the details of seizure 
management have been explained by clinicians of SAH-UGVS. Subjects of seizure 
management included:
 ^ The reason for precise timing of drug administration.
 ^ The potential side effects of medication.
 ^ The value of monitoring the serum drug concentrations.
 ^ The likely long term nature of treatment.
 ^ The long temi prospects for the dog.
2.4.1.3 Pretesting
Two pretests were undertaken. The first pretest was professional peer review. Five 
clinicians in SAH-UGVS were recruited for the first pretest. In the light of their 
comments, changes were made in the wording of instructions and questions, the order of 
questions, and more questions were added to elicit clearer information. In Section E, a 
question about detailed current AED therapy was added at the beginning in order to 
interpret reported AED side effects. Section H and J were deleted due to concerns about 
the length of the questionnaire. After correction, a revised version of questionnaire was 
drafted and the second pretesting was undertaken.
The second pretest was a lay review. The panel of five included veterinary nurses, owners 
of dogs without epilepsy, and a human doctor. In addition to completing (as appropriate) 
and commenting on the questionnaire, they were requested to record the length of time 
needed for completing the questionnaire. Few changes of wording and format were made 
according to their comments. The final questionnaire is in presented in APPENDIX ONE 
(page 130).
2.4.1.4 Inclusion Criteria and Implementing Mali Surveys
A  total of 37 dogs from Group One or Two who were alive in May 2001 were included in 
the questionnaire study.
Mailing packages, containing the questionnaire, a covering letter explaining the reasons for 
undertaking the study, and a stamped, addressed return envelope, were posted. Three
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weeks later, second mailing packages, containing another covering letter as a reminder, the 
questionnaire, and a stamped, addressed return envelope, were mailed to non-respondents.
2.4.2 Questionnaire Two: Behavioural Changes In Epileptic Dogs
After results of the first questionnaire were analysed, approximately 30% of respondents 
( 12/33) reported behavioural changes in their dogs, which included repetitive compulsive 
behaviour, overactivity, or more attention seeking. In the veterinary literature, it is Icnown 
that these behavioural changes may relate to seizure activity itself (prodrome and postictal 
period) or AED side effects. Furthermore, in human medicine, psychosis of epilepsy 
(POE) can be classified into interictal POE, postictal POE, alternative psychosis (forced 
normalisation), and AED-related psychosis (Kanner 2000; Stagno 2001). In order to 
clarify the causes of behavioural changes in our patients and explore the problem further in 
veterinary medicine, a questionnaire was designed to elicit more detailed information in 
these certain patients.
2.4.2.1 Format
This questionnaire was created in portrait orientation of A4-size, designed as a different 
format from the first questionnaire in order to clarify the different issues addressed by the 
questionnaire. At the top of first page, the University of Glasgow logo was placed. A title 
of ‘Behavioural Changes in Epileptic Dogs’ and a subtitle of ‘A Further Study of Seizure 
Management Assessment in Companion Animals from the Owners’ Perspective’ were 
displayed under the logo, followed by an invitation to make further comments. Spaces 
were placed between the introduction and the first section to achieve the same effect o f an 
introduction as the front cover in the booklet of Questionnaire One. On the last page, the 
same content of the back cover as the first questionnaire was placed at the bottom.
2A.2.2 Questionnaire Design
Question types used in the questionnaire included open-ended questions, closed-ended 
questions with ordered answer choices, and partially close-ended questions. The 
questionnaire consisted three sections. At the beginning of each section, an introduction of 
the topic in this section was described.
The first section was intended to elicit information detailing reported behavioural changes, 
when they started, and to assess whether any trigger factors or associated events were 
likely to be involved. In human medicine, it is found that psychosis of epilepsy occurs
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with higher percentage in patients who have had psychotic problems prior to seizure onset. 
Due to this finding in human patients, questions related to behavioural problems in the past 
history were included in this section.
The second section evaluated whether these behavioural changes were associated with 
treatment, seizure frequency, or the direct consequence of seizure activity. Detailed 
frequency and duration of these specific behaviours were requested to compare with 
frequency of seizure activity. The last section was related to how these dogs responded to 
owners when the behaviour occurred. The detailed questionnaire is presented in 
APPENDIX TWO (page 139).
2.4.2.3 Inclusion Criteria and Implementing Mail Surveys
Respondents to the first questionnaire who reported restlessness or other behavioural 
changes in their dogs were included in the second questionnaire study. One dog was 
excluded due to sudden death that occuned soon after the first questionnaire was returned. 
A total of 11 dogs were included in this questionnaire study.
Mailing packages, containing the questionnaire, a covering letter explaining the reason for 
undertaking the further study, and a stamped, addressed return envelope, were posted. 
Three weeks later, second mailing packages, containing another covering letter as a 
reminder, the questionnaire, and a stamped, addressed return envelope, were sent to non­
respondents.
2.4.3 Analysis of Data
The visual analogue scale (VAS) was applied as a 100-point measurement in the study. In 
responses to questions with VAS, the total length of the scale divided by the length from 
the left end to the cross, obtaining a value of percentage, which in turn was transformed 
into the VAS score in the range from 0 to 100. As scores of all responses to the certain 
question were obtained, a statistical software package (Microsoft Excel 97) was applied to 
obtain the mean, standard deviation (SD), and range of scores on VAS. In responses to 
questions with ordered answer choices, the data were presented as the percentage. In 
responses to question F2 and F3, the Spearsman rank correlation coefficient was applied to 
understand the association between the degree of the impact from owners’ perspective and 
the frequency of time off or been late for work due to caring for an epileptic dog.
CHAPTER THREE
RESULTS
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3.1 CASES REVIEW
A total of 48 dogs were referred to Small Animal Hospital of University of Glasgow 
Veterinary School (SAH-UGVS) between March 1999 and April 2001 for evaluation of 
seizures and that satisfied the criteria for inclusion in either Group One or Two (see 2.3.1 
Categories o f Seizure Cases Included in This Study, page 67). Detailed data are presented 
in Table 3.3, page 83.
3.1.1 Breed and Sex Distribution
Sixteen breeds were represented with a preponderance of three specific breeds: Labrador 
retriever (9/48), Border collie (8/48) and German shepherd dog (8/48). Breed distribution 
is illustrated in Figure 3.1.
Twenty-two of the dogs were male (18 entire and 4 neutered) and twenty-six dogs were 
female (5 entire and 21 neutered).
Figure 3.1 Breed distribution
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3.1.2 Age at Onset of Seizure Activity
Age at the onset of seizure activity was in the range of 2 months and 10 years old, with a 
mean o f 47 months (Figure 3.2, page 79). In the present study, 35% (17/48) of dogs had 
first seizure between 1 and 3 years old, and in 63% (30/48) o f dogs the first seizure 
occurred between 6 months and 5 years old.
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Figure 3.2 Distribution of age at onset of seizure activity 
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3.1.3 Duration of Seizure History When Presented
The duration of recurrent seizures at the time of referral ranged between 1 day and 48 
months, in which the mean was 9 months and the median 5.5 months. Fifty six percent 
(27/48) of dogs presented with a duration of seizure activity of less than 6 months (Group 
One ) and 44% (21/48) greater than 6 months (Group Two) (see Figure 3.3).
Figure 3.3 Duration of seizure history when referred
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3.1.4 Seizure Type
Sixty-six percent (32/48) of dogs exhibited generalised seizures, of which 91% (n=29) had 
generalised tonic clonic seizures (GTCS) and 9% (n=3) had generalised tonic seizures 
(GTS). Seventeen percent (8/48) of all the dogs included in the complete study presented 
with partial seizures, and 17% (8/48) of dogs exhibited both isolated generalised seizures 
and partial seizures (see Figure 3.4).
Figure 3.4 Seizure type and number of dogs
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3.1.5 Reasons for Referral
A retrospective review of the cases seen by clinicians at SAH-UGVS attributed the reason 
for referral to three broad groups: a desire on the part of the owner for increased 
confidence in the diagnosis of idiopathic epilepsy (50%, 24/48 cases); owners perception 
that seizure control was inadequate on the AED regimens (46%, 22/48); concern over the 
apparent side effects associated with AED therapy (4%, 2/48). In individuals with a less 
than 6-month history of recurrent seizures (Group One), reasons for referral in 70% of dogs 
(19/27) were the desire for further diagnosis; in dogs with seizure history greater than 6 
months (Group Two), 76% of patients (16/21) were referred due to owners perception that 
seizure control was inadequate (detailed in Table 3. 1).
Table 3. 1 The association between reasons for referral and the duration of seizure 
history when presented
f  f  I Group One G roup Two
easons or re erra Duration o f seizure history < 6 mo Duration o f seizure history >6 mo
The desire for further diagnosis 19/27 70% 5 /2 1 24%
Seizure control was inadequent 6/27 22% 16/21 76%
Concern of AED side effects 2/27 8% 0/21 0%
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3.1.6 AED Therapy at the Time of Referral
At the time of accession, 69% (33/48) of patients had been treated with or were cuiTently 
on anticonvulsant drug therapy. In individuals with a less than 6-month history of 
recurrent seizures, 52% (14/27) had been treated with AED, and in dogs with seizure 
history of greater than 6 months, 86% (18/21) were on AED therapy.
Phenobarbitone was the predominant AED prescribed, with 63% of dogs (30/48) being on 
phenobarbitone treatment at the time of accession. In the majority of patients (90%), 
phenobarbitone was administered every 12 hours, in one dog every 24 hours, and in 2 dogs 
every 8 hours. Dosages administered ranged from 1.2 to 14.7 mg/kg/day, with a mean 5.9 
mg/kg/day. Phenobarbitone dose categorised by duration of recurrent seizure history and 
AED history is presented in Table 3.2.
Table 3.2 Current phenobarbitone dose, duration of seizure history and AED history
Duration of seizure history 
<6 mo >6 mo
Duration of AED history 
<6 mo >6 mo
Total
Number o f dogs
<4 mg/kg/d 4 6 5 5 10
4-7 mg/kg/d 6 4 8 2 10
>7 mg/kg/d 3 7 3 
Phenobarbitone dose (mg/kg/day)
7 10
Range 1.6- 9.2 1.2- 14.6 1.6- 9.2 1.2-14.6 1.2-14.6
Mean 5.2 6.5 5.0 7.0 5.9
SD 2.3 3.9 2.2 4.0 3.3
In 19 out of 30 dogs on phenobarbitone therapy, serum phenobarbitone concentrations had 
been measured immediately prior to or at the time of referral (range 4.4 -  39.5 pg/ml, 
mean 24.3 pg/ml). In 31% (6/19) o f these patients, serum phenobarbitone concentrations 
were lower than 20 pg/ml (therapeutic range: 20 -35 pg/ml, 1); in 26% (5/19) of dogs the 
concentrations were within the one-third lower end of therapeutic range (20 -25 pg/ml) 
and 21% (4/19) were within the one-third upper end (30 - 35 pg/ml); in 11% (2/19) serum 
phenobarbitone concentrations were higher than 35 pg/ml. The distribution of serum 
phenobarbitone concentrations is presented in Figure 3.5 (page 82).
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Figure 3.5 Distribution of serum phenobarbitone concentrations
31%■ 26% 21%11%
<20 20-25 25-30 30-35
Serum phenobarbitone conc. (ug/ml)
11%
>35
Other antiepileptic drugs that had been used in the previous history included primidone 
(n=2), KBr (n=6), diazepam (n=l), phenytoin (n=l), and clonazepam (n=l). The dose of 
KBr ranged from 13.9 to 44.1 mg/kg/day, with the mean 26.4 mg/kg/day. Serum bromide 
concentrations were in the range from 0.5 to 1.2 mg/ml at the time o f referral, with the 
mean 0.8 mg/ml (therapeutic range 1 - 3  mg/ml) (Boothe 1998).
3.1.7 Behavioural Changes at the Time of Referral
At the time o f accession, 15% of patients (7/48) exhibited behavioural changes that had 
developed since seizure disorder started. The behavioural changes reported included 
repetitive and compulsive behaviour, destructive behaviour, overactivity and excitability, 
and aggression. The information from clinical records was not detailed enough to 
determine the possible cause or pattern o f behavioural changes.
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3.2 QUESTIONNAIRE ONE: AN ASSESSMENT OF SEIZURE 
MANAGEMENT IN COMPANION ANIMALS FROM THE 
OWNERS’ PERSPECTIVE
3.2.1 The Response
A total of 37 questionnaires were mailed in the study. Twenty-three questionnaires were 
returned within 3 weeks of the original mailing date and 10 questionnaires were returned 
after the follow-up mailing. A total of 33 questionnaires were received. One questionnaire 
was not completed, as the respondent considered it inapplicable to their pet which had not 
been administered AEDs, leaving 32 useable questionnaires. Therefore, the useable 
response rate was 86% (32/37) (Table 3.4).
Table 3.4 The response rate at different stages
Response rate of useable questionnaires
Original Mailing 22/37 59%
Follow-up 10/37 27%
Total 32/37 86%
3.2.2 Detailed Results
The questionnaire had specific sections related to AED therapy, and responses are divided 
into those concerned with patients to which AED therapy had been administered (n=25) 
and a group with no exposure to AED therapy (n=7).
3.2.2.1 Section A: Establishing the ideals for Assessing the Outcome of 
Seizure Management
Responses from owners with pets on AED therapy
A summary of the descriptive statements of the answers to the questions (A l, A3-6) is 
presented in Table 3.5 (page 87). The issue attributed the greatest significance was “the 
dog’s quality of life”, followed by “adequate seizure frequency”, “acceptable AED side 
effects”, and “concern of the cost of seizure management”. “Influence of caring for an 
epileptic dog on owners’ lifestyle” was of least concern, although answers to this question 
exhibited the greatest variation in this section.
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Table 3.5 Evaluation of the importance of factors in the assessment of seizure 
management in group with AED therapy
Question Response Range Mean SD±
Al Adequate seizure frequency 24/25 42-100 88^ 15.4
A3 Acceptable AED side effects 25/25 41-100 82L9 17.4
A4 The dog’s quality of life 25/25 56-100 92.8 9.1
A5 Minimal influence from caring for an epileptic dog 
on the owner’s lifestyle
25/25 0-100 58.3 35.5
A6 Concern of the cost of seizure management 25/25 0-100 65.9 32.9
In the 24 responses to question A2, a minority of respondents (4/24, 17%) identified a 
“reasonable” outcome as the patient being totally free from seizure activity with the greater 
proportion of responses (20/24, 83%) suggesting the concept of “reasonable” outcome 
included some seizure activity. Approximately one-third of respondents (8/24) considered 
decreased cluster seizures to isolated seizures as representing a reasonable outcome. 
Excluding cluster seizures, the minimal seizure interval suggested as “reasonable” (as 
described by the statements 1-6) varied from “one seizure every 2 weeks” (statement 2) to 
“less than one seizure every 6 months” (statement 6). The distribution of responses is in 
Table 3.6, with the most popular response (8/24, 33%) as “one seizure every 3 to 6 months.
Table 3.6 Responses distribution of minimal seizure interval in group with AED
Statement- seizure frequency Number of responses Percentage
1 One seizure / 1 week 0 / 2 4 0
2 One seizure / 2 weeks 1 / 2 4 4
3 One seizure / 1 month 1 / 2 4 4
4 One seizure / 2 months 4 / 2 4 17
5 One seizure / 3-6 months 8 / 2 4 33
6 Less than one seizure / 6 months 6 / 2 4 25
7 Seizure free 4 / 2 4 17
In the 11 responses to question A7, most owners repeated one o f the factors which had 
been described in previous questions, including AED side effects (2/11), the dog’s quality 
of life (5/11), and seizure control (1/11). Other factors indicated by respondents were the 
interaction between owners and clinician ( 1/ 11), control of behavioural changes (1/ 11), and 
the importance of diagnosis (1/11). In summary, this question didn’t reveal additional 
factors important for most owners in assessing seizure management.
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Responses from owners with pets not on AED therapy
A summary of the answers is presented in Table 3.7. “The dog’s quality of life remained 
the most important factor to owners in assessing the outcome of seizure management, and 
the order of factors was the same as group with AED therapy.
Table 3.7 Owners’ perspective of the importance of issues in assessing seizure 
management for respondents with pets not on AED therapy
Question Response Range Mean SD±
Al Adequate seizure frequency 7/7 70-100 92.0 11.9
A3 Acceptable AED side effects 7/7 45-100 90.9 18.8
A4 The dog’s quality of life 7/7 94-100 98.6 2.1
A5 Minimal influence from caring for an epileptic dog 
on the owner’s lifestyle
6/7 0-100 40.7 44.3
A6 Concern of the cost of seizure management 6/7 0-100 78.3 36.0
In the 6 responses to question A2, one third of owners (2/6) considered being seizure free 
as a “reasonable” outcome and a similar proportion included “seizure free” in a range of 
variable seizure frequency as a reasonable outcome. Only one respondent considered 
decreasing cluster seizures or status epilepticus to isolated seizures as “reasonable”. The 
range in responses to the minimal acceptable seizure interval perceived as “reasonable” 
was the same as that for owners with pets on AED therapy. Detailed results of minimal 
seizure interval are presented in Table 3.8.
Table 3.8 Results of minimal seizure interval (Q-A2) in group without AED therapy
Statem ent- seizure frequency Number o f responses Percentage
1 One seizure / 1 week 0/6 0
2 One seizure / 2 weeks 1/6 17
3 One seizure / 1 month 1/6 17
4 One seizure / 2 months 0/6 0
5 One seizure / 3-6 months 1/6 17
6 Less than one seizure / 6 months 1/6 17
7 Seizure free 2/6 32
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3.2.2.2 Section B: An Assessment of Seizure Management in their Own Dogs 
Responses from owners with pets on AED therapy
A summary o f the responses to the questions (B2-6, B8) is presented in Table 3.9. 
According to the mean of each factor, “the dog’s quality o f life” was the most successful 
factor, followed by “acceptable AED side effect”, “concern o f the cost of seizure 
management”, and “minimal influence from caring for an epileptic dog on owners’ 
lifestyle”. “Adequate seizure frequency” was the least successful factor, with the greatest 
variation in this section.
In question B2, 13 responses out of 24 had a score of less than 50. According to seizure 
frequency indicated in question B l, seizure frequency in these dogs varied from one 
isolated seizure or cluster seizures every 2 weeks to 2 months, except one dog with partial 
seizure every day. The distribution of values o f this factor is presented in Figure 3.6.
Table 3.9 An assessment of seizure management in individual dog of group with AED
Question Response Range Mean SD±
B2 Adequate seizure frequency 24/25 4-100 55.9 38.5
B3 Acceptable AED side effects 24/25 4-100 74.1 29.1
B4 The dog’s quality o f life 25/25 5-100 79.9 26.2
Minimal influence from caring for an epileptic dog on 
the owner’s lifestyle
24/25 0-100 65.5 35.2
B6 Concern of the cost of seizure management 24/25 3-100 72.7 28.7
B8 General assessment of seizure management in their dog 25/25 45-100 79.0 19.2
Figure 3.6 Distribution of values for “adequate seizure frequency”
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Responses from owners with pets not on AED therapy
A summary of the responses to the questions (B2-6, B8) is presented in Table 3.10. Based 
on the mean of each factor, “the dog’s quality of life” was the most successful factor, 
followed by “minimal influence from caring for an epileptic dog on owner’s lifestyle”. 
“Adequate seizure frequency” scored lowest, which was the same as for the respondents 
with pets on AED therapy.
Table 3.10 An assessment of seizure management in individual dog of group without 
AED therapy
Question Response Range Mean SD±
B2 Adequate seizure frequency 6/7 0-75 42.5 31.1
B4 The dog’s quality of life 6/7 94-100 97.8 2.2
Minimal influence from caring for an epileptic dog on 
the owner’s lifestyle 6/7 0-100 8&8 36.2
B6 Concern of the cost of seizure management 6/7 0-100 66.3 43.8
B8 General assessment of seizure management in their dog 5/7 1-89 45.2 37.1
In question B2, 3 responses out of 6 were with the value of the scale less than 50, in which 
the seizure frequency varied from 5 to 8 partial seizures every day to generalised cluster 
seizures every 2 to 4 months. In summary, the mean value of general assessment of 
seizure management was lower than group with AED therapy.
3.2.2.3 Section C: An Assessment of Quality of Life in Epileptic Dogs 
Responses from owners with pets on AED therapy
A summary of the responses to questions Cl-3 is presented in Table 3.11 (page 91). A 
minority of respondents (3/23) to question C l considered their dogs’ daily activity had 
increased compared with the period before the onset of seizure activity. According to 
further eomments, two of these dogs had presented with behavioural changes such as 
repetitive eompulsive behaviour, overactivity, or more attention seeking. In the two 
responses to question C3 indicating the dog’s general quality of life was improved 
compared to the period before the onset of seizure activity, one related to increased activity 
and the other was a presumed response as seizures had been present in this dog since 
adoption.
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Table 3.11 Results of assessment of epileptic dogs’ quality of life in group with AED
Question Response Response
Decreased The same Increased
Cl Daily activity 23/25 12 (52%) 8 (35%) 3 (13%)
Iiiteraction between the dog and 24/25 3 (13%) 16 (67%) 5 (20%)
family members
C3 General assessment of the dogs 25/25 11 (44%) 12 (48%) 2 (8%)
quality of life
The respondents (12/25), who indicated that they perceived the dog’s quality of life to have 
deteriorated (question C3), were requested to answer question C4 to indicate the reason. 
Of the 12 responses to question C4, “side effects of AED” was the largest group, followed 
by “inadequate control of seizures”. Furthermore, “behavioural change” was the 
commonest additional reason for deteriorating the quality of life o f epileptic dogs (3/12, 
25%). Responses of question C4 are detailed in Table 3.12.
Table 3.12 Results of question C4 - reasons for the dog’s quality of life deteriorating
Category Response Com m ents
1 Inadequate control o f seizures 5/12 42% None
2 AED side effects 7/12 58% None
3 Other - Behavioural changes 3/12 25% Repetitive compulsively behaviour, over activity, more attention seeking
- Breathless 1/12 8% No confirmation as relating to seizure management
Responses from owners with pets not on AED therapy
The majority of respondents indicated the dogs’ daily activity, interaction with family 
members and general quality of life were the same as before seizure started. Detailed 
results are presented in Table 3.13. Only one respondent considered the dog’s general 
daily life and quality of life decreased. This was due to a perception that there was 
inadequate control of seizures, with the patient exhibiting approximately 5 to 8 partial 
seizures daily.
Table 3.13 An assessment of quality of life in dogs of group without AED therapy
Question Response Answers
___________________________________________________ Decreased The_same______ Increased
Cl Daily activity
^2 Interaction between the dog and 
family members
General assessment of the dog’s 
quality of life________  ____________
6/7 1 (17%) 5 (8394) 0 (0%)
6/7 0 (0%) 5 (8394) 1 (17%)
6/7 1 (17%) 5 (8394) 0 (0%)
Results 92
3.2.2A Section D: An Assessment of Work Associated with Caring for 
Epileptic Dogs
Responses from owners with pets on AED therapy
In the responses to questions D1 and D2, a majority (20/25, 80%) of respondents indicated 
that family members shared the work associated with caring for the epileptic dog. All 
respondents were the primary people responsible for earing for the patient.
A summary of the responses of questions D3, D5 and D7 is presented in Table 3.14. In 
responses to question D3, the majority (18/24, 75%) of respondents seored this factor at 
less than 10 indicating that they did not consider the administration of the medication as a 
nuisance. The majority o f the 6 respondents (4/6) that identified the administration of 
medication as a problem indieated the requirement for giving medication at consistent time 
to be most important. Additional reasons included preparation o f medieation, difficulty in 
halving the tablets, and the need of carrying medication at all times, as well as tools for 
rectal administration of diazepam. Answers o f question D4 are detailed in Table 3.15.
Table 3.14 An assessment of work associated with caring for epileptic dogs
Question Response Range Mean SD±
D3 Administration of the medication is a nuisance 24/25
Regular veterinary examination and blood sampling to 
monitor drug serum concentration is a nuisance
Seeking emergency veterinary attention due to 
seizures at unexpected time is a nuisance
0-95
0-95
0-88
12.4
26.5 
34.2
21.3 
28.6
35.3
Table 3.15 Reasons of administration of medication is a nuisance
Category Response
1 The requirement for giving medication everyday 2/6 33%
2 The requirement for giving medication more than once a day 2/6 33%
3 The requirement for giving medication at consistent time 4/6 67%
4 The need to give more than one drug 2/6 33%
5 Difficulty in administering the drug 0/6 0%
6 Others 3/6 50%
In question D5, approximately 50% of respondents (10/21) did not consider regular 
veterinary examination and blood sampling for serum drug concentration monitoring as a
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nuisance (scoring less than 10). Two of the four owners who did not answer this question 
commented that repeat veterinary examination and blood sampling for serum drug 
concentration monitoring were not regularly suggested by the referring veterinarian. 
Questions D6 and D7 revealed that only five respondents had had to seek emergency 
veterinary treatment because of seizures following the visit to SAH-UGVS and their 
opinions on the significance of this event varied greatly.
Responses from owners with pets not on AED therapy
In responses to question D 1-2, 4 out of 6 respondents indicated that family members shared 
the work associated with caring for an epileptic dog. Questions D3 to D5 were 
inapplicable for this group, and in responses o f question D6, no respondent had sought 
emergency veterinary treatment due to seizure activity since the visit to SAH-UGVS.
3.2.2.5 Section E: An Assessment o f AED Side Effects
Responses from owners with pets on AED therapy
A summary of the responses to the questions E3 to ElO is presented in Table 3.16. 
Polyphagia, polydipsia and polyuria were exhibited by more than half of dogs in the study, 
in which polydipsia was the largest group but associated with least concern. Lethargy, 
ataxia and restlessness occurred in approximately 40 to 50 % of patients. Vomiting and/or 
diarrhoea were the least common AED side effect reported. O f the signs exhibited, ataxia 
was associated with the greatest degree of concern followed by restlessness.
Table 3.16 AED side effects in all dogs of the study
Question Patients exhibiting signs Degree o f ow ners’ concern
R ange Mean 5D ±
E3 Increased appetite 16/25 64% 0 - 1 0 0 47.5 32.5
E4 Drinking more 18/25 72% 0-90 39.0 30.9
E5 Urinating more 14 / 2  5 56% 5-85 42.3 29.9
E6 Sleeping much more than before 11/25 46% 18-85 46.3 20.9
E7 Ataxia 10/24 42% 40-84 6 8 . 1 14.2
E 8 Restlessness 12/25 48% 0 - 8 8 49.5 2 9 J
E9 Itchiness 5/25 20% 23-70 48.3 12.9
ElO Vomiting and/or diarrhoea 2/25 8% 6-77 41.6 24.7
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Based on the responses to question E l, the responses were divided into three subgroups: 
phenobarbitone monotherapy (PB), KBr monotherapy; phenobarbitone combined with 
potassium bromide (PB + KBr) (detailed in Table 3.17).
Table 3.17 The occurrence of side effects in patients with AED therapy
Question
PB
Patients exhibiting signs 
KBr PB+KBr
E3 Increased appetite 7/11 64% 1/4 25% 8/10 80%
E4 Drinking more 9/11 82% 0/4 0% 9/10 90%
E5 Urinating more 6/11 55% 0/4 0% 8/10 80%
E6 Sleeping much more than before 4/11 36% 1/4 25% 6/10 60%
E7 Ataxia 3/10 30% 1/4 25% 6/10 60%
E8 Restlessness 4/11 36% 1/4 25% 7 /10 70%
E9 Itchiness 1/11 9% 1/4 25% 3 /10 30%
E 10 Vomiting and/or diarrhoea 1/11 9% 0/4 0% 1/10 10%
PB: phenobarbitone monotherapy; KBr: potassium bromide monotherapy; PB + KBr 
combination therapy
In the subgroup of dogs on PB monotherapy (11/25), polydipsia remained the most 
common side effect with polyphagia, polydipsia and polyuria exhibited in more than half 
of dogs. In the subgroup of dogs on KBr monotherapy (4/25), side effects were only 
reported in one individual, in which the serum bromide concentration was 2.8 mg/ml. The 
reported side effects for each subgroup are presented in Figure 3.7.
Figure 3.7 Distribution of side effects in AED subgroups
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Results of owners’ concern about side effects analysed by different AED therapy are 
presented in Table 3.18. Ataxia remained owners’ highest concern in each group. In 
general, the degree of owners’ concern about AED side effects in poly therapy was higher 
than phenobarbitone monotherapy.
Table 3.18 The degree of ow ners’ concern in AED subgroups
Question
Range
PB
Mean SD± Range
PB+KBr
Mean SD±
KBr
Value
E3 Increased appetite 4-100 32.5 33.9 0-92 55.0 30.0 11
E4 Drinking more 0-90 32.5 36.3 13-88 46.9 26.5 N/A
E5 Urinating more 5-85 38.6 37.1 8-82 50.4 25.9 N/A
E6 Sleeping much more than before 22-47 37.3 10.9 18-79 41.5 22.4 38
E7 Ataxia 58-84 71.0 13.0 40-79 65.0 15.8 81
E8 Restlessness 0-88 45.0 41.1 15-82 48.3 23.9 79
E9 Itchiness 70 N/A N/A 44-52 48.0 4.0 52
ElO Vomiting and/or diarrhoea 77 N/A N/A 49 N/A N/A N/A
Based on the responses to question E l, dogs on phenobarbitone were divided into three
subgroups by dose administered: <4 mg/kg/day (n=4), 4-7 mg/kg/day (n=8), and >7
mg/kg/day (n=8). The results are presented in Table 3.19.
Table 3.19 The occurrence of side; effects in dogs with different phenobarbitone
dosages
Question Patients exhibiting signs
PB <4 mg/kg/d PB 4-7 mg/kg/d PB >7 mg/kg/d
E3 Increased appetite 2/4 50% 5/8 63% 7/8 88%
E4 Drinking more 3/4 75% 8/8 100% 6/8 75%
E5 Urinating more 1/4 25% 7/8 88% 5/8 63%
E6 Sleeping much more than before 4/4 100% 2/8 25% 4/8 50%
E7 Ataxia 0/4 0% 4/7 57% 4/8 50%
E8 Restlessness 2/4 50% 4/8 50% 5/8 63%
E9 Itchiness 1/4 25% 3/8 38% 0/8 0%
ElO Vomiting and/or diarrhoea 0/4 0% 1/8 13% 1/8 13%
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In general, the occurrence of side effects does not relate to phenobarbitone dosage. In the 
present study, except ataxia and vomiting/diarrhoea, all signs may exhibit in dogs with 
phenobarbitone less than 4 mg/kg/day. There was some positive correlation presented 
between the occurrence of polyphagia and phenobarbitone dosage. Ataxia occurred only in 
dogs with phenobarbitone dose higher than 4 mg/kg/day. The distribution of occurrence of 
phenobarbitone side effects in dogs with different range of dosages is presented in Figure 
3.8.
Figure 3.8 Distribution of occurrence of phenobarbitone side effects in dogs with 
different range of dosages
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Responses from owners with pets not on AED therapy
Owners of this group of dogs were only requested to answer question E2. A summary of 
responses of question E2 is presented in Table 3.20. The responses to question E2 
indicated the main reason for these dogs not to be on AED therapy was “the seizure 
interval is longer than one month”, followed by “mild seizure severity”. Only one dog had 
been taken off AED due to side effects (the dog exhibiting 5 to 8 partial seizures per day).
Table 3.20 Reasons for dogs currently with no AED therapy
Category Response
1 The severity o f  seizure activity is mild (only partial seizures) 3 /7 43%
2 The seizure interval time is longer than one month 5/7 71%
3
My dog was on medication previously but stopped it due to the 
side effects 1/7 14%
4 It is difficult to administer the medication 0 /7 0%
5 Others 0 /7 0%
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3 .2 .2 .6  Section F: The Impact of Owning an Epileptic Dog on Owners’ Day-to- 
day Activity
Responses from owners with pets on AED therapy
A summary o f responses to question F2 and F4 is presented in Table 3.21 (page 97). The 
responses to question F2 indicated that 38 % of owners with commitment (6/16, 4 with 
full-time and 2 with part-time employment) did not consider caring for an epileptic dog 
had caused them conflicts with their commitments (value of visual analogue scales less 
than 10). In responses to question F4, 63 % (5/8) of owners, who were not in full-time or 
part-time employment, did not consider caring for an epileptic dog had caused them 
conflicts with their commitments. The perceived impact of owning an epileptic dog on 
respondents’ day-to-day activities is presented in Figure 3.9.
Table 3.21 The impact of owning an epileptic dog on owners’ day-to-day activity in 
group with AED therapy
Question Response Range Mean SD±
F2 Owners with commitments 16/17 0-100 34.6 28.9
F4 Owners without commitments 8/8 6-76 22.8 24.0
Figure 3.9 Distribution of answers of question F2 and F4
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In responses to question F2 and F3, a nonsignificant positive correlation (r^= 0.48, f>0.05) 
was presented between the degree of the impact from owners’ perspective and the 
frequency of time off or been late for work due to caring for the epileptic dog. Only one 
respondent (1/8) to question F5 indicated that caring for an epileptic dog was a factor 
preventing them from taking up employment.
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Responses from owners with pets not on AED therapy
The responses to question F2 indicated that the respondents (4/5, 3 with full-time and 1 
with part-time job) did not consider caring for an epileptic dog had caused them conflicts 
with their work commitments (value of visual analogue scales less than 10). One 
respondent reported a conflict (full-time employment) with requirements for time-off or 
being late for work a couple of times in a 6-month period. The only response to question 
F4 indicated a mild impact on that individual’s day-to-day activities (scale value 21). A 
summary of answers of question F2 and F4 is presented in Table 3.22.
Generally, respondents from the owners of pets on AED therapy indicated a greater impact 
(higher visual analogue scores) than respondents from the non-treatment group.
Table 3.22 The impact of owning an epileptic dog on owners’ day-to-day activity in 
group without AED therapy
Question Response Range Mean SD±
F2 People with commitment 5/5 0-100 20.8 39.6
F4 People without commitment 1/2 21 N/A N/A
3.2.2.7 Section G: The impact of Owning an Epileptic Dog on Owners’ 
Ability/decision to Stay Away Overnight
Responses from owners with pets on AED therapy
Three of the 25 respondents did not stay away from home overnight. A summary of the 
responses to questions G1 and G2 are presented in Table 3.23. Compared with the period 
before the onset of seizure activity, 36 % of respondents (8/22) had changed the way they 
organised the care of their epileptie dog when they stayed away from home overnight, and 
more respondents left the dog at home with someone able to care o f it.
Table 3.23 How owners organised the care of dogs when they stayed away overnight, 
in the group with AED therapy
Category Q G l-  before seizures started Q G2- after seizures started
Response Responses
1 Take them with you 10/22 46% 9/22 41%
2 Kennel/ boarding 3/22 14% 3/22 14%
2  Ensure that someone is at home to 
care for them 10/22 46% 13/22 59%
4 Other -  leave them relatives or friends 3/22 14% 1/22 5%
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In the responses to question G3, approximately half of respondents (12/22) indicated that 
their dogs’ seizures had affected their ability/decision to stay away overnight, in which the 
main reason for that was “the owner was too worried to leave the epileptic dog” (9/12), 
followed by “the owner couldn’t find someone able to care for an epileptic dog” (5/12), 
and “the dog usually has seizures when the owner is away or after return” (3/12). Detailed 
responses to question G3 are listed in Table 3.24.
Table 3.24 Reasons why seizures in dogs affected their owners’ ability/decision to stay 
away overnight
Category Response
I couldn’t find someone able to care for an epileptic dog 5 /12 42%
I am too worried to leave the dog 9 /1 2 75%
My dog usually has seizures when I am away or after I return 3 /1 2 25%
Other 1/12 8%
A summary of responses to question G5, generally assessing the impact of owning 
epileptic dog on owners’ free time, is presented in Figure 3.10.
an
Figure 3.10 The impact of owning an epileptic dog on owners’ free time
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Responses from owners with pets not on AED therapy
A summary o f the responses to questions Gl and G2 are presented in Table 3.25 (page 
100). Compared with the period before the onset of seizure activity, only one respondent 
(1/6, 16%) had changed the way they organised the care of the epileptic dog when they 
stayed away overnight. One response was inapplicable as the owner had not stayed away 
overnight since the onset of seizures. Only one respondent to question G3 and G4 (1/5)
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indicated that the patient’s seizure problem had affected their decision /ability to stay away 
overnight; this was for two reasons “the owner is too w onied to leave the dog” and “the 
dog usually has seizures when the owner is away or after the return”. Apart from this 
response indicating a mild impact of owning an epileptic dog on the owner’s free time 
(with scale value of 21), the majority of respondents (6/7) reported no impact on their free 
time (scale value less than 10).
Table 3.25 How owners organised the care of dogs when they stayed away overnight, 
in the group without AED therapy
Category Q G l- before seizures started  
Response
Q G2- after seizures started  
Responses
1 Take them with you 4/7 57% 5/6 83%
2 Kennel/ boarding 0/7 0% 0/6 0%
2  Ensure that someone is at home to 
eare for them 4/7 57% 3/6 50%
4 Other -  leave at home 1/7 14% 1/6 16%
3.2.2.8 Section H: Owners’ Opinions on Further investigation of Seizures in 
their Dogs
Responses from owners with pets on AED therapy
In approximately two-third of cases (17/25), the referral to SAH-UGVS was suggested by 
the referring veterinary surgeon with the other third of referrals (9/25) being requested by 
the owner. One response indicated the refenal was both suggested by vet and requested by 
the owner (question HI).
For the majority (23/25), the reasons for referral were to find out whether there was any 
underlying disease causing seizures, and for approximately 40 % of cases (11/25), referral 
was due to perceived inadequate seizure management and a desire of a further opinion 
(question H2). In responses to question H3, the main reason of the previous seizure 
management being considered unsatisfactory included “seizure frequency was 
unacceptable”, followed by “owner was worried about the dog” and “dog’s quality of life 
was not good” (summarised in Table 3.26, page 101).
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Table 3.26 Reasons why the previous seizure management considered unsatisfactory
Category  Response
1 Seizure frequency was unacceptable 11/12 92%
2 Side effects were unacceptable 2 /1 2 17%
3 The dog’s quality o f  life was not good 6 /1 2 50%
4 The effort associated with caring for the epileptic dog influenced 
the owner’s lifestyle too much 2 /1 2 17%
5 The owner was worried about the dog 9 /1 2 75%
6 Other -worries o f  long-term side effects o f  AED 1/12 8%
A summary o f the responses to question H4-6 is presented in Table 3.27. Three 
respondents commented they still did not know the cause o f seizures or that their lifestyle 
had not been changed and did not answer the questions. A summary of the responses to 
question H6 from the perspective o f the influence of pet health insurance (question H7) is 
presented in Table 3.27 and Figure 3.11.
Table 3.27 Owners’ opinions on further investigation of seizure disorder in group 
with AED
Question Response Range Mean SD±
Knowing more about the cause o f  seizures helped the 
owner to understand the dog’s problem 2 2 /25 1 0-100 71 .6 26 .6
Knowing more about the cause o f  seizures helped the 
owner accept any lifestyle changes they may have to make. 2 2 /25 9 -1 0 0 62 .0 32.1
, The cost o f  further diagnostic procedures to know more 
about the cause o f  seizures is worthwhile 2 4 /25 0 -1 0 0 62.3 30 .8
H6 Without pet health care insurance to pay for investigation 14/15 0 -9 9 48 .8 29 .8
H6 With pet health care insurance to pay for investigation 10/10 3 0 -1 0 0 81.3 20 .7
Figure 3.11 The influence of pet insurance to owners in considering the cost of further 
investigation is worthwhile in group with AED therapy
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Responses from owners with pets not on AED therapy
In half of responses (4/7), the referral was suggested by vet and in the other, it was 
requested by the owner, in which one response indicated the referral was combined both 
circumstances. In all responses, to question H2, the reason o f referral was “to find out 
whether there was any underlying disease causing seizures”. In one response, an additional 
reason was “seizure management was inadequate and the owner needed another opinion”.
A summary o f the responses of question H4-6 is presented in Table 3.28. One owner 
commented he still did not know the cause of seizures and did not answer some questions. 
A summary of the responses to question H6 from the perspective of the influence of pet 
health insurance (question H7) is presented in Table 3.28 and Figure 3.12.
Table 3.28 Owners’ opinions on further investigation of seizure disorder in group 
without AED therapy
Question Response Range Mean SD±
Knowing more about the cause o f  seizures helped the 
owner to understand the dog’ problem 6/7 6 0 -1 0 0 87.3 14.4
Knowing more about the cause o f  seizures helped the 
owner accept any lifestyle changes they may have to make. 5/7 0 -9 9 37 .6 45 .4
The cost o f  further diagnostic procedures to know more 
about the cause o f  seizures is worthwhile 7/7 4 6 -1 0 0 88.3 17.9
H 6 Without pet health care insurance to pay for investigation 2/2 4 6 -1 0 0 73 .0 27 .0
H 6 With pet health care insurance to pay for investigation 5/5 8 5 -1 0 0 9 4 .4 5.2
Figure 3.12 The influence of pet insurance to owners in considering the cost of further 
investigation is worthwhile in group without AED therapy
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Considering that the responses to question H4-6 should not be influenced by whether the 
dog was on AED therapy, all responses to the questionnaire were interpreted jointly and 
summarised in Table 3.29. In considering the responses to question H6 for the cases in 
which the full investigation protocol was undertaken, the influence of pet health insurance 
in these cases were also examined (Table 3.30).
Table 3.29 Owners’ opinions on further investigation of seizure disorder from all 
responses of the study
Question Response Range Mean SD±
Knowing more about the cause of seizures helped the 
owner to understand the dog’ problem 28/32 10-100 74.9 25.3
Knowing more about the cause of seizures helped the 
owner accept any lifestyle changes they may have to make. 27/32 0-100 57.4 36.2
The cost of further diagnostic procedures to know more 
about the cause of seizures is worthwhile 31/32 0-100 68.2 30.5
H6 Without pet health care insurance to pay for investigation 16/17 0-100 51.8 30.5
H6 With pet health care insurance to pay for investigation 15/15 30-100 85.7 18.2
Table 3.30 Responses from eases, on which the full investigation protocol performed
Question Response Range Mean SD±
The cost of further diagnostic procedures to know more 
about the cause of seizures is worthwhile 22/23 4-100 77.6 27.5
H6 Without pet health care insurance to pay for investigation 9/10 4-100 63.7 32.5
H6 With pet health care insurance to pay for investigation 13/13 30-100 87.2 18.0
In order to compare the perception of clinicians and owners in reasons for referral, all 
responses to the questionnaire were interpreted jointly and categorised by the duration of 
seizure history when presented (divided into Group One or Group Two). Within these 32 
dogs, 13 dogs presented with a duration of seizure activity less than 6 months and 15 dogs 
greater than 6 months. Detailed results from the perception o f owners and clinicians are 
presented in Table 3.31 and Table 3. 32 (page 104).
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Table 3. 31 The association between the duration of seizure history and reasons for 
referral from owner’s perception
Reasons for referral Group One Duration of seizure history < 6 mo
Group Two 
Duration of seizure history > 6 mo
The desire for further diagnosis 16/17 94% 14/15 93%
Seizure control was inadequent 4/17 24% 8/15 53%
Concern of AED side effects 1/17 6% 0/15 0%
Table 3. 32 The association between the duration of seizure history and reasons for 
referral from clinician’s perception
Reasons for referral Group One Duration of seizure history < 6 mo
Group Two 
Duration of seizure history > 6 mo
The desire for further diagnosis 13/17 76% 4/15 27%
Seizure control was inadequent 2/17 12% 11/15 73%
Concern of AED side effects 2/17 12% 0/15 0%
A summary of the solicited comments owners made on the back cover of questionnaire is 
presented in Table 3.33 (page 104).
Table 3.33 General comments
Comments Response
The cost of treatment at UGVS has been a high burden, as the animal was not insured.
The reassurance the owner received from both own vet and clinicians at UGVS is important and 
helped them cope with the lifestyle of caring an epileptic dog.
Local follow up should be implemented including blood checks for assessment of medication control. 
(The owner also indicated they never received any information on serum drug concentration 
monitoring until 3 months before the questionnaire study was undertaken.
The control of seizures is much more important than knowing the cause of seizures.
The owner explained the reason for not performing further diagnostic investigation in the dog: further 
diagnostic procedures might be too stressful to the dog due to its age. In addition, current stress levels 
were minimal.
The study is worthwhile. Also ask some questions related to the genetic aspect in epilepsy.
The reason of not performing further diagnostic procedures was due to the risk (CSF tap). The owner 
is worried about side effects of AED, although blood tests were carried out frequently. The owner 
also wondered whether the dog was too quickly started on medication to which it soon developed 
drug tolerance.
Behavioural changes were the most severe problem at that moment, and it had changed the owner’s 
lifestyle very much.
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3.3 QUESTIONNAIRE TWO: BEHAVIOURAL CHANGES IN
EPILEPTIC DOGS
3.3.1 The Response
A total of 11 questionnaires were mailed in the study. Nine questionnaires were returned 
in 3 weeks after the original mail, and two were returned after the follow-up mailing. The 
response rate of the study was 100 % (Table 3.34).
Table 3.34 The response rate of the study
Response rate of useable questionnaires
Original Mailing 9/11 82%
Follow-up 2/11 18%
Total 11/11 100 %
3.3.2 Detailed Results
3.3.2.1 The Behavioural Change and the Frequency (Q~1, Q-15 and Q-16)
A  summary of the responses to question 1 is presented in Table 3.35. The commonest 
behavioural changes reported were “more attention seeking” and “overactivity and 
excitability”, followed by “excessive vocalisation”; these three features were reported in 
more than half of dogs in the study. “Repetitive, compulsive behaviour”, “destructive 
behaviour”, “aggression” and “inappropriate urination and/or defaecation” presented in 
smaller populations. An additional behavioural change reported in the “other” category 
was excessive hunger. One respondent indicated their pet’s behaviour had returned to 
normal after AED therapy was adjusted at SAH-UGVS. A summary of behavioural 
changes and the frequency in each dog (question 1,15 and 16) is presented in Table 3.36 
(page 106).
Table 3.35 Behavioural changes in epileptic dogs
Category Response
1 Attention seeking 7/10 64%
2 Repetitive, compulsive behaviour 2/10 19%
3 Destmctive behaviour 2/10 19%
4 Excessive vocalisation (such as barking or whining) 6/10 55%
5 Overactivity and excitability 7/10 64%
6 Aggression 2/10 19%
7 Inappropriate urination and/or defecation 2/10 19%
8 Other- excessive hunger 2/10 19%
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Table 3.36 The frequency of the behaviour in each dog (Q-1, Q-15 to 16)
Behaviour Frequency
Dog 1 Attention seeking 
Repetitive, compulsive behaviour 
Excessive vocalisation 
Overactivity and excitability 
Inappropriate urination and defecation
Off and on all the day
Dog 2 Repetitive, compulsive behaviour Controlled at present
Dog 3 Excessive hunger-licking the floor Everyday after feeding and lasted for 1 hour
Dog 4 Attention seeking 
Destructive behaviour 
Excessive vocalisation 
Aggression
30 minutes per day
Dog 5 Attention seeking 
Excessive vocalisation 
Overactivity and excitability
Up to one hour per day
Dog 6 Attention seeking 
Excessive vocalisation 
Overactivity and excitability
After each seizure and lasted for 2-3 days
Dog 7 Attention seeking 
Excessive vocalisation
All the day
Dog 8 Attention seeking 
Overactivity and excitability 
Inappropriate urination and defecation 
Excessive hunger
Attention seeking and excessive hunger- everyday 
Inappropriate urination- once per 2 weeks 
Overactivity- 1 or few hours after a seizure
Dog 9 Attention seeking 
Repetitive, compulsive behaviour 
Overactivity and excitability 
Aggression
Approximately every 6 weeks and lasted for 1 week
Dog 10 Overactivity and excitability All the day
Dog 11 Destructive behaviour 
Excessive vocalisation 
Overactivity and excitability
All the day
3.3.2.2 The Onset of the Behavioural Changes (Q-2 and Q-3)
Questions 2 and 3 were related to the onset of behavioural changes. The majority (7/10) of 
respondents to question 2 indicated the onset of behavioural changes was after seizure 
management started (for detail see Table 3.37, page 107).
Question 3 (respondents were asked to describe when the behavioural changes started in 
detail) was designed to allow cross checking of the responses to question 2 with our 
clinical records. In five responses (5/9), the onset of behavioural changes was after seizure
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activity occurred but before AED were introduced, and in the other four responses (4/9), 
the onset of behavioural changes was after AED were introduced (Table 3.37, page 107).
Responses to question 2 and 3 were compared for cross checking. Some responses were 
inapplicable for comparison, as one or other of the questions was not answered. Of the 
eight paired responses available for cross checking, in 3 responses the information did not 
correspond.
Table 3.37 The onset of behavioural changes from Q-2 and Q-3
Category Response
Question 2 Question 3
1 Within 6 months before the onset of seizures 2/10 20% 0/9 0%
2 After seizures started but before seizure treatment started 1/10 10% 5/9 56%
3 After seizure treatment started 7/10 70% 4/9 44%
3.3.2.3 Trigger Factors or the Reason of the Certain Behaviour (Q-4 to Q-6) 
Behavioural changes and separation anxiety
In the responses to question 4, three owners (3/11, 27%) indicated the described behaviour 
was related to separation between the dog and family members; one respondent 
commented that, although the behaviour was also present when the owner were at home, it 
deteriorated when they were away.
Behavioural changes and exercise
In the responses to question 5, approximately half the patients (5/11, 46%) were having the 
same amount of exercise as in the period before seizure activity started, with the remaining 
patients (6/11, 54 %) having less exercise; one owner commented the decreased exercise 
was related to the dog’s age and ability to exercise, not seizures per se.
Other factors reported by respondents
Three owners indicated some further factors related to the behavioural changes observed in 
their dogs, which included ( 1) a younger dog initiating play behaviour, (2) stress, and (3) 
when the dog was kept in one room to avoid him chewing the carpet.
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3.3.2.4 History of Behavioural Problems (Q-7 to Q-9)
The responses to question 7 revealed that two dogs had had similar behaviour in the past 
(defined as prior to 6 months before seizures started in the study). In addition, one 
respondent indicated that the patient had exhibited other behavioural problems in the past, 
in which the dog repeatedly ran away during exercise but spontaneously returned hours 
later; this reported behaviour was eonsidered related to the general behaviour of this dog.
3.3.2.5 Behavioural Changes and AED Therapy (Q-10)
A summary of the responses to question 10 is presented in Table 3.38. Forty percent of 
owners (4/10) did not perceive a relationship between the behavioural ehanges and seizure 
management, with the other respondents indicating some relationship between AED 
therapy and the behavioural changes.
Two thirds (4/6) of the cases, thought to be related to AED therapy, involved 
phenobarbitone / KBr combination therapy. The monotherapy regimens were represented 
by one patient each on PB and KBr monotherapy. Details of these 6 patients are presented 
in Table 3.39 (page 109).
Table 3.38 Behavioural changes and AED therapy
___________________________ Category   Response
. The behaviour started (or worsened) immediately after phenobarbitone was
 ^ started.
2 The behaviour started (or worsened) after phenobarbitone dose was increased. 3/10
3 The behaviour started (or worsened) after phenobarbitone dose was decreased. 0/10
, The behaviour started (or worsened) after phenobarbitone was started, but was not . „
related to the change of dosage.
5 The behaviour started (or worsened) immediately after KBr was started 1/10
6 The behaviour started (or worsened) after KBr dose was increased. 2/10
7 The behaviour started (or worsened) after KBr dose was decreased. 0/10
Q The behaviour started (or worsened) after KBr was started, but was not related to ni\r\
the change o f dosage.
g The behaviour started (or worsened) after AED was started, but was not related to 
the change of drug and dosage.
. ^ There is no relationship between the behavioural changes and seizure .y.„
management.
11 Other 0/10
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Table 3.39 The onset and progress of the behavioural changes
AED therapy
Dog 5 
PB
Dog 2 t  
KBr
Dog?
PB+KBr
Dog 8 
PB+KBr
Dog 1 
PB+KBr
Dog 11 
PB+KBr
. Immediately after phenobarbitone was 
started
✓
2 After phenobarbitone dose was increased
3 After phenobarbitone dose was decreased
✓
N/A
^ After phenobarbitone was started, but was 
not related to the change of dosage /
5 Immediately after KBr was started /
6 After KBr dose was increased
7 After KBr dose was decreased
N/A
/
g After KBr was started, but was not related 
to the change of dosage /
t  Behavioural changes in the dog responded to a decrease in the potassium bromide dose.
3.3.2.6 Behavioural Changes and Seizure Activity (Q-11 to Q-14)
The purpose of question 11 was to establish if there was evidence that suggested the 
reported behavioural changes might be analogous to the psychosis reported in epileptic 
human patients (Kanner 2000). In the 10 responses to question 11, the majority (7/10) 
indicated that the behavioural changes were not associated with seizure frequency. In 3 
dogs, the behavioural changes started or deteriorated when seizure frequency increased.
The purpose of question 12 was to differentiate the behavioural changes from prodrome 
and post-ictal phase of seizure activity. The responses were summarised in Table 3,40. 
Four respondents (4/11) indicated the behaviour might be associated with prodrome and 3 
respondents indicated it was related to the post-ictal phase of the seizure. Approximately 
36% of responses indicated the behavioural was not associated with seizure activity.
Table 3.40 Behaviour and seizure activity
Category Response
1 The behaviour happens few hours to days before a seizure. 4/11 36%
2 The behaviour happens few hours to days after a seizure. 3/11 28%
3 There is no relationship between the behaviour and seizure activity. 4/11 36%
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The purpose of questions 13 and 14 was to determine if there is a relationship between the 
usual time that the patient had seizures and reported behavioural changes. The majority of 
respondents indicated there was no eonsistent time for seizure activity (7/11) or the 
behavioural changes they reported (9/11). Furthermore, in the responses which indicated 
specific times for both seizures and behavioural disturbance, the two phenomena were not 
related (for detail see Table 3.41). In summary, the responses did not suggest a 
relationship between the usual time that patients had seizures and the reported behavioural 
changes.
Table 3.41 Comparison of certain occurring time of seizure and the behaviour
Q-13
Occurring time for 
seizure activity
Seizure frequency
Q-14
Occurring time for the 
behaviour
Details of behavioural changes
Dog 3 Early morning Once per month After feeding
Excessive hunger- licking the floor 
after feeding, off and on for about 
1 hour
Dog 5 Mostly daytime
Cluster seizures 
every week to eveiy 
3 months
Afternoon or evening
Attention seeking, excessive 
vocalisation, and overactivity up to 
one hour everyday
3 .3 .2 7  The Response of the Reported Behaviour (Q-17 and Q-18)
A summary of the responses to question 17 and 18 is presented in Table 3.42. Greater than 
50% of owners tried managing the situation by paying more attention (6/10) or ignoring 
the behaviour (6/10). Other approaches to management included: inten'upting the 
behaviour by introducing other interesting stimuli (4/10) and punishment (4/10). 
Examining the relationship between these methods and the patients’ response suggested 
that generally, the behaviour was difficult to influence (6/10). Only one patient responded 
to being ignored and the owner commented that the behavioural changes in this dog were 
mild and never became a nuisance. No patients responded to punishment.
Table 3.42 Responses of the behaviour
The way owners used to control the behaviour Number o f owners Dogs with response
1 Paying more attention 6/10 1/6
2  Try to interrupt the behaviour by introducing other 
interesting stimuli 5/10 2/5
3 Punishment 4/10 0/4
4 Ignoring the behaviour 6/10 1/6
5 Other 0/10 N/A
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3.3.3 Summary of Questionnaire Two
In order to detemiine the possible cause or pattern of the behavioural changes, the 
responses of individual patients were reviewed and are summarised in Table 3.43.
Table 3.43 Summary of the responses of individual patient
The possible cause or pattern of the behavioural changes _________  Responses
The behavioural changes were assoeiated with AED therapy (AED-related activity) 7/11
The onset of behavioural changes was the same as seizure activity (interietal activity) 1/11
The behavioural problem was related to postictal phase of seizure activity (postictal activity) 2/11
The reported behaviour was likely to be related to the general behaviour of the dog 1/11
In the seven patients with AED-related behavioural changes, one patient’s behaviour 
(excessive hunger only) was apparently related to the common side effect of 
phenobarbitone or phenobarbitone combined with bromide therapy. In the other six 
patients, the behavioural changes included attention seeking, repetitive and compulsive 
behaviour, excessive vocalisation, overactivity and excitability and inappropriate urination 
/ defaecation. Details of the relationship between the behavioural changes and AED 
therapy in these six patients were described in 3.3.2.5 Behavioural Changes and AED 
Therapy (Q-10) (page 108). Two out of six respondents also indicated the behavioural 
changes were exhibited during prodrome; one patient’s behaviour also deteriorated when 
the dog was separated from the owner. One respondent also indicated that the behavioural 
changes were also exhibited during the postictal phase and deteriorated when seizure 
frequency increased.
In one patient, the onset of behavioural change was the similar to the seizure problem, but 
without any relationship between the behaviour and seizure frequency or seizure activity; 
the behaviour was considered as interietal activity. The respondent indicated that even 
when the seizure frequency was controlled well by AED therapy, the frequency of the 
behaviour was the same as before.
In the two patients with behavioural changes mainly related to the postictal phase of 
seizure activity, one patient’s behaviour usually lasted for 2 to 3 days and the other for 7 
days. The latter respondent commented that when diazepam was administered rectally to 
control cluster seizures, the postictal behaviour lasted for briefer time. Furthermore, the
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same respondent also indicated the behaviour had been exhibited before the onset of 
seizure disorder but deteriorated after seizures occun*ed.
In one patient, the behaviour was not related to AED therapy, seizure activity, or seizure 
frequency. In addition, the onset of behaviour had preceded the onset of seizure activity by 
more than 6 months. In summary, the reported behaviour of the dog was considered to be 
associated with the general behaviour of the dog. In this dog, the behavioural changes 
reported were attention seeking, destructive behaviour, excessive vocalisation and 
aggression.
CHAPTER FOUR
DISCUSSION
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4.1 General Aspect of the Study 
The Significance of the Population Surveyed
All owners/patients surveyed for this study were derived from the client base of the 
Neurology Service of SAH-UGVS and consequently the results obtained pertain to this 
particular population. As the composition of such a refenal population is likely to be 
affected by a number of factors (including disease severity, proximity to the referral centre, 
owners’ mobility, owners’ socioeconomic status, individual practitioner preferences for 
referral etc) and although the conclusions of the study are thought to be representative of 
the clinic owner population profile, extrapolation to the general dog owning public is 
inappropriate.
The highly motivated nature of this client profile may also be significant in responses to 
this study (see below).
Reflections on the Response Rate to the Questionnaires
High response rates were achieved to both the questionnaires. The initial survey assessing 
seizure management from owners’ perspective had an 86% response rate, with the second 
survey concerning behavioural changes described by respondents to the survey having a 
response rate of 100%. Although these response rates are eneouraging (see below), there 
are factors that might contribute to the apparently high response rate.
First, the high response rate may reflect a study of a referral population. Compared with 
the general dog owning population, owners who have accepted referral to a specialist clinic 
may also have greater determination to understand their pet’s problem, wish to contribute 
to further studies and have a strong desire to explore avenues that may potentially lead to 
successful management.
Second, the method of recruiting subjects may affect the response rate. The decision 
whether to pursue a complete population survey or a sample study is based on the issue 
under investigation and the nature of the population to be studied. The reported response 
rates of examples of veterinary sample studies using mailed questionnaires were 
approximately 30 to 40% (Blackshaw & Day 1994; Leppanen et al. 2000a; Leppanen et al. 
2000b). In the present survey, a complete population study was performed. A professional 
relationship had been developed between owners and the service clinicians before the
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questionnaires were mailed, which is likely to foster greater trust and interest from the 
subjects approached. In one study of a related issue undertaken by the veterinary teaching 
hospital of The Ohio State University (owner perception of the care of epileptic dogs on 
long-term phenobarbitone therapy), a high response rate was also achieved (86%, 19/22) 
(Lord & Podell 1999). Response rate is also affected by the period of time over which 
subjects are studied. For example, in a complete population study of owner assessment of 
the outcome of total hip arthroplasty in dogs, case accrual extended over 15 years and there 
was a reported response rate of 41%; this lower-than-hoped-for response rate was 
interpreted as reflecting the importance of the interaction between owners and clinicians 
(Skurla et al. 2000). In this present study, accrual has been over the past two years and the 
majority of patients had undergone follow-up.
Third, the high response rate may reflect the effort put into the design of the 
questionnaires, including pretesting the wording and layout to achieve a user friendly 
presentation with relevance to the interests o f the sampled owners (all responses indicated 
they would like to receive a summary of the results). There was also a carefully timed 
follow-up of non-respondents to encourage replies, which increased the response rate to the 
first questionnaire from 59% to 86% (see 3.2.1 The Response, page 86).
The Source of Biases
Non-response bias
Even though the non-response rate of the study was low (14%, 5/37), results must still be 
interpreted with some caution, as this indicates the possibility for non-response bias. For 
example, of the five non-respondents, three of the associated patients were on AED 
therapy. One patient was known to have refractory seizure activity with apparent 
behavioural change and one was blind following a status epilepticus. It is likely that both 
these patients would have had an increased care requirement likely to affect the owners’ 
life and a lower degree of satisfaction of seizure management would be suspected 
(affecting the response to questions o f section B, C, F and G in Questionnaire One). 
Accordingly, the present results could overestimate the success of seizure management 
from the owners’ perspective. However, it was impossible to assess either the presence or 
magnitude of the bias.
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The Use of Visual Analogue Scales
Visual Analogue Scales (VAS) provide a simple technique for quantifying subjective 
experience (McCormack et a l 1988). They have been widely used for repeated 
measurements on subjects and for comparison between subject studies. The main 
advantage of VAS is that, unlike numerical scales or verbal rating scales, they provide an 
unlimited number of possible responses along a single continuum, and have been claimed 
to offer a high degree of ‘sensitivity’ i.e., a discriminating capacity superior to that of other 
scales (Price et a l  1994). Ease of construction, use, and versatility are other proposed 
advantages of VAS (McCormack et a l 1988).
Visual analogue scales have been established as valid and reliable in a range of clinical and 
research applications, such as measuring pain, depression and mood in human patients. 
The majority of studies have assessed validity by correlating VAS scores with the scores of 
an appropriate established scale. Some studies have undertaken validation by testing the 
VAS ability to discriminate between subject groups described by objective criteria, which 
provides a more objective means of establishing the validity o f VAS than correlations with 
other scales. Test re-test reliability and inter-rater reliability techniques have been used to 
assess the reliability of VAS (McCormack et a l  1988).
However, there is controversy regarding whether the VAS score represents a ratio or is 
ordinal data. One study of the assessment of pain evaluated the level of order consistency 
between a VAS and a discrete seven-point scale for the same variable, in which the non­
linear properties of VAS assessment were demonstrated (Svensson 2000). The positions of 
the cut-off points on the VAS that re-scale the continuous analogue recordings to a seven- 
point discrete scale are presented in Figure 4.1. The distance between the cut-off positions 
on the VAS is not equidistant. The implication of this non-linear property of the VAS 
assessment is that a median value of VAS assessments cannot be interpreted or described 
by words related to the concept of pain intensity. It has been suggested that the lack of a 
reliable interpretation of the significance of the positions on a VAS means that VAS 
assessments are not reliable in clinical research.
Figure 4.1 The positions of the cut-off points on the VAS in the bias-eliminated 
calibration versus the discrete seven-point scale (labelled A to G)
No pain at all Unbearable pain
ÎAÎ B  I C  i D  i E  j F  i G  i
I I I  I I  I I I
3.5 13.5 46.5 55.5 81.5 89.5
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However, another study recording the pain response to graded changes in noxious thermal 
stimuli suggested the VAS gave a linear scale and implied that the VAS score can be 
treated as ratio data (Price et a l 1994). In another study, patients were requested to 
consider different amounts of pain and repeated their VAS rating after each consideration. 
Comparing these VAS scores suggested that VAS is a linear scale and a change in the VAS 
score represents a relative change in the magnitude of pain sensation (Myles et a l 1999).
Some studies report a tri-modal distribution of VAS scores, with clusters at the midpoint 
and extremes of scales, suggesting that subjects do not always make use of the full 
potential of the scale or treat it as a eontinuum (McCormack et a l  1988). In the present 
study, a few respondents apparently exhibited such a phenomenon.
Ease of use is another major advantage of the VAS over other scales. However, some 
studies point out that the VAS requires an ability to transform a complex subjeetive 
experience into a visuo-spatial display, involving perceptual judgement and accuracy. Age 
and the loss of ability to think abstractly, mental disorganisation and confusion, and 
perceptual skills and memory have all been suggested as factors which may contribute to 
response error (McCormack et a l 1988).
In summary, the use of VAS is controversial and it is impossible to attribute these factors 
specifically to response bias and assess their magnitude. However, for some authors, VAS 
are no weaker than other comparable psychological measures and have many additional 
advantages (McCormack et a l 1988).
Questionnaire Design
Reflection on the responses to the questionnaires revealed unexpected problems related to 
questionnaire design. In the first questionnaire assessing seizure management from 
owners’ perspective, most errors in completion of the form were in questions associated 
with AED side effects, in which respondents were asked about which side effects the dog 
had exhibited and how these specific side effects concerned them (see 3.2.2.5 Section E: 
An Assessment of AED Side Effects, page 93, Q-E3 to Q-EIO). Commonly, respondents 
indicated no such side effects in their dog whilst stating how the problem womed them, or 
conversely, they recognised the specific sign in the dog without indicating their degree of 
concern. Such confusion may stem from the different structure of this particular set of 
questions compared to other parts of questionnaire and the number o f clusters of questions 
respondents had to review.
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111 the second survey concerning behavioural changes, major problems were apparent in the 
responses to questions relating to the onset of reported behavioural changes and its 
relationship with AED therapy. For some respondents, this may have reflected the chronic 
seizure history of their dogs leading to problems in recollection. In addition, as the 
behavioral changes usually developed gradually, the onset o f behavioural changes was 
vague in the respondents’ memory. Minor and distant events are more difficult to target in 
a question and the greater the demands a question places on memory, the less accurate the 
respondents’ answers and the less accurate the survey conclusions derived. Increasing the 
number of questions about a subject is thought to improve the quality of respondents’ 
recollection in a questionnaire survey. By asking more than one question about events, 
more time will elapse for the respondents to think (Fowler 1984). However, in cross 
checking the responses to different questions relating to the same event in this study, some 
responses did not apparently correspond in the study and revealed the decreased reliability 
for the answers to certain questions (see 3.3.2.2 The Onset o f the Behavioural Changes (Q- 
2 and Q-3), page 106).
As such internal cross checking of responses in this study was only possible for two 
questions, it is impossible to assess the reliability in other responses and therefore 
impossible to assess the magnitude of the potential bias.
4.2 Cases Review
The predisposition to idiopathic epilepsy in certain breeds
In this study, there is a preponderance of three specific breeds exhibiting idiopathic 
epilepsy: Labrador retriever. Border collie and German shepherd dog. All three breeds 
have been described as having predisposition to idiopathic epilepsy in the veterinary 
literature and furthennore, the genetics in Labrador retrievers and German shepherd dog 
have been studied (see 1.2.2 Genetic Aspect of Idiopathic Epilepsy, page 20). However, 
the preponderance of specific breeds may also reflect the breed distribution of canine 
general population in Scotland. In one study of idiopathic epilepsy in 125 dogs undertaken 
at the University of Berne, Switzerland, a breed predisposition for Labrador retriever 
(27/125, 21.6%) was represented, with less German shepherd dogs exhibiting idiopathic 
epilepsy (7/125, 5.6%). The breed distribution in this study may also reflect that of the 
local canine population.
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Comparing clinician’s perception of reasons for referrai with that of owners
In this study, half of cases were in Group One (epilepsy of less than 6-months duration, see 
2.3.1 Categories of Seizure Cases Included in This Study, page 67) and the other half of 
cases were in Group Two (epilepsy of greater than 6-months). For the majority of patients 
in Group One, the perception of clinicians and owners was that the underlying reason for 
referral was the desire for further diagnosis. For the cases in Group Two, clinicians 
overestimated “inadequate seizure management” as the main reason for referral suggesting 
this for 73% (11/15) of cases, whilst owners only identified this reason for 53% (8/15) of 
cases (see Table 3. 31 and Table 3. 32, page 104). This finding, that about half the owners 
of dogs with long-term history of epilepsy referred for a second opinion may be looking for 
increased confidence in the diagnosis, suggests that clinicians should discuss further 
investigation before adjusting the patient’s AED therapy. Such an approach, by increasing 
confidence in the diagnosis, may provide owners with more confidence in AED therapy 
adjustment and accepting the balance between AED efficacy and side effects.
Factors underlying apparent treatment failure
Phenobarbitone appears to be the first choice AED in primary veterinary clinics that refer 
cases to SAH-UGVS. However, the dose at the time of accession was relatively low in 
one-third of patients (see 3.1.6 AED Therapy at the Time of Referral, page 81). The 
reason for this may due to the different dose ranges quoted in the Veterinary Data Sheet 
Compendium 1999-2000 (National Office of Animal Health Ltd, Enfield, 1999) and the 
BSAVA Small Animal Formulary (Tennant ed., British Small Animal Veterinary 
Association, Cheltenham, 1999), two important sources of dose infoiination for veterinary 
clinicians, in which the dose range suggested in Veterinary Data Sheet Compendium is 
lower than that in BSAVA Formulary and the current literature. For more than half of the 
patients, serum phenobarbitone concentrations at the time of accession were lower than the 
quoted therapeutic ranges or were within the lower end of the therapeutic range (3.1.6 
AED Therapy at the Time of Referral, page 81). In fact, there has been a variation in the 
therapeutic ranges being reported for the dog in the veterinary literature. Initially, the 
therapeutic range of phenobarbitone had been extrapolated from humans (15-40 pg/ml) 
and veterinary clinical trials had confirmed these targets (15-45 pg/ml) (Farnbach 1984b). 
The low end of therapeutic ranges suggested in both the BSAVA Formulary and 
Veterinary Data Sheet Compendium is 15 pg/ml. However, the current literature 
suggested that seizures are better controlled when serum concentrations are above 20
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pg/ml and serum concentrations above 35 jag/mi had been reported as the highest 
correlation with the development of hepatotoxieity (Dayrell-Hart et a l  1991). There is an 
implication for this finding in relation to both undergraduate and post-graduate education 
suggesting that the value of measuring the serum phenobarbitone concentrations and 
understanding that the current literature should be emphasised in relation to case 
management.
Few patients had been treated with potassium bromide prior to referral (6/48, 3.1.6 AED 
Therapy at the Time of Referral, page 81). Excepting one patient, in which the referring 
veterinarian had established the standard regimen in use at SAH-UGVS (AED regimen, 
page 68) through phone consultation, other patients were on a maintenance doses lower 
than 30 mg/kg, had not been administered a loading dose at the beginning of the therapy 
and their serum bromide concentrations had not been monitored prior to refen'al. The 
initial bromide dose differs according to different protocols from 20 mg/kg to 30-40 mg/kg 
(Schwartz-Porsche 1992; Podell 1996; Boothe 1998). Some authors also prefer not to use 
the loading dose; the reason for this is that the majority of their patients had already had 
serum phenobarbitone concentrations at the top of the therapeutic range and they 
considered the protocol of potassium bromide at 20 mg/kg, without loading dose, allowed 
for a gradual adaptation to the cumulative sedative effects of bromide and phenobarbitone 
(Podell 1996). The initial bromide dose used at SAH-UGVS is 30 mg/kg with a loading 
dose of 450 mg/kg, targeting a semm bromide concentration o f 1 mg/ml (Boothe 1998). In 
the majority of patients administered this protocol at SAH-UGVS, the steady-state 
concentration achieved was less than 1 mg/ml(unpublished data). Consequently, the initial 
dose of 20 mg/kg was considered to be too low to achieve therapeutic serum bromide 
concentrations. The implication is that potassium bromide remains a relatively new AED 
to most veterinary surgeons that refer cases to SAH-UGVS. Bromide, due to its efficacy 
and safety, has become the preferred add-on AED and has been reported to improve 
seizure control in about 58 to 83% of dogs with idiopathic epilepsy (Schwartz-Porsche 
1992; Podell & Fenner 1993; Trepanier et a l  1998). Another advantage of bromide is that 
it is the AED of choice in patients that have developed liver disease (Thomas 2000). 
Again, there is an implication here for an increased emphasis on the use of this preparation 
in the management of epilepsy in the dog in the provision of undergraduate and post­
graduate veterinary education.
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4.3 Assessing Seizure Management from Owners' Perspective
The majority of owners understood that successful therapy might not mean the complete 
elimination of seizure activity (see 3.2.2.1 Section A: Establishing the Ideals for Assessing 
the Outcome of Seizure Management, page 86). Only one-third of owners considered 
decreased cluster seizures to isolated seizures as a reasonable outcome. This may relate to 
personal experience from the pattern of seizure activity in their dogs. “Quality of life”, 
“adequate seizure frequency” and “acceptable AED side effects” were the three main 
concepts chosen by owners to use in assessing seizure management; the concepts “concern 
of the cost of seizure management” and “influence of caring for an epileptic dog on 
owners’ lifestyle” were of less concern.
In general, in their assessment of the seizure management in their own dogs, owners with 
pets not on AED therapy was less satisfied with circumstances than those owners whose 
pets were on AED therapy (see 3.2.2.2 Section B: An Assessment o f Seizure Management 
in their Own Dogs, page 89). However, there was a small sample size with great variance 
in the group of dogs not on AED therapy. In this group, all owners agreed the dogs’ 
qualities of life were good. However, the responses “seizure frequency”, “concern of the 
cost of seizure management”, and “caring for an epileptic dog on owners’ lifestyle” 
exhibited great variation (see Responses from owners with pets not on AED therapy, page 
90). Additionally, 4 of 6 responses in the section showed tri-modal distribution of VAS 
scores, which might affect the results dramatically, especially in a small sample size. For 
the two respondents who expressed low scores for seizure frequency, one patient exhibited 
five to eight partial seizures daily and the other reported clustered, generalised seizures 
every two months. Although those owners made the decision not to administer AED 
therapy, this decision might be questioned for these two patients.
More than half of owners indicated the dogs’ general daily activity or quality of life was 
decreased, which was mainly due to AED side effects (see 3.2.2.3 Section C: An 
Assessment of Quality o f Life in Epileptic Dogs, page 90). It was concluded AEDs with 
fewer side effects are required. The responses to the seetion on AED side effects 
suggested dogs on potassium bromide alone exhibited fewer side effects than dogs on 
phenobarbitone. However, due to the small sample size, further study of potassium 
bromide as monotherapy would be required to eonfirm this.
Dogs on phenobarbitone or bromide exhibiting the side effect of lethargy or sedation, 
whieh results in decreasing general activity, are reflecting the main mechanism of the
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anticonvulsant action of these drugs- enhancement of inhibitory processes. Antiepileptic 
drugs in which the main mechanism of action is a reduction of excitatory transmission or 
modulation o f membrane cation conductance, supposedly do not cause sedation or 
lethargy; this may be an important consideration for choosing AED therapy that maintains 
the general activity and quality of life as before the onset of seizures. However, such drugs 
are not currently available for the canine patient.
The majority of the owners did not consider the administration of the medication a 
nuisance and coped well with medicating more than one time every day (see 3.2.2.4 
Section D: An Assessment of Work Associated with Caring for Epileptic Dogs, page 92). 
However, the requirement of medicating at consistent times was the main concern over 
medication that was expressed. This may reflect another potential advantage of bromide, 
in which, due to the long half-life, accurately medicating at consistent times is not eritical.
Regular veterinary examination and blood sampling to monitor serum concentration were 
of greater concern to more owners, even though more than half of owners did not report 
this as a significant problem (3.2.2.4 Section D: An Assessment of Work Associated with 
Caring for Epileptic Dogs, page 92). In addition, as mentioned previously, two owners 
who did not answer the relevant question commented that they could not express an 
opinion because veterinary examination and serum monitoring were not regularly 
requested by their practice. Given the positive attitudes expressed by the majority of 
owners, it is suggested that regular veterinary examination and serum drug concentration 
monitoring should be suggested more widely to aehieve appropriate seizure management.
In general, owning an epileptie dog did not have a major impact on owners’ work/day-to- 
day activities and free time. However, half of owners with dogs on AED therapy indicated 
epilepsy in their dogs did affeet their decision/ability to be away from home, which was 
mainly a reflection of respondents concern for their dog and difficultly in finding people 
able to provide care (see 3.2.2.7 Section G: The Impact of Owning an Epileptic Dog on 
Owners’ Ability/decision to Stay Away Overnight, page 98). Seizure frequency recorded 
in these patients ranged from more than one generalised seizure per month to a seizure-free 
interval of 18 months. Using the criteria for acceptable seizure control expressed in the 
literature (discussed in 1.4.1 General Principles of Antiepileptic Drug Therapy, page 31), it 
is evident that, in the patients cared for by the group of respondents who expressed an 
inability/unwillingness to be away from home overnight, seizure eontrol was generally less 
acceptable (6/13, 46%) than amongst those belonging to individuals who felt able to be 
away from home overnight (13/18, 72%). This implies that, for the majority of owners.
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adequate seizure control decreases the impaet of owning epileptic dogs on owners’ free 
time, however, for some owners, even if seizures are well controlled, the seizure disorder 
in their dog still negatively affects their decision/ability to be away from home. This 
reflects that the self selection bias may exist when inteipretating the owner’s perception of 
this topic.
A few owners (4/23, see 3.2.2.8 Section H: Owners’ Opinions on Further Investigation of 
Seizures in their Dogs, page 100) indicated they were still uncertain of the cause of 
seizures in their pet even if the diagnosis of idiopathic epilepsy was made following the 
full investigation protocol described (see 2.2 INVESTIGATION PROTOCOL FOR 
PATIENT WITH EPILEPSY, page 60). This implies the concept of diagnosis of 
idiopathic epilepsy by exelusion is difficult for some owners to comprehend. However, for 
the majority of owners, the further diagnostic procedures did help them understand their 
dog’s condition. Furthermore, even for the patients without a pet health insurance plan, 
after the full investigation protocol was performed, most owners (6/9) agreed the cost of 
further diagnostie proeedures to loiow more about the cause o f seizures was worthwhile 
(VAS scores greater than 50; see 3.2.2.8 Section H: Owners’ Opinions on Further 
Investigation of Seizures in their Dogs, page 100).
4.4 Behavioural Changes in Epileptic Dogs
In human medicine, “psychosis of epilepsy” is a term applied to a group of psychotie 
disorders in which potential aetiopathogenic mechanisms are believed to be closely related 
to those underlying the seizure disorder (Kanner 2000). The term psychosis has been used 
to describe not only psychiatric illnesses but also affective disorders such as depression, 
mania, hypomania, as well as other states of clouded consciousness. Four time periods 
need to be considered when psychiatric or behavioural symptoms are evaluated in patients 
with epilepsy: prodrome (which may not occur in every patient and may precede a seizure 
by minutes to hours); ietus (including aura and main seizure component); postictal period; 
the interietal phase (Stagno 2001). The psychoses of epilepsy are further classified as 
interietal psychosis, postictal psychosis, alternative psychosis (also known as ‘forced 
normalisation’) and AED-related psychosis (Kanner 2000).
In the present study, a subgroup of patients exhibited behavioural changes (33%, 16/48), of 
which 11 patients were available for further study to establish if there was evidence that
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suggested the reported behavioural changes might be analogous to the psychosis reported 
in epileptic human patients. Even though the term ‘psychosis’ is considered inapplicable 
to describe behavioural problems in veterinary medieine, it is thought reasonable to 
evaluate the behavioural ehanges in epileptie dogs and characterise this as interietal, 
postictal, forced nomialisation or AED-related activity. Behavioural changes related to 
AED therapy, postictal activity, and interietal activity were recognised in the study (see 
3.3.3 Summary of Questionnaire Two, page 111).
In human medicine, phenobarbitone is known to produce hyperactivity, irritability, and 
belligerence in children or elderly patients. These effects are not related to dose or serum 
coneentrations. Barbiturates also may cause sedation, insomnia, tearfulness, mood shifts, 
and increased aggressiveness (Stagno 2001). In the veterinary literature, the use of 
phenobarbitone has infrequently been associated with hyperactivity and restlessness that 
appears especially during the first few weeks of therapy, is not dose related and resolves 
within a few weeks of initiating therapy (see Side effects o f phenobarbitone, page 41). In 
the present study, there was some evidence that behaviour may be related to 
phenobarbitone dose in some patients (see 3.3.2.5 Behavioural Changes and AED Therapy 
(Q-10), page 108). However, further studies would be required to confirm the finding.
The adverse effeets of bromide reported in human medicine are primarily neurological and 
include phenomena such as headache, vertigo, hallucinations, delirium, ataxia and stupor 
(see Side effects of bromide, page 47). Abnormal behaviour, such as irritability or 
restlessness, have been described in the veterinary literature but with limited details 
(Thomas 2000). In the present study, in the 14 patients on potassium bromide alone or in 
combination with phenobarbitone, four owners reported behavioural changes related to 
bromide therapy, which, at 29% of the population, suggests a potentially significant 
clinical effect of using this preparation. Results of this study suggest the incidence of 
behavioural change may be dose related (see 3.3.2.5 Behavioural Changes and AED 
Therapy (Q-IO), page 108), which reflects the literature; and may require a reduction in the 
dose (Thomas 2000).
In human epileptic patients, postictal psychiatric disturbances occur relatively commonly. 
According to the suggested diagnostic criteria of postictal psychiatric disturbances, 
symptoms are manifested immediately upon a seizure or within a week of the return to 
normal mental functioning (i.e., after a lucid interval), and last days, rarely weeks. The 
event may be characterised by psychosis, depression, mania, hypomania, or anxiety-related 
symptoms (Stagno 2001). In the veterinary literature, it is known that hyperactivity or
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restlessness can occur in the postictal phase and the postictal phase refers to the phase 
immediately following seizure activity, which lasts from minutes to days. Interestingly, in 
one of our patients exhibiting postictal behavioural changes, the behaviour sometimes 
appeared after a lucid interval of few days following a seizure, and lasted for 1 week, 
which has similarities to the phenomenon described in human literature.
The cause of postictal psychiatric disturbances in human medieine remains unlaiown, 
although Todd’s phenomenon, a transient disturbance o f neurological function has been 
suggested. Some authors regarded postictal psychoses as similar to other postictal focal 
neurological deficits. They have suggested that postictal paresis, aphasia, amnesia, 
emotional changes and psychosis in human patients may all be manifestation of 
homeostatic phenomena, which are induced by recurrent seizures, to reduce epileptic 
hyperexcitability, and presumably temiinate ictal events, prevent ictal spread and persist to 
maintain the interietal state (Stagno 2001).
Interietal psychoses can present intermittently or persistently. EEC investigation is 
necessary to detemiine whether intermittent or brief psychoses are related to seizure 
activity. Virtually, all theories that relate emotional or behavioural changes to epilepsy 
implicate abnormalities of limbic system. A temporal lobe focus appears to raise the 
incidence of interietal psychosis in epileptic patients, as do partial seizures with secondary 
generalisation (Stagno 2001). In general, the presence of interietal psychosis suggests the 
presence of underlying central nervous system pathology, which implies symptomatic or 
cryptogenic epilepsy in human patients (Kanner 2000).
In this study, behavioural changes in one dog were eonsidered by the owner to represent 
interietal activity. The patient exhibited partial seizures and the onset of behavioural 
changes related to seizure disorder. Behavioural changes observed in the patient were an 
increase in general activity (e.g., restless) and reduced sleep periods as compared to before 
the onset of seizure activity. Seizure activity was well-controlled by phenobarbitone 
therapy, but the pattern of behavioural ehanges remained the same. The diagnosis of 
idiopathic epilepsy was made by the investigation protocol described previously (see 2.2 
INVESTIGATION PROTOCOL FOR PATIENT WITH EPILEPSY, page 60). However, 
MR imaging may be eonsidered in the patient potentially to refine the diagnosis. In human 
medicine, some authors suggest, in patients with interietal psychosis, high-resolution MR 
studies should be performed in search of small, multiple tumours sueh as gangliogliomas 
and hamartomas. Such tumours may be difficult to identify on standard MRI studies 
(Kanner 2000). In summary, instead of idiopathic epilepsy, cryptogenic epilepsy may be a
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more appropriate term to describe the problem in this patient but this eould only be 
established by the passage of time and post-mortem.
This study revealed a relatively large proportion of eases exhibiting behavioural changes, 
which appeared to be AED-related. Once patients exhibit this problem, a dose reduetion or 
diseontinuation of the particular AED may be necessary. However, when AED-related 
behavioural changes have been observed in dogs managed with both phenobarbitone and 
bromide, seizure management would be difficult to achieve, due to the limited choice of 
AED for dogs. The demand for further choiee of AEDs with well-documented efficacy 
and tolerance in dogs is suggested.
CHAPTER FIVE
CONCLUSIONS
Conclusions izo
From a clinician’s perspective, the major goals in the management o f idiopathic epilepsy 
have traditionally been thought of as to the reduction o f seizure frequency and of the 
severity of individual seizures, with minimal postictal complications so that the condition 
does not substantially eompromise the quality of life for the dog and family, whilst 
avoiding serious side effects associated with the use of AED therapy. This study has 
demonstrated that, from the owners’ pereeption, the “dogs’ quality of life”, “adequate 
seizure frequency” and “acceptable AED side effects” were the three main concepts for 
owners to use in assessing seizure management. The coneepts o f “eoncern of the cost of 
seizure management” and “influence of caring for an epileptic dog on owners’ lifestyle” 
were of less significance.
The study also demonstrated that owning an epileptic dog did not have a major impact on 
owners’ woiiUday-to-day activities and free time. The majority of owners did not consider 
the administration of the medication a nuisance and coped well with medicating more than 
once daily and, for some dogs, with the administration of more than one drug. For more 
than half of the owners, regular veterinary examination and blood sampling for serum AED 
concentration monitoring did not cause a significant problem. However, as mentioned 
previously, the highly motivated nature of the elient profile from a referral population may 
be significant in responses to this study. Further study of non-referral populations would 
be required to understand owners’ attitude in eanine seizure management from the general 
population.
Achieving a confident diagnosis of idiopathic epilepsy is not only the basis of achieving 
successful seizure management from the clinician’s point o f view, but also helped most 
owners to understand their dog’s condition and gave them more confidence in AED 
therapy adjustment and aceepting the balance between AED efficacy and side effects. The 
majority of owners agreed that the cost of further diagnostic procedures was worthwhile.
Given the positive attitude expressed by the majority of owners, regular veterinary 
examination and serum drug concentration monitoring should be suggested more widely to 
achieve appropriate seizure management. Furthermore, based on the results of ease review 
in the study, in both undergraduate and post-graduate education the value of measuring 
AED serum concentrations, as well as the use of bromide in canine epilepsy, should be 
emphasised. The study also demonstrated that dogs on potassium bromide alone exhibited 
fewer side effects than dogs on phenobarbitone. However, due to the small sample size, 
further study of potassium bromide as monotherapy would be required to conflnn this.
Conclusions izy
This study also revealed a relatively large proportion of cases exhibiting behavioural 
changes, which mainly appeared to be AED-related in our patients. Clinicians should 
increase the awareness of behavioural changes in epileptic dogs. Determining the pattern 
of behavioural changes and the potential causes is not straightforward, and detailed, diary 
recorded seizure and behaviour activities may help to make objective judgement. Once 
patients exhibit AED-related behavioural changes, a dose reduction or discontinuation of 
the particular AED may be necessary. Further prospective study would be required to 
eonfirm the relationship between dose of spécifié AED and behavioural changes. A study 
of a non-referral population would help demonstrate more accurately the prevalence and 
presentation of behavioural changes in dogs with idiopathie epilepsy.
